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The infection with HIV-1 nowadays does not represent a condition with a deadly outcome. Due to 
current therapeutic approaches, the infection with HIV-1 represents a chronic condition in which viral load 
is kept at undetectable levels, but patients depend on a lifelong therapy without a chance of cure. The 
eradication of integrated viral DNA still remains the biggest challenge in curing HIV-1.  
The aim of this work was to contribute to a better understanding and definition of genomic regions and 
epi-genomic features that HIV-1 targets for integration, and give a detailed description on the importance 
of chromatin accessibility, as well as the importance of certain genomic features in the process of HIV-1 
integration.   
The first part of this project deals with the importance of HMT G9a activity and H3K9me2 
histone mark distribution and deposition in the context of HIV-1 integration in primary CD4+ T cells, 
which was studied by the application of G9a inhibitor BIX0129, also known as a very potent latency 
reversing agent. The significance of G9a activity and facultative heterochromatin mark H3K9me2 
deposition has previously been shown to affect T cell development and impact shaping of the nuclear 
architecture. In this work it was demonstrated that the chemical inhibition of G9a and depletion of 
H3K9me2 by BIX01294 has an increasing effect on HIV-1 integration. The increase in integration was 
also followed by increased viral transcriptional activity, as well as spatial repositioning of the provirus 
from the preferred nuclear periphery towards the nuclear center. Similar spatial repositioning has been 
demonstrated for genes highly and recurrently targeted by HIV-1 for integration (RIGs). However, genic 
nuclear repositioning upon BIX01294 treatment did not affect transcriptional profiles of HIV-1 RIGs, as 
demonstrated by RNA microarray analysis, but other groups of genes mainly involved in iron metabolism 
and inflammatory response were upregulated upon BIX01294 treatment. In addition, HIV-1 integration 
patterns were shown not to be affected by H3K9me2 depletion, and the virus was still targeting similar 
genic regions for integration. The analysis of chromatin mark distribution and chromatin binding elements 
upon BIX01294 treatment on RIGs revealed increased binding profiles of open chromatin mark 
H3K36me3 which is followed by increased LEDGF/p75 binding upon H3K9me2 depletion. The observed 
phenomenon might provide an explanation for the observed increased viral integration upon BIX01294 
treatment, considering that LEDGF/p75 is a prominent host cell factor involved in the viral integration 
process.  
Overall, the first part of this study clearly demonstrated that chromatin accessibility significantly affects 
HIV-1 integration levels which are directly proportional to viral expression levels and viral activity.   
 
The second part of this study deals with the relevance of R-loops, as specific genomic structures, 
as sites selected for HIV-1 integration in primary CD4+ T cells and macrophages. It was demonstrated that 
the GFP tagged IN enzyme of HIV-1, in a high occurrence, colocalizes with R-loops in cells, and that for 
the occurrence of this process a functionally active IN is required. This finding implicated that the 
observed colocalization is not randomly taking place and that HIV-1 is actively docked to R-loop forming 
genomic sites. In addition, biochemical as well as computational meta data analysis revealed that HIV-1 
RIGs are enriched in R-loops and that R-loop forming sites can accommodate integrated viral DNA. 
Further on, it was demonstrated that HIV-1 IN has R-loop binding capacity and is also capable of 
performing the strand transfer reaction on R-loop containing DNA templates. It was also demonstrated 
that R-loop depletion by RNase H1 overexpression in several cell lines, as well as in primary cells, 
significantly impairs HIV-1 integration, indicating that R-loop presence is crucial for efficient HIV-1 
integration. In line with this result was the finding that RIGs expression was not affected by R-loop 
removal, indicating that only the presence of R-loops, as structural genomic elements, is more affecting 
HIV-1 integration compared to gene expression levels. The final finding is also in line with previous work 
from our lab.  
In summary, the second part of this study provides strong evidence that R-loops represent structural 
genomic elements targeted by HIV-1 for integration and also gives new insight into HIV-1 IN functional 
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Die Infektion mit HIV-1 ist heutzutage nicht mehr ein Zustand mit tödlichem Ausgang. Dank 
moderner therapeutischer Maßnahmen ist die Infektion ein chronischer Zustand in dem die Viruslast in 
Patienten auf nicht nachweisbaren Niveau gehalten wird. Jedoch sind Patienten auf lebenslange Therapie 
angewiesen, ohne eine Chance auf Heilung. Die Eradikation integrierter viraler DNA bleibt die größte 
Herausforderung in der Heilung einer HIV-1 Infektion.  
Das Ziel dieser Arbeit war es, zu einem besseren Verständnis und einer detaillierten Definition von HIV-1 
Integrationsstellen beizutragen, als auch einen detaillierten Überblick über die Bedeutung und Relevanz 
von Chromatin Struktur und spezifischer genomischer Elemente im Kontext des HIV-1 Integrations 
Prozesses zu geben.  
Der erste Teil dieser Arbeit befasst sich mit der Aktivität von G9a und der Komposition von 
Chromatin Merkmal H3K9me2 im Zusammenhang mit HIV-1 Integration in primären CD4+ T-Zellen. Um 
den Effekt von G9a Aktivität und H3K9me2 Komposition in Zusammenhang mit HIV-1 integration zu 
ermessen, wurde BIX01294, als prominenter chemischer Inhibitor von G9a angewendet. BIX01294 ist 
auch als sehr effizientes Latenzumkehrmittel bekannt. In vorherigen Studien wurde gezeigt das die 
Aktivität von G9a und der Aufbau von Heterochromatin Markierung H3K9me2 einen signifikanten 
Einfluss auf die Entwicklung von T-Zellen haben, als auch einen großen Einfluss auf die Chromatin 
Architektur des Zellkerns. Als Teil dieser Arbeit wurde gezeigt dass die chemische Hemmung von G9a 
und die darauf folgende gehemmte Ablagerung von H3K9me2, durch BIX01294, eine signifikante 
Wirkung auf HIV-1 Integration haben. Die durch BIX01294 ausgelöste erhöhte HIV-1 Integration hatte 
auch eine erhöhte virale Transkriptionsaktivität zur folge, sowie eine räumliche Neupositionierung des 
Provirus von der bevorzugten Kernperipherie zum Kernzentrum. Eine ähnliche räumliche 
Neupositionierung im Zellkern wurde auch für Gene gezeigt die HIV-1 wiederholt für seine Integration 
selektiert (RIGs). Jedoch hatte die Neupositionierung von RIGs keinen Einfluss auf ihre Transkription, 
dass via RNA microarray Analyse gezeigt wurde. Gruppen von Genen die durch die Behandlung mit 
BIX01294 eine erhöhte Transkription zeigten gehörten hauptsächlich zu Genen die in Prozessen wie 
Eisenstoffwechsel oder Entzündungsreaktionen involviert sind. Darüber hinaus wurde gezeigt, dass HIV-1 
Integrationsmuster nicht durch den Schwund von H3K9me2 beeinflusst werden, und dass das Virus 
immer noch ähnliche Regionen zur Integration favorisiert. Die Analyse der Verteilung von Chromatin 
Markierungen und der Chromatin Bindungselemente nach H3K9me2 Schwund ergab dass HIV-1 RIGs 
eine erhöhte Bindung von Chromatin Markierungen spezifisch für offenes Chromatin hatten, was zur 
Folge auch eine erhöhte LEDGF/p75 Bindung aufgewiesen hat, ausgelöst durch H3K9me2 Schwund nach 
der Behandlung mit BIX01294. Dieses Resultat könnte eine Erklärung für die erhöhte HIV-1 Integration 
darstellen da LEDGF/p75 ein prominenter Wirtszellenfaktor ist der in die virale Integration involviert ist.   
Insgesamt zeigte dieser Teil der Arbeit, dass die Zugänglichkeit von Chromatin das HIV-1 
Integrationsniveau signifikant beeinflusst, und dass das virale Integrationsniveau direkt proportional zu 
viraler Genexpression und virale Aktivität ist.  
 
Der zweite Teil dieser Studie beschäftigt sich mit der Bedeutung von R-Loops als Strukturen 
favorisiert für die HIV-1 Integration in primären CD4+ T-Zellen und Makrophagen. Es wurde gezeigt, das 
die HIV-1 IN in hohem Maße mit R-Loops in Zellen kolokalisiert und dass für ein hohes Auftreten dieser 
Kolokalisierung eine aktive IN erforderlich ist. Dies implizierte, dass die beobachtete Kolokalisierung 
nicht zufällig erfolgt und dass HIV-1 aktiv an R-Loops angedockt wird. Darüber hinaus zeigten 
molekulare Ergebnisse, als auch Computeranalysen dass HIV-1 RIGs in R-Loops angereichert sind und 
dass R-Loops integrierte virale DNA enthalten können. Weiterhin wurde gezeigt, dass die HIV-1 IN eine 
R-Loop Bindungskapazität besitzt und auch in der Lage ist die Strang-Transfer-Reaktion an einem R-
Loop durchführen kann. Es wurde auch gezeigt, dass die R-Loop-Depletion durch RNase H1 in mehreren 
Zelllinien sowie in primären Zellen die HIV-1-Integration signifikant beeinträchtigt, was darauf hinweist 
dass die Präsenz von R-Loops für eine effiziente HIV-1-Integration von entscheidender Bedeutung ist. In 
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Übereinstimmung mit diesem Ergebnis war auch die Feststellung, dass die RIG-Expression nicht durch 
die Entfernung der R-Loops beeinflusst wurde, was darauf hindeutete dass die Anwesenheit von R-Loops, 
als Strukturen im Genom, die Integration von HIV-1 stärker beeinflusst als das Expressionsniveau dieser 
Gene. Dieses Resultat übereinstimmt auch mit bisherigen Erkenntnissen aus unserem Labor.   
Zusammenfassend liefert der zweite Teil dieser Studie eindeutige Beweise dafür, dass R-Loops 
strukturelle genomische Elemente darstellen die sich HIV-1 zur Integration aussuchen kann. Außerdem 
liefert dieser Teil der studie auch neue Erkenntnisse über bisher nicht erforschte Funktionsmerkmale der 
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I.I. Human immunodeficiency virus 1 (HIV-1)  
 
Human immunodeficiency virus 1 (HIV-1) is a lentivirus that primary infects cells of the host 
immune system. HIV primary infects CD4+ T cells, macrophages and dendritic cells causing a 
depletion of immune cell numbers (mainly CD4+ T cells) potentially causing a disease assigned 
as Acquired Immune Deficiency Syndrome (AIDS).  
HIV-1 remains a major global and public health challenge (Sharp & Hahn, 2011; UNAIDS. 
AIDS by the numbers (2015)). More than 36 million individuals live with HIV world-wide. And 
about 2 million new infections are occurring each year (UNAIDS. Fact Sheet 2018. 1–6 (2018). 
  
HIV-1 origin and phylogenetic position  
 
Strong phylogenetic evidence, which can be traced back to a single transmission event, suggests 
that HIV-1 originated by zoonotic cross-species transmission of the simian lentivirus; Simian 
immunodeficiency virus (SIV) from the chimpanzee subspecies Pan troglodytes troglodytes to 
humans (Gao et al, 1999; Keele et al, 2006; Sharp & Hahn, 2011).  
 
HIV-1 is characterized by extensive and dynamic genetic diversity. This heterogeneity is driven 
by several factors. A major source of HIV-1 genetic heterogeneity is the lack of proofreading 
ability of the viral enzyme reverse transcriptase (RT) (Roberts et al, 1988; Op de Coul et al, 
2001), the rapid turnover of HIV-1 in vivo (Ho et al, 1995), host selective immune pressure 
(Michael, 1999), as well as recombination events during replication (Temin, 1993). Mentioned 
phenomena contribute to HIV-1 being a virus with several distinct molecular subtypes and 
recombinant forms. Such a high diversity of the virus has significant implications on general 
understanding of viral transmission, pathogenesis and diagnosis (Buonaguro et al, 2007).  
 
According to the Baltimore classification of viruses (1971) which is based on structural features 




classified into virus group VI (single stranded (ss) RNA-RT viruses, + strand (sense), with a 
DNA intermediate in its life cycle), family Retroviridae, genus Lentivirus.  
Due to its variability, HIV-1 variants can be further classified into three major phylogenetic 
groups: group M (main), group O (outlier) and group N (non-M/non-O) (Gürtler et al 1994; 
Simon et al, 1998; Ayouba et al, 2000). Viruses classified into group M are responsible for most 
of the infections worldwide. This group can be further subdivided into 10 recognized 
phylogenetic subtypes (A-K).  
Classification of HIV-1 subtypes was originally based on subgenomic regions of individual 
genes. Nowadays, with sequencing method improvements, HIV-1 phylogenetic classification is 
based on nucleotide sequences derived from multiple subgenomic regions (gag, pol and env 
gene) of the same viral isolate or on full-length sequence analysis (Buonaguro et al, 2007) 
(Figure 1.1.). 
 
Apart from HIV-1, in 1986 a related virus was isolated from African individuals and named 
HIV-2, which is known to be less pathogenic than HIV-1 (Clavel et al, 1986) and has two major 
subtypes, A and B. The lower infectivity of HIV-2 is assigned to its relatively poor capacity for 






Figure 1.1. Phylogenetic tree of HIV subtypes and simian lentiviruses.  
The phylogenetic tree shows the similarity between HIV and SIV generated by full genome alignment of 87 








HIV-1 & AIDS 
 
A large sero-epidemiological study conducted in 1984 clearly showed that HIV causes AIDS. In 
addition, this research was the basis of the development of the first diagnostic tests for HIV 
infection (Schupbach et al, 1984; Brun-Vezient et al, 1984). 
From a historical point of view, an estimated number of 75 million people worldwide have been 
infected with HIV. Untreated HIV replication causes progressive CD4 T cell loss and a wide 
range of immunological abnormalities, which can also lead to an increased risk of infectious and 
oncological complications. Since the mid-1980s, when the first successful reverse transcriptase 
inhibitor was produced, antiretroviral drugs are highly effective in inhibiting HIV replication. 
Viral suppression enables immune recovery and the near elimination of the risk for developing 
AIDS (Deeks et al, 2015).  
Still, the problem of not being able to fully eradicate the virus from infected individuals persists. 
Apart from mentioned reasons for HIV-1 heterogeneity which represent one of the difficulties for 
HIV-1 cure strategies and beside the viral immune escape, the major reason why HIV-1 infection 
can not be eradicated by current therapies is due to the property of the virus to establish latent 
infection in resting CD4 T cells. These latently infected cells do not express viral proteins and 
therefore remain undetectable for the immune system and refractory to the current antiretroviral 
therapies (Chun et al, 1995; Lassen et al, 2004; Williams & Greene, 2007). In addition, non-T 
cell derived viral reservoir represents another challenge in eradicating the virus from infected 
individuals. Several studies showed that the viral genome can also be found in different cell 
types, such as monocytes/macrophages (Le Douce et al, 2010; Kumar et al, 2014), other myeloid 
cells (Scadden et al, 1990; Churchil et al, 2006) and even epithelial cells (Veazey et al, 1998; Liu 










I.II. HIV-1 structure 
 
HIV-1 virion structure 
 
The HIV-1 viral particle (virion) has a spherical shape with a diameter of 100 nm. HIV-1 is an 
enveloped virus in which the envelope functions as a protector for inner viral components and 
contains proteins that allow the virus to recognize host cells. Inside the virion viral structural 
proteins assemble into a shell, or the viral capsid (CA) which protects and organizes the viral 
genome. HIV-1 virions can adopt two distinct morphological states (Ganser-Pornillos et al, 2008; 
Briggs & Kräusslich 2011; Sundquist & Kräusslich 2012). First the virion buds from a producer 
cell in its immature form, having a spherical CA which is composed of the immature (precursor) 
structural protein Gag. In order to become infectious, the immature virion undergoes 
morphological changes into the mature form (Figure 1.2.). This process of HIV-1 maturation is 
triggered by site-specific proteolytic processing; cleavage of the precursor Gag protein by the 
viral protease. This cleavage creates new structural proteins among which the capsid protein or 
p24 is one of the most important ones and it resembles into a new cone-shaped CA. The mature 
CA contains the viral RNA genome which is associated to enzymes important for integration 
(integrase – IN) and reverse transcription (reverse transcriptase – RT). The mature CA and its 
contents together constitute the virion core. The core is the structural part which is introduced 
into the cytoplasm of an infected cell at the start of a new round of viral replication.  
Apart from the core, which contains two copies of the single stranded viral RNA genome and is 
closely bound to nucleocapsid proteins (Figure 1.2., right), the virion contains viral enzymes IN, 
RT, proteases, ribonucleases,  as well as an  envelope.  
The envelope is composed of a lipid bilayer which originates from the host cell plasma 
membrane in the process of budding. The envelope of a virion contains proteins inherited from 
the host cell and some copies of the viral envelope protein. The viral envelope protein is 
composed of three molecules of glycoprotein 120 (gp120) and three molecules of glycoprotein 41 
(gp41) (Figure 2; legend on the right). The function of viral envelope proteins is the attachment 
to a host target cell, fusion of the lipid membranes of the viral particle and host cell membrane 








Figure 1.2. Schematic representation of HIV-1 virion structure. 
Left: Structure of an immature HIV-1 virion. The viral capsid is not yet assembled. Gag molecules (purple) are 
concentrated under the viral envelope (yellow and green) and in complex with the viral RNA genome (red). 
Right: Structure of a mature HIV-1 virion. The viral core is assembled upon Gag cleavage by the viral protease. 
Upon protease cleavage nuclear core (NC) proteins (purple dots) associate with the viral RNA genome (red) and 
mature matrix proteins (MA) are docked to the viral envelope (yellow and green).  
A more detailed composition of HIV-1 virion building blocks is shown in the legend on the right (adapted from: 
Pornillos & Ganser-Pornilos, 2013).  
 
Structure of the HIV-1 genome  
 
The genome of HIV-1 is a coding RNA with nine open reading frames which code for fifteen 
different proteins (Coffin et al, 1997). The size of the HIV-1 HXB2 complete genome is 9719 bp 
(Genbank accession number K03455.1). The HIV-1 genome contains three major genes gag, pol 
and env which encode the main structural proteins and enzymes of the virus (Figure 1.3).  
The 5’ and 3’ ends of the viral genome each contain a Long Terminal Repeat (LTR) sequence, 
which participate in the process of proviral integration into the host genome. Both LTRs are 
composed of identical nucleotide sequences, and divided into three identical regions (U3, R, U5). 
However, once the virus has been integrated, the 5’ end LTR serves as a promoter for the viral 
genome, and the 3’ LTR is important in the polyadenylation of the transcribed viral RNA (Krebs 




same nucleotide sequence. Still, it has been suggested that the transcriptional activity of the 5’ 
LTR is more potent in comparison to the 3’ LTR, which is also very similar to the scenario 
occurring in other retroviruses (Klaver & Berkhout, 1994).  
Viral proteins are translated 
as polyproteins which are 
further processed and 
proteolytically cleaved to 
produce the mature 
proteins. From the gag 
polyprotein precursor, the 
matrix protein (MA or 
p24), capsid (CA or p7), 
nucleocapsid (NC or p17) 
and p6 protein are 
generated.  From the gag-
pol polyprotein important 
viral enzymes as protease (PR), reverse transcriptase (RT) and integrase (IN) are generated. The 
env gene encodes a 30 amino acid signal peptide – SP and two glycoproteins assigned as gp120 
and gp41. Apart from the three major HIV-1 genes, additional six genes (tat, rev, nef, vpr, vif, 
vpu) encode HIV-1 accessory proteins which are participating in the life cycle of HIV-1 (Figure 
1.3). Inside of virions, the HIV-1 genomic RNA is found as a non-covalent dimer with a 5’ cap, a 
3’ polyadenylated tale and annealed to a host tRNALys3 molecule (Coffin et al, 1997; Watts et al, 
2009). The tRNALys3 acts as a primer for RT-catalyzed synthesis of viral DNA (vDNA) 




Figure 1.3. Scheme of HIV-1 genome structure and its functional products. 
HIV-1 genome is 9719 bp in size and contains 9 open reading frames. Viral 
LTRs are represented in gray rectangles, whereas the viral genes are depicted in 
colorful rectangles. The functional products of the three major viral genes (gag, 




I.III. HIV-1 life cycle 
 
The life cycle of HIV-1 is 
a multistep process which 
can be divided into eight 
stages:  
1) binding;  
2) fusion; 
3) reverse transcription;  
4) integration;  
5) replication;  
6) assembly;  
7) budding and  
8) maturation (Figure 1.4). 
 
Binding & fusion 
 
As already mentioned, HIV-1 is an enveloped virus. The viral envelope is formed during the 
budding process and contains both viral and cellular proteins. Viral proteins present in the 
envelope are gp120 or the surface subunit of the envelope and gp41, the transmembrane subunit. 
gp120 interacts with specific cellular receptors; the CD4 receptor and two chemokine receptors 
CCR5 and CXCR4 (Dalgleish et al, 1984; Klatzmann et al, 1986; Alkhatib et al, 1996; Choe et 
al, 1996; Endres et al, 1996; Deng et al, 1996, Feng et al, 1996). Based on its ability to bind these 
receptors HIV-1 can be divided into different strains; CCR5 (R5 strain), CXCR4 (X4) strain or 
both (R5X4).  
Previously it has been assumed that HIV-1 directly fuses with the plasma membrane of the target 
cell (Stein et al, 1987; McClure et al, 1988; Melikyan, 2008). However, fusion occurs after a 
conformational change in gp41 (the transmembrane unit of the HIV-1 envelope) (Chan & Kim, 
1998). But it was also shown that HIV-1 entry can occur via virion endocytosis (Miyauchi, 
2009).  
 
Figure 1.4. Overview of HIV-1 life cycle. 
The illustration depicts the most important stages in the life cycle of HIV-1 from 
the moment of entering the target cell to possible scenarios of an active 
transcription of the virus and virion production, or reversion into latency (from: 




After HIV-1 virion fusion, uncoating steps take place, which means that the viral CA is 
disassembled and the viral genome is released into the cytoplasm. 
   
Reverse transcription 
 
Reverse transcription is the process in which the viral RNA genome is reversely transcribed into 
cDNA (complementary DNA). The produced cDNA represents the substrate for the integration 
process. The most important enzyme involved in the process of reverse transcription is the viral 
enzyme reverse transcriptase (RT) (Baltimore, 1970). 
Two important features of RT are necessary to carry out reverse transcription;  
1) it is a DNA polymerase that can copy either an RNA or DNA template and  
2) it has RNase H properties - it can degrade RNA only if it is a part of a DNA-RNA duplex.  
 
RT requires a primer 
and a template for its 
function. The viral 
genomic RNA is plus-
stranded and the primer 
for the first minus-
stranded DNA is a host 
cell tRNALys3 whose 3’ 
is complementary to a 
sequence close to the 5’ 
end of the viral RNA, 
known as the primer 
binding site (pbs). The 
ends of the viral RNA 
are direct repeats, called 
“R”. They function as a 
bridge that allows the 
newly synthesized 
 




minus-strand DNA to be transferred to the 3’ end of the viral RNA, where the synthesis of the 
minus-strand can continue along the genome. The HIV-1 RNA genome contains two purine-rich 
regions (the so called polypurine tract – ppt) that are resistant to RNase H degradation by the RT. 
This ppt region functions as a primer for the initiation of the plus-strand DNA synthesis. After 
reverse transcription a DNA product is generated that is longer than the initial RNA genome. 
Both ends of the DNA contain sequences from each end of the RNA template (U3 from the 3’ 
end and U5 from the 5’ end), meaning that each end of the viral DNA has the same sequence; 
U3-R-U5. These are the Long Terminal Repeats (LTRs), that represent the ends of the integrated 




After reverse transcription, the viral cDNA is actively transported from the cytoplasm to the 
nucleus, through the nuclear pore complex (NPC) in a large nucleoprotein complex known as the 
Preintegration Complex (PIC). The PIC is derived from the core of the infecting virion 
(Bowerman et al, 1989) and, apart from the viral DNA, contains the viral integrase (IN), the 




In vitro studies showed that IN 
requires magnesium for its activity. 
The CCD (Catalytic Core Domain) 
of HIV-1 IN contains the DDE 
(aspartic acid - aspartic acid - 
glutamic acid) motif essential for 
the catalytic function of the enzyme 
(Kulkosky et al, 1992; Leavitt et al, 
1993). The amino acid residues of 
the DDE motif require a pair of 
Mg2+ ions for its catalytic function 
in the process of integration and the 
presence of Mg2+ ions was shown 
to be very important in the 
stabilization of the intasome (Miri 
et al, 2014; Engelman & 
Cherepanov, 2014).  
In addition, studying integration 
intermediates revealed DNA cutting 
and joining steps of the viral DNA 
during the process of integration (Fujiwara & Mizuuchi, 1988; Brown et al, 1989).  
Before the start of any enzymatic activity of IN and the integration of the vDNA into the target 
host DNA, the intasome has to be formed. “The intasome comprises a homo-hexadecamer of IN 
with a tetramer-of-tetramers architecture featuring eight structurally distinct types of IN 
protomers supporting two catalytically competent subunits” (Ballandras-Colas et al, 2017), which 
stably bind and assemble on both ends of the vDNA (Lesbats et al, 2016).  
Upon intasome formation, the first step of integration represents the 3’ end processing and 
removal of two nucleotides from both 3’ ends of the viral DNA. The resulting 3’ ends of the 
vDNA in all cases terminate with the conserved CA-3’ sequence. The second step of integration 
is the DNA strand transfer in which the “sticky” 3’ ends of the vDNA attack a pair of 
phosphodiester bonds on opposite strands across the major groove of the host target DNA. At this 
 
 





intermediate step, the 3’ends of the vDNA are covalently joined to the target DNA. The single 
strand gaps and the two-nucleotide overhang at the 5’ end of the vDNA have to be repaired by 
cellular enzymes in order to complete the integration process. The joining sites of the two target 
DNA strands in the case of HIV-1 IN activity are five base pairs apart, resulting in a five 
base-pair duplication (Brown et al, 1987; Bushman et al, 1990; Engelman et al, 1991) (Figure 
1.6).  
 
Viral replication, assembly, budding & maturation  
 
Upon successful integration, the viral genome can be actively transcribed and new infectious 
virions can be produced. During active transcription of HIV-1, the viral mRNA is transported out 
of the nucleus and viral proteins are translated in the cytoplasm. The produced viral proteins are 
involved in the process of virion assembly and budding from the host cell membrane.  
 
Virion assembly and release of HIV-1 virions are processes that occur predominantly at the 
plasma membrane of infected cells (Sundquist & Krausslich, 2012; Freed 2015). The building 
“blocks” of an HIV-1 virion are composed of two copies of the viral RNA genome, which are 
associated to cellular tRNALys,3 to prime later on cDNA synthesis, viral Env protein, the Gag 
polyprotein and the three major viral enzymes: IN, RT and PR.  The Gag polyprotein is the main 
mediator in the process of virion assembly, which means that it binds the host cell plasma 
membrane and mediates protein-protein interactions that promote virion assembly. Via its 
binding to the host cell plasma membrane, the Gag polyprotein affects the docking and 
concentration of Env proteins and the packaging of the viral genome via its RNA packaging 
sequence (Ψ) (Sundquist & Kräusslich, 2012).   
 
Even though the viral Gag polyprotein is the main actor in mediating virion assembly, in the 
process of virion budding the virus takes advantage of the host cell endosomal machinery, the so 
called endosomal sorting complex required for transport (ESCRT). The ESCRT pathway is to 
terminate Gag polymerization and catalyze virion release (Morita & Sundquist, 2004; Bieniasz, 





Maturation of the viral particle starts simultaneously with the budding process or right after 
budding. The main mediator in this process is the viral PR. PR cleaves off the Gag and 
Gag-Pro-Pol polyprotein in order to produce fully processed viral MA, CA, NC, p6, PR, RT and 
IN (Hill et al, 2005). During the process of maturation, the mentioned viral proteins undergo 
significant rearrangements in order to shape the mature and infectious viral particle (Figure 1.2.).  
 
I.IV. HIV-1 integration  
 
Viral DNA variants  
 
Successful integration of the viral genome into the host cell genome is a prerequisite for  
productive HIV-1 infection. However, the viral cDNA can also persist as non-integrated viral 
DNA, which is ubiquitously formed in infected cells (Hamid et al, 2017).  
Non-integrated vDNA can be represented in the form of 2LTR or 1LTR circles (2 or 1 Long 
Terminal Repeat circles). Most 2LTR circles are formed due to the process of autointegration - 
meaning that the viral DNA integrates into itself creating modified forms of double-stranded 
DNA circles (Lee & Craigie, 1994). A minor fraction of 2LTRs is created in the process of the 
end-joining reaction of linear viral DNA, whereas 1LTR circles have been shown to represent a 
product of recombination between the 5’ and 3’ LTR of the vDNA (Farnet & Haseltine, 1991), 
but can also be formed due to aberrant reverse transcription by strand displacement failure (Hu & 
Hughes, 2012). Non-integrated forms of vDNA do not support viral replication and represent a 
dead-end of the viral life cycle (Farnet & Haseltine, 1991).  
Certain cellular factors contribute to the formation of non-integrated vDNA forms. Cellular 
nucleases as RAD50, MRE11 and NBS1 have been shown to be involved in the formation of 
1LTR circles (Sloan & Wainberg, 2011). The inactivation of factors of the DNA repair 
machinery as Ku70/80, ligase IV and XRCC4 causes an impairment of 2LTR circle formation 
indicating their importance in the circularization reaction necessary for the creation of those 
non-integrated viral DNA forms (Li et al, 2001; Jeanson et al, 2002). In addition, 2LTR circles 
can be formed as a result of cellular DNA repair mechanisms activated due to foreign DNA 
sensing (Shoemaker, et al 1980). Interestingly, a host cell protein, BAF, involved in the process 





The persistence of non-integrated DNA forms of HIV-1 in infected cells is debated and different 
studies demonstrate opposing results in that regard (Butler et al, 2002; Sharkey et al, 2005; 
Murray et al, 2012; Pace et al, 2013). However, an observed rapid drop of 2LTRs in T cells is 
possibly a consequence of cell division and not direct degradation of 2LTR circles (Stein et al, 
2016). In contrast, macrophages, as non-dividing cells, represent a certain reservoir of 2LTR 
circles where persistent levels of 2LTR circles have been detected up to 21 days after infection 
(Gillim-Ross et al, 2005).  
Non-integrated vDNA forms are usually studied as a marker for nuclear import (Bushman, 2003; 
Hamid et al, 2016), as well as a marker for on going viral replication in patients on combined 
Antiretroviral Therapy (cART) (Pace et al, 2013). In a functional context, non-integrated forms 
of vDNA represent a dead end of viral replication.  
 
Factors involved in HIV-1 integration 
 
The entire  host genome is in theory available for HIV-1 integration. However, certain genomic 
features seem to be preferred for integration in comparison to others. Integration site selection of 
retroviruses does not seem to depend on the underlying sequences of the host genome, but it is 
also not a random process (Mitchell et al, 2004). Sites targeted by HIV-1 for integration are 
frequently actively transcribed genomic regions (Schröder et al, 2002; Ikeda et al, 2007; Brady et 
al, 2009; Maldarelli et al, 2014; Wagner et al, 2014) associated to marks of active transcription as 
histone H3/H4 acetylation (Wang et al, 2007; Marini et al, Lucic et al, 2019). Regions targeted by 
HIV-1 for integration are mainly composed of nucleosomal DNA (Pruss et al, 1994), contain 
repetitive genomic elements (Stevens & Griffith, 1994), and are mainly in introns of transcribed 
genes (Cohn et al, 2015).  
In the context of structured elements of the genome, HIV-1 integration sites were shown to be 
outside of centromeric regions (Carteau et al, 1998) and lamina associated domains (LADs) 
(Guelen et al, 2008; Marini et al, 2015; Achuthan et al, 2018), and in line with that, away from 
repressive chromatin marks as H3K27me3 or DNA CpG methylation (Wang et al, 2007). 
In addition, HIV-1 integration site selection seems to be affected by the organization of the 




regions (Han et al, 2004; Cohn et al, 2015), the virus also shows integration preference for genes 
harboring marks of structured elements as enhancers (Wang et al, 2007; Chen et al, 2017b). 
Spatially, HIV-1 preferentially occupies the outer shell of the host cell nucleus where it binds 
elements of the nuclear pore complex (Marini et al, 2015). In contrast, a recent study 
demonstrated that CPSF6 acts as the main nuclear viral trafficking factor, leading the virus 
towards gene rich regions away from the nuclear periphery. In addition, the loss of CPSF6 caused 
viral integration into lamina associated domains (LADs) (Achuthan et al, 2018). However, this 
study was performed in HEK293T cells (Human Embryonic Kidney cell line), which are not 
primary targets of HIV-1. The HIV-1 integration site dataset used in this study (Sowd et al, 
2016), generated from HEK293Tcells, was cross-compared with DamID (DNA adenine 
methyltransferase identification) data (Meuleman et al, 2013), generated from human embryonic 
stem cell line SHEF2, in order to show the lack of association of viral integration sites with the 
NPC. In addition, in order to underlie the deterministic role of CPSF6 in nuclear positioning of 
the virus, CPSF6, LEDGF7p72 knockout (KO) cells, as well as double knockout cells of 
HEK293T and CD4+ T cells were included into the integration site and FISH/imaging analysis. 
The results showed that integration sites retrieved from KO cells represent mainly cell type 
specific genes, and the FISH results demonstrated that the majority of those genes indeed have a 
perinuclear position (Achuthan et al, 2018). Accordingly, cell activation status as well as cell type 
specificity seem to be important factors that need to be taken into account in the context of HIV-1 
integration. Those factors can significantly affect the viral life cycle, but also the fate of the host 
cell (Churchil et al, 2006; Liu et al, 2008; Le Douce et al, 2010). In the next section the most 





HIV-1 integrase (IN) is a protein containing 288 amino acids (32 kDa) which is encoded by the 
end of the viral pol gene. It is synthesized as a part of the Gag-Pol polypeptide precursor by viral 
protease-mediated cleavage.  
The enzyme contains three independent functional domains; (1) the N-terminal domain (NTD) 




(Zheng et al, 1996). This domain possibly favors protein multimerization which is a key step in 
viral integration (Zheng et al, 1996; Lee et al, 1997).  
(2) The central domain or the catalytic domain (CCD) of the enzyme contains a D, D-35, E motif 
which is necessary for the catalytic activity and represents a domain which is highly conserved 
between retroviral IN enzymes and transposases. The CCD is essential in vDNA binding 
(residues Q148, K156 and K159) (Engelman et al, 1993; Jenkins et al, 1997; Heuer & Brown, 
1997; Drake et al, 1998; Esposito & Craigie, 1998; Johnson et al, 2006). Structurally the CCD 
shows an RNase H folding pattern. The RNase H-like fold was shown to be one of the 
evolutionary oldest protein folds (Ma et al, 2008). The Ribonuclease H-like (RNHL) superfamily 
members (called also the retroviral integrase superfamily) share the position of active site 
residues, which typically include aspartic acid, glutamic acid and in some cases histidine (Yang 
et al, 1990; Majorek et al, 2014), which is also the case for HIV-1 IN, where the CCDs active site 
is composed of Asp64, Asp116 and Glu152. The active site contains a conserved spacing of 35 
amino acids between Asp116 and Glu152 (D,D(35)E motif). During the integration process the 
CCD interacts with the vDNA and the target DNA. Mutations in the D,D(35)E motif cause 
inhibition of IN activity (Kulkosky et al, 1992; Leavitt et al, 1993). Importantly, all IN activities 
require the presence of a metallic cation cofactor which is coordinated by two residues of the 
catalytic triad (D64 and D116) (Goldgur et al, 1998; Maignan et al, 1998).  
(3) The C-terminal domain (CTD) binds non-specifically to DNA and is mainly involved in 
stabilizing the complex of IN and the DNA. Residues 220-270 are responsible for the DNA 
binding function. The CTD contains three lysine residues, in particular, lysine residues at position 
264, 266 and 273, which can be acetylated. These post-translational modifications regulate IN 
strand transfer activity and viral integration (Cereseto et al, 2005; Lusic & Siliciano, 2017). It has 
also been demonstrated that the same three lysine residues (K264, K266 and K273), have RNA 
binding properties and when mutated cause the production of non-infectious viral particles (Kessl 
et al, 2016).  
 
The function of IN is crucial in the process of HIV-1 integration. However, the enzyme itself is 
only functional in its multimeric form (van Gent et al, 1993; van den Ent et al, 1999), structurally 




shown to be very important in the process of IN multimerization, but also in facilitating the Mg2+ 
ion-dependent catalytic activity of the viral enzyme (Lee et al, 1997). 
Integration starts upon intasome formation in which IN stably binds both ends of the vDNA 
(Lesbats et al, 2016). Also, apart from the crucial presence of Mg2+ ions for the catalytic function 
of IN, they have been shown to have an important role in intasome stabilization (Miri et al, 2014; 
Engelman & Cherepanov, 2014).  
 
Other factors involved in HIV-1 integration 
 
Apart from IN other viral and host cell factors are involved in enabling the integration process of 
HIV-1.  
 
Viral factors  
 
Most of the viral proteins which are known to participate in the integration process are involved 
in the nuclear entry of the PIC. Among these proteins are CA, MA, Vpr and the central 




The HIV-1 CA is involved in early viral post entry events and participates in PIC moving all the 
way to the nucleus of the infected cell, while viral uncoating is taking place (Campbell & Hope, 
2015). During that process, several proteins interact with CA, and very likely, affect the 
navigation process towards the nucleus (Di Nunzio et al, 2012; Hilditch & Towers, 2014; Chin et 
al, 2015).  
The CA protein has an important role in the PIC nuclear entry, especially in non-dividing cells as 
macrophages (Yamashita & Emerman, 2004). Via its interaction with other cellular factors, CA 
was shown to affect HIV-1 integration profiles in infected cells (Schaller et al, 2011; Koh et al, 
2013; Sowd et al, 2016).  
Cyclophilin A (CypA) is a prominent example of a protein that via its direct interaction with CA 




effects of Cyp-CA interactions seem to be cell type dependent (De laco & Luban, 2014). The 
knockout of CypA impairs HIV-1 infectivity in Jurkat cells, whereas viral infectivity is not 
affected in other cell types (Braaten & Luban, 2001). CypA can also have a stabilizing effect on 
the viral CA core by binding to it and thereby causing a delay in the uncoating process, but it can 
at the same time have a destabilizing effect too (Li et al, 2009; Shah et al, 2013; De laco & 
Luban, 2014). What kind of effect Cyp-CA interactions may have in the context of CA core 
stabilization seem to be regulated by dose-dependent presence of CypA (Li et al, 2009; Liu et al, 
2016). 
A colocalization between CA and CPSF6 (host cell factor involved in RNA binding and 
processing) has also  been demonstrated in the cytoplasm (Peng et al, 2014). In addition, the 
depletion of CPSF6 causes a decrease in viral infectivity (Lee et al, 2010; Sowd et al, 2016), a 
reduction in vDNA and CA localization in the nucleus (Chin et al, 2015), as well as decreased 
viral integration (Sowd et al, 2016). 
Moving from the cytoplasm closer to the nucleus, it was shown that CA directly interacts with 
NUP358, a component of the NPC, via the NUPs cyclophilin homology domain (CHD) (Schaller 
et al, 2011; Di Nunzio et al, 2012). CA does not contain a nuclear localization signal (NLS) and 
might localize to the nucleus by its interaction with NUP358 on the outer side of NPC (Lee et al, 
2010; Schaller et al, 2011). In addition, in the context of nuclear entry, it has been demonstrated 
that CA directly binds another protein of the nuclear pore complex - NUP153 (Matreyek et al, 
2013). According to demonstrated interactions of CA and nuclear pore complex proteins, as well 
as the fact that the HIV-1 integration process has to occur rapidly after nuclear entry and that it 
occurs in the outer shell of the nucleus  (Di Primo et al, 2013; Marini et al, 2015), it is evident 
that HIV-1 integration is also, in part, regulated by CA and proteins interacting with CA 
(Matreyek & Engelman, 2013).   
Further on, it has recently been shown that CA stays associated to nuclear PICs in primary 
macrophages and its presence also affects viral infectivity (Peng et al, 2014; Bejarano et al, 
2019). Mentioned findings indicate that CA is not only playing a role in the docking of PICs to 
the nuclear envelope and NPC, but also exerts functions inside the nucleus. In line with that are 
recent findings showing that CFSF6 via its interaction with CA functions as the main regulator of 




2016), but also moving it away from heterochromatic regions at the nuclear periphery and more 




The MA protein was shown to be implicated in the nuclear import of HIV-1 cDNA, given the 
fact that it contains two nuclear localization signals (NLSs) (Burinsky et al, 1993; Nadler et al, 
1997; Hearps & Jans, 2007). However, the role of MA in the nuclear import does not seem to be 
crucial since it was shown that HIV-1 can still infect macrophages even without having a 




Vpr is a small virion-associated, nucleocytoplasmic shuttling regulatory protein, which is best 
known for its function of arresting the cell cycle in G2 phase that is completed by the induction 
of apoptosis (Rogel et al, 1995). The cause of cell cycle arrest activates the host cell DNA repair 
machinery, which plays an important role in completing the integration process (Votteler & 
Schubert, 2008; Yan et al, 2019). It is still under debate how Vpr can induce apoptosis, but it has 
also been demonstrated that uninfected bystander cells can be targeted by Vpr (Cummins & 
Badley, 2010; Abbas, 2013).  
Vpr was one of the first viral proteins that were shown to be associated in the docking process of 
the PIC to the NPC and binding to NUPs (Popov et al, 1998; Fouchier et al, 1998; Lusic & 
Siliciano, 2017). 
 
Host cell factors 
 
LEDGF/p75 (lens epithelium-derived growth factor) 
 
LEDGF/p75 is probably the most important host cell factor involved in HIV-1 integration. 
LEDGF/p75 was first identified as a transcriptional mediator protein that promotes 




of different studies LEDGF/p75 was identified as a cellular protein that tightly binds HIV-1 IN 
(Cherepanov et al, 2003; Turlure et al, 2004; Emiliani et al, 2005).  
 
LEDGF/p75 is ubiquitously expressed by the PSIP1 gene and represents a protein containing 530 
amino acids (Ge et al, 1998a). Apart from LEDGF/p75, cells also express a shorter splice variant 
- LEDGF/p52. Both proteins share the first 532 amino acids of the N-terminus, but contain 
unique C-terminal ends (Ge et al, 1998a; Ge et al, 1998b). Only the longer LEDGF/p75 form was 
found to directly interact with HIV-1 IN (Cherepanov et al, 2003; Cherepanov et al, 2005), via its 
IN-binding domain located at the C-terminus of the protein, which is missing in the shorter p52 
variant (Cherepanov et al, 2005; Busschots et al, 2007).  
 
In a series of studies it was also demonstrated that the interaction between LEDGF/p75 and IN is 
important for the nuclear localization of IN (Cherepanov et al, 2003; Maertens et al, 2003; Llano 
et al, 2004a). In addition, IN mutants, designed to be unable to bind to LEDGF/p75, lose their 
ability to associate to chromatin (Emiliani et al, 2005). Imaging studies showed that LEDGF/p75 
can be bound to condensed chromosomes during mitosis. Accordingly, it has been demonstrated 
that in the presence of LEDGF/p75, HIV-1 IN could accumulate on chromatin too (Maertens et 
al, 2003; Craigie & Bushman, 2012). In line with this finding is the described ability of 
LEDGF/p75 to specifically read the histone modification H3K36me3 via its PWWP domain 
(Pradeepa et al, 2012; Eidahl et al, 2013), which gives strong indication that LEDGF/p75 is 
responsible for the tethering of IN to chromatin.  
In addition, LEDGF/p75 was shown to facilitate integration in gene bodies (Sowd et al, 2016), 
which are usually decorated with H3K36me3 - a mark of transcribed genomic regions associated 
with elongating RNA Pol2 (RNA Polymerase 2) (Venkatesh et al, 2012). LEDGF/p75 also, apart 
from its function of tethering IN to chromatin, protects IN from degradation and evidently affects 
HIV-1 integration profiles (Llano et al, 2004b; Poeschla, 2014).  
Structural analysis of LEDGF/p75 showed that the PWWP chromatin-binding domain is located 
at the N-terminus of the protein, together with an NLS, as well as two copies of an A/T hook 
domain which is involved in DNA binding.  





CPSF6 (Cleavage and polyadenylation specificity factor 6) 
 
CPSF6 is a member of the Pre-messenger RNA cleavage factor I complex and takes place in 
mRNA polyadenylation site determination (Rüegsegger et al, 1996). CPSF6 is predominantly 
localized in the nucleus where it interacts with HIV-1 CA (Lee et al, 2010; Fricke et al, 2013), 
but has also been shown to interact with CA in the cytoplasm (Peng et al, 2014). The protein is 
composed of the N-terminal domain, which is involved in RNA recognition, a proline-rich 
central domain, and a C-terminal domain rich in arginine and serine residues (S/R). The C-
terminal S/R-rich domain is involved in the binding of CA (Price et al, 2012). Apart from its 
interaction with HIV-1 CA it was shown that CPSF6 can be implicated in the nuclear import of 
the PIC (Lee et al, 2012; Bhattacharya et al, 2014; Rasheedi et al, 2016), and also seems to play a 
role in the targeting of HIV-1 integration sites (Achuthan et al, 2018). In addition, it has been 
shown that CPSF6 depletion decreases the nuclear localization of vDNA and CA (Chin et al, 
2015), and has a decreasing effect on viral integration (Sowd et al, 2016). Certain amino acid 
substitutions in the viral CA, as N74D and A77V, which are located in the CPSF6 RNA binding 
domain, have been identified having a decreasing effect on the interaction between virus and host 
cell (Lee et al, 2010; Saito et al, 2016).  
Although CPSF6 is not considered to be essential for viral integration, CPSF6-binding mutants of 
HIV-1, interestingly, seem to make the virus insensitive to the depletion of other cofactors, as 
TNPO3, NUP358 and NUP153, which are also involved in the process of nuclear entry and 




Cyclophilin A (Cyp A) is a product of the PPIA gene and represents a peptidyl-prolyl cis-trans 
isomerase, usually involved in the process of cis-trans isomerization of certain peptide bonds. 
The active site of Cyp A represents a hydrophobic pocket that binds  to proline-rich peptides. It 
was shown that Cyp A affects HIV-1 infection via its direct interaction with CA (Sokolskaja et 
al, 2004; Luban 2007). The effect of Cyp A on HIV-1 infection seems to be cell type specific (De 
laco & Luban, 2014), considering that it was shown that Cyp A depletion in Jurkat cells has a 




Saito et al, 2016). Interestingly, Cyp A can affect any post-entry step of the HIV-1 infection. It 
was shown to affect the viral uncoating process (Li et al, 2009; De laco & Luban, 2014), the 
efficiency of the RT process (De laco & Luban, 2014), the interaction and utilization of other 
factors involved in the nuclear entry of the PIC, and to affect integration site selection of the virus 
(Schaller et al, 2011; Yamashita & Engelman, 2017).  
 
Other host cell factors participating in HIV-1 integration were identified in studies in which the 
technology of short-interfering RNA (siRNA) was applied. In such screens proteins involved in 
the nuclear import as NUP153, RANBPs, TNPO3 and RGPD8 were identified to be associated 
with the trafficking of HIV-1 (Varadarajan et al, 2005; Brass et al, 2008; Konig et al, 2008; 
Luban 2008; Christ et al, 2008).  
 
RANBP2 (RAN binding protein 2) or NUP358 
 
RANBP2 (or NUP358) is a protein located at the outer part of the NPC and has the capacity to 
bind RAN, which is a small GTP-binding protein involved in nuclear trafficking. RANBP2 is 
enriched in FG repeats, contains a cyclophilin-related nucleoporin and a domain that binds UBC9 
important for SUMO1 transfer. It has been demonstrated that HIV-1 CA can directly bind to this 




NUP153 is a nucleoporin of the inner nuclear basket showed to be involved in the PIC import via 
its interaction with CA (Di Nunzio et al, 2013; Matreyek, 2013), as well as in the export of 
HIV-1 Rev protein (Zolotukhin, 1999). It was also demonstrated that NUP153 can affect HIV-1 
integration site distribution (Koh et al, 2013) and to bind directly the integrated viral genome 










TNPO3 was shown to be involved in the PIC import into the nucleus (Brass et al, 2008; Konig et 
al, 2008; Christ et al, 2008).   
 
RGPD8 (RANBP2-like and GRIP domain containing 8) 
 
RGPD8 is shown to accumulate at the NPC and is believed to assist in RNA and protein transport 
(Bushman et al, 2009) 
 
Other host cell factors 
 
Other proteins involved in HIV-1 integration that were mainly identified in siRNA screens were 
described as members of the cell microtubule system. Among them are MAP4 (a 
microtubule-associated protein), MID1IP1 (a regulator of microtubule organization) and CAV2 
(involved in plasma membrane invaginations) (Bushman et al, 2008). Accordingly, other studies 
suggest that HIV particles may traffic along microtubules to reach the nucleus (McDonald et al, 
2002). Also, in a yeast two-hybrid system, other members of the microtubule machinery, 
MAP1A and MAP1S have been identified to bind HIV-1 CA cores in vitro, colocalize with the 
virus, and when depleted, cause impaired infection as a result of impaired CA trafficking  
(Fernandez et al, 2015).  
It has also been shown that Dynein is involved in the movement of the virus along microtubules 
and that its depletion causes an accumulation of viral particles in the periphery of the cell 
(McDonald et al, 2002; Arhel et al, 2006). In addition, Dynein was demonstrated to take function 
in viral uncoating too (Lukic et al, 2014; Pawlica et al, 2014).  
Finally, Kinesins, as another group of proteins associated to the microtubule machinery, have 
been demonstrated to be involved in the process of HIV-1 infection. They have been shown to 








 I.V. Cells targeted for HIV-1 infection 
 
It has been reported that HIV-1 has the capability to infect a wide range of different cell types in 
vitro. For instance, it was demonstrated that cells from organs as the liver, lungs, salivary glands, 
eyes, prostate, testicles and adrenal glands could be infected. However, the only cell types that 
are in vivo regularly detected to be infected by HIV-1 are cells of the lymphoid and myeloid cell 
lineage, and among them, predominantly CD4+ T lymphocytes and macrophages (Telesnitsky & 
Goff, 1997). 
 
HIV-1 infection of CD4+ T cells and macrophages  
 
A critical point in the HIV-1 life cycle is the viral entry. It was shown that viral entry is not only 
dependent on the expression of the primary CD4 receptor on the cell surface, but also on 
expression of co-receptors as CCR5 or CXCR4, which are differentially expressed on CD4+ T 
cells (Grivel et al, 2000; Doms, 2001). CXCR5 is highly expressed on the vast majority of 
peripheral T cells, whereas CCR5 is not expressed by all CD4+ T cells. Its expression is 
upregulated as part of the late differentiation of effector and effector memory T cells (Veazey et 
al, 2000; Poles et al, 2001; Okoye & Picker, 2013). Still, CD4+ T helper cells represent major 
target cells for HIV-1 in the blood, since they can express high levels of the CD4 receptor and are 
highly permissive for HIV-1 production (Maddon et al, 1986; Lifson et al, 1986).  
Other immune cells also express CD4 and HIV-1 co-receptors and serve as viral targets too. 
Among these cells macrophages were described to carry markers of productive HIV-1 infection 
in vivo (Koenig et al, 1986), even though they express low levels of the CD4 receptor. 
Macrophages are infected by CCR5 tropic HIV-1 (R5 viruses – using CCR5 as co-receptor 
during infection). Together with dendritic cells and CD4+ T memory cells macrophages are the 
first immune cells facing the virus in the mucosa (Shen et al, 2011). A significant portion of 
macrophages is directly productively infected in the mucosa with HIV-1 (Shen et al, 2009). In 
addition, macrophages secrete cytokines that attract and recruit T lymphocytes to sites of 
infection. They can even facilitate viral infection by enlarging the number of viral target cells at 




Further on, macrophages are more resistant to viral cytopathic effects than activated CD4+ T cells 
(Perelson et al, 1996; Reynoso et al, 2012), and in particular long-lived macrophages may harbor 
the virus for longer periods, which represents a major obstacle for virus eradication 
(Koppensteiner et al, 2012).  
In summary, apart from CD4+ T cells which represent the main targets for HIV-1 infection, 
macrophages represent long-term reservoirs of the virus and can help to establish viral infection 
at viral entry sites.  
 
The importance of activation and chromatin status in primary CD4+ T cells in HIV-1 infection 
 
In the context of HIV-1 infection in primary CD4+ T cells it is notable that HIV-1 preferentially 
infects and replicates in activated CD4+ T cells (Margolick et al, 1987).  
Although integrated HIV-1 DNA can be detected in resting CD4+ T cells from infected 
individuals (Chun et al, 1995: Chun et al, 1997), it is still unclear how these cells are infected. 
According to one hypothesis, HIV-1 can directly infect resting CD4+ T cells (Brady et al, 2009; 
Pace et al, 2012). The prevailing view is that resting CD4+ T cells with integrated HIV-1 DNA 
are derived from activated infected CD4+ T that  reverted back to a resting memory state (Han et 
al, 2014; Sengupta & Siliciano, 2018).  
Activated CD4+ T cells are highly permissive for HIV-1 infection, but resting cells seem to resist 
infection. Blocks to infection in resting cells occur at different post-entry steps of the viral life 
cycle (Doitsch et al, 2010).  
Widely accepted is that a deoxynucleoside triphosphate triphosphohydrolase (SAMHD1 – SAM 
domain and HD domain-containing protein), which is expressed in resting CD4+ T cells, dendritic 
cells, monocytes and macrophages, but not in T cell lines, prevents the reverse transcription of 
HIV-1 RNA in resting CD4+ T cells and macrophages by limiting the access of free dNTPs 
(Goldstone et al, 2011; Powell et al, 2011). By exposing this function, SAMHD1 represents a 
major HIV-1 restriction factor in resting CD4+ T cells (Baldauf et al, 2012; Descours et al, 2012), 
and acts as a lineage-specific infection barrier for HIV-1 (Hrecka et al, 2011; Laguette et al, 
2011).   
The activation of CD4+ T cells occurs through simultaneous engagement of the T-cell receptor 




complex (MHCII) peptide and co-stimulatory molecules on the surface of an antigen presenting 
cell (APC). 
One of the most important co-stimulatory 
molecules on the surface of an APC is the B7 
protein (Figure 1.7.). The interplay of these two 
activation signals (coming from the MHC and B7) 
determines the outcome of a T cell’s response to an 
antigen (Sharma et al, 2011).  
 
Activation of CD4+ T cells causes major changes in 
cell function, gene expression, metabolism as well 
as changes in chromatin organization. It has been shown that CD4+ T cells upon activation 
undergo a global increase in chromatin accessibility, showing higher amounts of open chromatin 
features such as increased acetylation of lysine 27 of histone 3 (H3K27Ac), as compared to 
resting cells (Gate et al, 2018).  
Target cell chromatin organization plays an important role in HIV-1 integration site selection as 
well as viral fate, especially regarding replication and virion assembly (Lusic & Siliciano, 2017). 
Chromatin composition as well as its importance and effects on HIV-1 life cycle will be 
discussed further on.   
 
I.VI. HIV-1 integration site selection  
 
As previously briefly mentioned in the chapter of HIV-1 integration, the integration of HIV-1 
vDNA can hypothetically occur throughout the host cell genome, but it has been  demonstrated 
that integration is rather a non-random process (Mitchell et al, 2004; Bushman et al, 2005).  
Certain genomic factors affect the process of integration site selection among which the target 
DNA sequence plays a specified role, its chromatin composition, as well as their interplay with 





Figure 1.7. Schematic overview of the T cell 




Genomic regions targeted for HIV-1 integration 
 
On a global sequence specific level, HIV-1 integration sites show features of DNase I 
hypersensitivity (Verdin, 1991), they are enriched in genic and GpC island rich regions and show 
high G/C skew (Brady et al, 2009).  
Even though there is considerable variation among various retroviruses, each of them displays 
certain weak consensus sequence preferences. These consensus sequences extend at least over 20 
nucleotides, which can be determined by aligning large numbers of integration sites (Figure 1.8.). 
Although the consensus sequence is palindromic, reflecting the average of all integration sites in 
both directions, individual integration sites are not necessarily symmetric. Since retroviruses have 
a high mutation rate, it is plausible that mutations in IN, which alter its interaction with the host 
DNA, can also alter the preferred sequence where the vDNA is integrated (Demeulemeester et al, 
2014; Serrao et al, 2014; Hughes & Coffin, 2016). However, the consensus sequences for viral 
integration are always palindromic.  
 
Figure 1.8. Consensus motif of HIV-1 integration site. 
A 30 bp sequence consensus motif for HIV-1 integration. The preferred site of integration is marked with the 
dotted line. The sequence was generated by analyzing and comparing 100 bp around viral integration sites by 
MEME algorithm (Bailey & Elkan, 1994) (adapted from: Cohn et al, 2015).  
 
About 80% of HIV integration events are in genes. For both HIV and MLV, integration site 
preferences reflect, at least in part, the chromatin distribution of host factors to which the 
respective INs bind (LEDGF/p75 and BET proteins). In the absence of LEDGF/p75, the 
efficiency of HIV integration is reduced (Llano et al, 2006; Engelman & Cherepanov, 2008), as 
well as its preference for integrating into actively expressed genes, although integration is not 




of HIV-1 and MLV, that the PICs interact with other host factors which affects integration site 
selection (as previously described). 
 
DNA sequence specificity 
 
In several independent studies which included the analysis of different cell lines, it was shown 
that HIV-1 preferentially integrates into gene rich regions, close to Alu elements, distant from 
gene transcription start sites (TSS) and rather into intronic than exonic regions of genes (Stevens 
& Griffith, 1994; Schroder et al, 2002; Lewinski et al, 2006; Barr et al, 2006; Singh et al, 2015). 
This preference was confirmed in vivo in resting CD4+ T cells from infected patience 
(Demeulemeester et al, 2015) as well as by viral outgrowth assays performed from patients under 
retroviral therapy (Cohn et al, 2015). In addition, it was shown that HIV-1 in different cell types 
recurrently integrates in the same set of highly expressed genes which are not randomly 
distributed in the genome, but are rather positioned in clusters on targeted chromosomes. These 
genes were assigned as recurrent integration genes (RIGs) (Marini et al, 2015; Lucic et al, 2019). 
These genes are included in different lists of HIV-1 integration sites derived from either in vitro 
experiments or from patient material. One of these genes is BACH2 (Basic Leucine Zipper 
Transcription Factor 2). In a study of HIV-1 integration sites derived from patient data it was 
shown that this gene contained even 15 independent HIV-1 integration events in intron 4 
(Maldareli et al, 2014). Some other interesting RIGs are STAT5B (Signal Transducer And 
Activator Of Transcription 5B) and MKL2 (MKL1/Myocardin Like 2) which are, as well, 
frequently appearing on different HIV-1 integration site lists (Sherrill-Mix et al, 2013; Maldarelli 
et al, 2014; Wagner et al, 2014; Cohn et al, 2015). An interesting fact is that all of the three 
mentioned genes encode proteins which are cellular growth factors or mediate the process of 
DNA transcription, and are directly or indirectly included in the cell cycle. Some studies suggest 
that HIV-1 integration into certain genes may lead to clonal expansion and contribute to the 
persistence of HIV-1 infected cells (Maldarelli et al, 2014; Cohn et al, 2015; Laskey et al, 2016). 
In line with this observation is the finding that HIV-1 integrations are frequently occurring in 
cancer-associated genes and can be found in the same patient at the same genomic spot in 
multiple cells that harbor the provirus. In the group of “cancer-associated genes” CREBBP, 




genes are all involved in processes as cell growth, proliferation and mitosis (Rezaei & Cameron, 
2015).  
Considering that HIV-1 integrations are frequently found in those genes, it may be possible that 
certain genomic regions are preferred for viral integration over others. It has also been 
demonstrated that in CD4+T cells HIV-1 integration genes are distributed in clusters over the 
human genome and may also move together in clusters during cellular activation (Marini et al, 
2015; Lucic et al, 2019).    
The analysis of HIV-1 patient samples revealed that BACH2 and MKL2 had a very peculiar 
pattern of viral integration. Upon prolonged cART exposure, integrated viral DNA could only be 
detected upstream of the transcription start site in intron 5 of BACH2, and intron 4 or 6 of 
MKL2. In addition, the analyzed proviral integration sites had the same transcriptional 
orientation as the host target gene, and again confirmed HIV-1 integration close to Alu genomic 
elements (Maldarelli et al, 2014; Cohn et al, 2015). 
In a strictly host sequence specific context, apart from detecting HIV-1 integrations in active 
transcription units (Mitchell et al, 2004; Wang et al, 2007), it was demonstrated that viral 
integrations seem to be favored in GC genomic regions which overlap with regions of high gene 
density (Craigie & Bushman, 2012; Goncalves et al, 2016). HIV-1 integrations are also 
frequently found at sites showing DNaseI hypersensitivity and distribution of CpG islands over 
longer genomic stretches (Brady et al, 2009). It was also shown that HIV-1 integration frequently 
occurs at DNA sections that wrap around nucleosomes (Pruss et al, 1994; Wang et al, 2007). 
DNA that wraps around nucleosomes was shown to be enriched in AT repeating motifs (Segal et 
al, 2006). This finding is in contrast to the observed preference of the virus to integrate into GC 
rich genomic sites (Brady et al, 2009). However, the viral preference for integration into 
nucleosomal DNA is still in correlation with integration site data from CD4+ T cells that show 
that when longer stretches of DNA (up to 10 Mb) are analyzed for HIV-1 integration sites, the 
overall integration is favored at GC rich genomic sites. Although the observed trend is less 
obvious when shorter genomic intervals (shorter than 2 kb) are analyzed (Brady et al, 2009). 
Apart from the host cell DNA sequence features, chromatin marks as well as genome 
organization significantly impact the distribution of viral integration sites (Wang et al, 2007; 





General chromatin features of HIV-1 integration sites 
 
Chromatin is an important determinant of  HIV-1 integration site selection. HIV-1 preferentially 
targets regions of open chromatin, as it has been shown that the viral PIC selectively targets open 
chromatin regions (Albanese et al, 2008). Upon integration  into regions of open active chromatin 
(euchromatin) the provirus can be actively transcribed, whereas integration into condensed 
inactive chromatin regions (heterochromatin) would result in transcriptionally inactive proviruses 
(Maldarelli et al, 2014; Cohn et al, 2015; Laskey et al, 2016; Lusic & Siliciano, 2017). 
Several studies showed a link between certain chromatin features and the frequency of HIV-1 
integration sites (Ikeda et al, 2007; Wang, 2007; Marini et al, 2015). For example, it was shown 
that H3K9 acetylation (a mark of transcriptionally active genes) and trimethylated H3Lys36 
(H3K36me3 – a mark associated with the elongating RNA Pol2 regions and actively transcribed 
genes) are related to frequently targeted HIV-1 integration sites (Marini et al, 2015), which is in 
line with the finding that LEDGF/p75, as the main IN binding partner, can specifically read the 
H3K36me3 chromatin mark via its PWWP domain (Pradeepa et al, 2012; Eidahl et al, 2013). In 
addition, HIV-1 integrations are frequently found in regions of open-accessible chromatin 
harboring marks as H3/H4 acetylation, but away from repressive chromatin marks as H3K27me3 
or DNA CpG methylation (Wang et al, 2007; Goncalves et al, 2016).  
 
I.VII. Chromatin organization and nuclear architecture  
 
The nucleus is a highly dynamic and structured environment. The functional organization of the 
genome can be described in a hierarchical fashion, where the interplay of spatial and temporal 
factors act together to enable major nuclear functions (Misteli, 2007). The genomic DNA is 
compacted and organized into functional domains by the activity of several protein complexes 
and distinct DNA-binding inter-players inside of the nuclear space. The nucleus is separated from 
the cytoplasm by the nuclear envelope, which does not function only as a physical barrier, but 
significantly contributes to genome organization and regulation (Buchwalter et al, 2019). The 
nuclear envelope is perforated with nuclear pore complexes, which enable the communication 
between the inner nuclear space and the cytosol, while at the same time impacting genome 




2010). The next section describes chromatin structure starting from the histone modifications, 
and then moving towards higher order genomic structures which  shape the nuclear architecture, 




The DNA fiber is compacted by histone proteins, and this DNA-histone complex is defined as 
chromatin. Chromatin is further compacted into chromosomes and the mitotic chromosome 
represents the final level of DNA compaction. 
The basic repeating structural and functional unit of chromatin is the nucleosome, which contains 
eight histone proteins and about 146 pairs of (bp) DNA (Van Holde, 1988; Wolfe, 1999). 
Histones are a family of small, positively charged proteins termed H1, H2A, H2B, H3 and H4 
(Van Holde, 1988). Pairs of histone proteins H2A, H2B, H3 and H4 form an octamer of histones 
to compose the nucleosome core.  
Histone H1 is holding the 
nucleosome core and the 
wrapped DNA around it (146 
bp), and additionally wraps 
another 20 bp long stretch of 
DNA around the histone 
octamer (Figure 1.9.). 
 
The compaction of DNA into 
nucleosomes has, generally, a 
repressive effect on gene expression. However, the positioning of nucleosomes at gene elements 
as promoters, has a significant impact on gene regulation in cells (Wolfe, 1999; Wyrick et al, 
1999). Nucleosomes are not rigid structures. In vitro they can be shifted and positioned in a way 
that enables the access of RNA Polymerase and the transcription of nucleosomal DNA 
(Meersseman et al, 1992; Studitsky et al, 1997). In vivo, chromatin remodeling elements are 
directly interacting with nucleosomes and affect their movement along the DNA, even without 
DNA release from the nucleosome core (Elgin & Workman, 2000; Tsukiyama 2002).  DNA 
 
Figure 1.9. Schematic representation of a histone octamer (adapted 




structure analysis in the nucleosome core revealed that the DNA structure in nucleosomes is 
significantly different when compared to “naked” DNA. Nucleosomal DNA was shown to have 
an unexpectedly high curvature, caused by the binding of histone proteins, which can affect the 
DNA sequence-dependent recognition of chromatin remodelers or transcription factors, as well as 
the movement of nucleosomes (Richmond & Davey, 2003).  
HIV-1 IN shows preference in binding to nucleosomal DNA (Pryciak & Varmus 1992), and the 
integrated viral genome has been shown to have precisely positioned nucleosomes on the LTRs  
(Verdin, 1991; Verdin et al, 1993; Van Lint et al, 1996). 
 
Apart from forming the chromatin fiber and compacting DNA, histones are important 
determinants in the process of gene expression, as they make the chromatin more or less 
accessible to transcription factors and other enzymes. Easier access for polymerases and other 
enzymes is either achieved by the displacement of histones upon the action of  chromatin 
remodeling complexes (Smith & Peterson, 2005), or by enzymatic modifications of histone 
amino acid residues (“histone tails”) (Figure 1.9) by the addition of phosphate, acetyl, methyl, 
crotonyl, ubiquitin or SUMO modifications, as well as modified by the activity of ADP-ribosyl 
transferases (Jason et al, 2002; Fischle et al, 2005; Gomez et al, 2006; Keppler & Archer, 2008).   
 
In the process of histone acetylation, which is performed by the enzymatic activity of histone 
acetyl transferases (HATs), an acetyl group is added to the ∑-amino group of histone lysine side 
residues. The acetyl group is negatively charged, and by its addition to positively charged histone 
lysine residues, a neutralization of the histon’s electric charge occurs, causing loosening of the 
tight association to the DNA (Bannister & Kouzarides, 2011). The opposite reaction, which is the 
removal of acetyl groups, is performed by histone deacetylases (HDACs) and causes compaction 
of the chromatin structure (Wang et al, 2009; Frank et al, 2016).  
In the context of HIV-1, it has been described that during an acute infection or reactivation from 
latency HATs as CBP, GCN5 or P/CAF are recruited to the proviral LTR (Marzio et al, 1998; 
Benkirane et al, 1998; Lusic et al, 2003; Turner & Margolis, 2017) and thereby influencing 
proviral transcription. In addition, it has also been demonstrated that HATs can affect Tat activity 
by its direct acetylation (Ott et al, 1999; Col et al, 2001). Marks of acetylated histones frequently 




H4K8ac, and H4K16ac (Benkirane et al, 1998; Lusic et al, 2003; Brady et al, 2009; Turner & 
Margolis, 2017).  
On the other hand, the importance of HDACs in the HIV-1 life cycle has been noticed when 
HDAC inhibitors were shown to reactivate the virus from latency (Shirkawa et al, 2013; Archin 
et al, 2014). In addition, HDAC1 was one of the first proteins demonstrated to bind to the 
proviral LTR in complex with other transcriptional repressors (Romerio et al, 1997; Coull et al, 
2000) and cause proviral silencing. Further work confirmed the binding of a variety of different 
proteins to the proviral LTR such as YY1, LSF, c-myc, Sp1 or NF-kB which cause the 
recruitment of HDACs and subsequent proviral silencing (Romerio et al, 1997; Coull et al, 2000; 
Williams et al, 2006; Jiang et al, 2007). Some HDAC inhibitors are currently even under clinical 
investigations as latency reversing agents (LRAs) (Turner & Margolis, 2017) .  
 
Histone methylation predominantly takes place at histone lysine and arginine residues. The 
addition of the methyl group, by histone methyltransferases (HMTs) and their active SET 
domain, does not cause any change in the charge of histone proteins. The position of the added 
methyl group, as well as the number of added methyl groups (-mono, -di or -tri-methylation) 
(Murray, 1964; Paik & Kim, 1967; Hempel et al, 1968) can have different outcomes in the 
context of chromatin compaction and accessibility. Depending on the context and potential of 
histone modifications a variety of multi-protein complexes are recruited to the chromatin, 
allowing for tightly regulated transcriptional control (Greer & Shi, 2012). The removal of methyl 
groups is performed by histone demethylases (HDMs). Different groups of enzymes regulate the 
demethylation of lysine (Forneris et al, 2005; Tsukada et al, 2006) and arginine residues 
(Cuthbert et al, 2004; Wang et al, 2004).  
H3K4me3 is a mark associated with active promoters and has been linked to both proviral 
activation and repression (Le Douce et al, 2012). H3K36me3 marks gene bodies of actively 
transcribed genes and is the mark most frequently associated with  HIV-1 integration sites (Brady 
et al, 2009), probably due  to the fact that host integration factor LEDGF/p75 specifically reads 
this chromatin mark (Pradeepa et al, 2012). Interestingly, recently it has been demonstrated that 
active genes which are frequently targeted for HIV-1 integration have a distinct distribution of 
H3K9me2 chromatin mark (Lucic et al, 2019), which is usually linked to facultative 




HIV-1 has first been described in microglia cells by investigating the activity of transcriptional 
repressor CTIP2. The study found that CTIP2 negatively affects HIV-1 transcription by the 
simultaneous recruitment of Tat and HP1- (Marban et al, 2005). HP1-  (heterochromatin 
protein 1-) binds methylated lysine residues and causes transcriptional repression (James and 
Elgin, 1986). One of the main H3K9 HMTs is SUV39. However, in the context of HIV-1 latency 
it has been demonstrated that the direct knockdown of another HMT; G9a, or its chemical 
inhibition by BIX01294 has a more increasing effect on viral transcription and is even synergized 
by the addition of HDAC inhibitor SAHA (Imai et al, 2010). Recent work demonstrated that the 
combination of H3K9me and H3K27me machineries can specifically affect the regulation of 
HIV-1 latency and force the virus to engage even in a deeper state of latency (Matsuda et al, 
2015).  
H3K27me2/me3 are chromatin marks are mainly decorating repressive chromatin regions which 
are linked to reduced genetic activity (Wang et al, 2008). H3K27me3 and the presence of its 
HMT EZH2 have been shown to be linked to HIV-1 latency (Friedman et al, 2011; Matsuda et al, 
2015). Different levels of H3K27me3 at the viral LTR have been demonstrated to affect the 
ability of TNF-  (a strong proinflammatory cytokine) to reactivate HIV-1 from latency 
(Friedman et al, 2011). In addition, EZH2 inhibitors in combination with HDAC inhibitor SAHA 
and the bromodomain inhibitor JQ1 have been demonstrated to have a more pronounced effect on 
reverting HIV-1 from latency (Tripathy et al, 2015), compared to the effects of single LRAs.  
 
When focusing on histone phosphorylation, it has been shown that this chromatin modification 
mainly affects serine, threonine and tyrosine residues (Xhemalce et al, 2011). The phosphate 
group is added from an ATP molecule to a hydroxyl group of a targeted amino acid of the histone 
tail by the enzymatic activity of kinases. The phosphate group is negatively charged and its 
addition to a histone tail has a significant impact on chromatin structure, mainly causing its 
compaction (Bannister & Kouzarides, 2011). The best known function of histone 
phosphorylation occurs during cellular response to DNA damage, when phosphorylated histone 
H2A(X) marks large chromatin domains around the site of DNA breakage (Rosseto et al, 2012). 
It has been demonstrated that retroviral integration causes a transient formation of 
phosphorylated histone H2A(X) regions at viral integration sites (Daniel et al, 2004). In addition, 




increase in phosphorylated histone H2A(X) sites was detected upon treatment with DNA damage 
response (DDR) inducing agents or cancer chemotherapies, compared to non-infected cells. The 
authors of the study propose a new marker and strategy to detect and eliminate latently infected 
cells (Piekna-Przybylska et al, 2017).  
 
Chromatin organization as well as the activity of chromatin modifying machineries significantly 
impact transcriptional control and, accordingly, many cellular processes. In line with that are 
results of several studies demonstrating that chromatin modifications and chromatin modifying 
enzymes impact HIV-1 transcription. Understanding the interplay between HIV-1 latency and its 
reversal, and the maintenance of normal host cell function could provide a more detailed insight 
and better understanding on general chromatin regulation, but also provide clues for a more 
targeted application of LRAs and a potential eradication of latent HIV-1 (Lusic & Siliciano, 
2017; Turner & Margolis, 2017).   
 
The 3D genome organization  
 
The composition of genomic DNA including AT/GC skew, gene density, distribution of 
repetitive elements or virus derived elements represents a linear perspective of genome 
organization (Bickmore & van Steensel, 2013). The first level of genome structuring represents 
the compaction of DNA together in a complex with histone proteins forming the nucleosome, 
which represents the elementary repetitive unit of chromatin (Van Holde, 1988; Wolfe, 1999). 
The further organization of chromatin, including the formation of chromatin loops, contacts, 
chromatin domains, chromosomes and chromosomal territories represent higher orders of 
genome organization (van Steensel et al, 2001; Cremer et al, 2006; Bickmore & van Steensel, 
2013).  
 
Chromosomes and chromosome territories 
 
Ever since the pioneering work on cell division, chromosomes have been proposed to reside in 
distinct chromosome territories (Rabl, 1885; Boveri, 1909). Nowadays it is established that 




2016). More recent studies, applying genome capturing techniques (C-techniques), provide 
evidence that a single chromosome represents a specialized individual territory in which genomic 
segments that are closer to each other  interact more with each other (cis-interactions), compared 
to genomic segments which are on the other arm of the same chromosome, or even on another 
chromosome (trans-interactions) (Lieberman-Aiden et al, 2009; Kalhor et al, 2012; Sexton et al, 
2012; Zhang et al, 2012; Bickmore & van Steensel, 2013). However, it has also been 
demonstrated that certain trans-interactions can be very robust. Such trans interacting sequences 
are usually located in regions of high gene density and transcriptional activity, and also show 
DNase I hypersensitivity (Simonis et al, 2006; Lieberman-Aiden et al, 2009; Hou et al, 2012; 
Kalhor et al, 2012; Sexton et al, 2012). It has also been shown that colocalization of genomic loci 
in trans can have effects on gene expression (Noordermeer et al, 2011), emphasizing the 





Series of recent studies provide evidence that single chromosomes are composed of distinct 
chromatin domains or topologically associated domains (TADs). TADs are comprised of long 
stretches of chromatin spreading over up to several million bases (Jackson and Pombo, 1998; Ma 
et al, 1998; Dixon et al, 2012; Nora et al, 2012; Sexton et al, 2012). TADs are defined as genomic 
compartments in which two genomic regions are observed to associate more frequently, 
compared to regions outside the TAD (Dixon et al, 2012; Nora et al, 2012; Sexton et al, 2012; 
Dixon et al, 2016). TADs have been demonstrated to remain stable during cell division and show 
high similarity among evolutionary related species. (Cremer & Cremer, 2010; Dekker & Heard, 
2015; Sexton & Cavalli, 2015). TADs frequently contain “sub-TADs” (Phillips-Cremins et al, 
2013; Rao et al, 2014), mainly composed of locally separated loops or insulated neighborhoods 
(Rao et al, 2014; Dowen et al, 2014; Ji et al, 2016). Sub-TADs usually represent features that can 
have a distinct organization in different cell types, depending on cell type specific functions 
(Phillips-Cremins et al, 2013; Dowen et al, 2014; Ji et al, 2016; Dixon et al, 2016). The 
organization of TADs significantly influences gene expression, DNA replication and 




chromatin domains and their effect on genome activity depends on the chromatin site which 
creates a domain (Boettiger et al, 2016). For instance, domains harboring polycomb proteins have 
a remarkably different organization compared to other chromatin domains. A hallmark of 
polycomb domains is the decoration of chromatin with H3K27me3 mark and the dense 
compaction of chromatin forming a mainly repressive chromatin environment (Morey & Helin, 
2010; Boettiger et al, 2016; Dixon et al, 2016). 
Also, chromatin marked with H3K9me2/me3 induces a special compartmentalization of the 
chromatin. H3K9me2 and H3K9me3 are frequently considered to be repressive marks, but many 
examples show their involvement in marking actively transcribed genes (Kwon & Workman, 
2001; Bickmore & van Steensel, 2013). Those, usually long stretches of DNA covered with 
H3K9me2 and H3K9me3 which cover up to 45% of the genome are also referred to as large 
organized chromatin domains - LOCKs (Wen et al, 2009; Hathaway et al, 2012).  
Beside the importance of certain chromatin stages and presence of histone modifications and 
protein complexes in TADs, the interaction between different types of TADs is an important 
element of genome organization. One of the most important proteins involved in the shaping of 
TAD interactions is the insulator protein CTCF, which is a zinc finger DNA binding protein 
(Phillips-Cremins & Corces, 2013; Ghirlando & Felsenfeld, 2016). In line with this is the finding 
that TAD borders of mammalian cells are significantly enriched in CTCF binding sites (Dixon et 
al, 2012). The binding of insulator proteins as CTCF is demonstrated to be a highly regulated 
process which finally affects the transcriptional activity of certain chromatin domains. For 
instance, the binding of isolator proteins to DNA can affect and regulate interactions between 
enhancers and gene promoters, as well as affect the genomic distribution of euchromatin and 
heterochromatin and thereby influence gene expression/repression (Phillips-Cremins & Corces, 
2013; Ghirlando & Felsenfeld, 2016; Dixon et al, 2016).  
 
The nuclear periphery and the nuclear pore complex  
 
The nuclear periphery is composed of the nuclear envelope (NE), the nuclear lamina (NL) and 
nuclear pore complex (NPC). Apart from these structural elements the underlying chromatin and 




Parts of the chromatin fiber which are occupying the tight space under the NL in the nuclear 
periphery are often organizing nuclear territories assigned as Lamina-associated domains 
(LADs). LADs are regions of condensed chromatin enriched in repressive chromatin marks as 
histone 3 lysine 9 dimethylation (H3K9me2), which is a mark of heterochromatin and silenced 
genes (Pombo & Dillon, 2015). Regions of open chromatin and actively transcribed genes are 
rather excluded from LADs.  
The NPC has been shown to associate with both silent and active chromatin domains, and can 
therefore represent an environment having an activating or repressing effect on gene expression 
(Raices & D’Angelo, 2017). First studies on the chromatin surrounding the NPCs showed an 
association of silent chromatin with the NPC (Brown et al, 2008; Jacinto et al, 2015). However, 
more recent studies showed that genes associated to the NPC can be either activated or silenced, 
and not exclusively repressed as previously thought  (Ibarra et al, 2016; Pascual-Garcia et al, 
2017; Toda et al, 2017; Raices et al, 2017). Considering that  NPCs can have activating or 
repressing effects on genes closely associated to them, as well as the fact that have the capacity of 
binding active and silent chromatin it becomes evident that those structures also have the 
potential to create and shape the nuclear landscape around them. The chromatin surrounding 
NPCs is mostly having and open and decondensed structure (Schermelleh et al, 2008; Lemaitre & 
Bickmore, 2015). It has also been demonstrated that super enhancers can cluster in their 
proximity (Ibarra et al, 2016) and that certain groups of genes need the association with nuclear 
pore proteins for their expression (Raices et al, 2017). In addition, the “gene-gating” hypothesis 
proposes an explanation in which compact chromatin associates with the nuclear lamina, while 
transcribed genes associate with the NPC, which would facilitate the nuclear export of RNA. 
Also, the non-random distribution of NPCs in the nuclear envelope reflects the non-random 
organization of chromatin in the nuclear periphery (Blobel, 1985; Ciabrelli & Cavalli, 2015; 
Lemaitre & Bickmore, 2015). Mentioned findings indicate that NPCs take an active role in 
shaping the chromatin in the nuclear periphery, and influence gene expression (D’Angelo, 2017).  
 
Lamina Associated Domains (LADs)  
 
The nuclear lamina (NL) represents a scaffold element of the nucleus, located in its periphery and 




Ulianov et al, 2019), DNA repair and nuclear assembly (Burke & Stewart, 2013; de Leeuw et al, 
2017). The NL is composed of lamin proteins which are organized into dense, net-like structures, 
and also interact with other lamin-binding proteins.  
The NL of mammalian cells is composed of 4 lamin isoforms; two type A lamins (lamin A and 
C), and two type B lamins (lamin B1 and B2). Type A lamins are encoded by the LMNA gene, 
whereas type B lamins are encoded by the LMNB2 gene (Krohne et al, 2005; de Leeuw et al, 
2017).  
 
Mammalian cell LADs are usually large and gene-poor domains spanning from 0.1 to 10 Mb, 
covering about 40 % of the genome in a cell population (Guelen et al, 2008; Peric-Hupkes et al, 
2010; Ciabrelli & Cavalli, 2015).  
LADs that are present in all so far analyzed cell types are defined as constitutive LADs, whereas 
LADs that differ between cell types or change their association to the NL depending on the cell 
cycle are known as facultative LADs (Dixon et al, 2016; Bonev & Cavalli, 2016; Lusic & 
Silliciano, 2017). Apart from having a role in shaping the nuclear architecture, LADs are 
important in gene expression determination. Genes located inside LADs were shown to have low 
transcriptional activity, lacking any active histone mark. In addition, single cell studies in 
mammalian cells showed that less than one third of LADs are located less than 1 µm from the NL 
at any time in the cell cycle, indicating a dynamic character of lamin tethering (Kind et al, 2013). 
In addition, certain gene promoters consistently found in LADs have certain mechanisms of 
avoiding the repressive effect of the LAD environment, whereas other types of LAD-associated 
promoters can be activated when moved away from the LAD (Leemans et al, 2019).  
The repressive nature of LADs is evolutionary conserved and is supported by genome-wide 
studies, showing that the average gene expression levels in LADs are lower than outside of them 
(Guelen et al, 2008; van Bemmel et al, 2010; Kind et al, 2013; Ciabrelli & Cavalli, 2015).  
Mammalian LADs also show very sharp borders. These borders are genetically defined since 
they contain bidirectional transcription units where the active domains are mainly pointing 
outward from LADs and bearing CpG islands and CTCF binding sites (Guelen et al, 2008), 
where CTCF binding is important in shaping LAD borders and chromatin looping between its 




Also, more recent studies underlie the importance of lamins in shaping the interactions between 
TADs and the effect on genome regulation based on these interactions (Zheng et al 2018; Ulianov 
et al, 2019). The loss of lamins was shown to disrupt LAD organization, change the interaction 
between active and inactive chromatin domains and cause global changes in transcription (Zheng 
et al, 2018).  
Considering specific chromatin marks, it has been demonstrated that mammalian LADs harbor 
specific features as enrichment in G9a-dependent H3K9me2 chromatin mark which is important 
fort LAD tethering to the NL (Guelen et al, 2008; Kind et al, 2013).  
 
Chromatin composition in the nuclear periphery 
 
The global nuclear architecture is shaped by the enzymatic activity of many different proteins, 
but a special subset of them is involved in the organization of the mainly transcriptionally 
repressive environment in the nuclear periphery. The interactions of the NL and chromatin is 
maintained due to the activity of several chromatin modifying enzymes and DNA binding 
proteins (LAP2B, EMD, BAF, LBR, HP1). Histone methyltransferases (HMTs) G9a/GLP and 
histone deacetylases (HDACs) are shown to interact with NL proteins (Somech et al, 2005; 
Holaska & Wilson, 2007; Montes de Oca et al, 2009) and may locally dimethlyate H3K9 and 
deacetylate histones of chromatin positioned in close proximity to the NL, as well as contributing 
to the repression of genetic activity close to the NL Figure 1.10.). Large domains of repressive 
chromatin marks as H3K27me3 (established by the activity of Polycomb Repressive Complex 2 
– PRC2), H3K9me2 and H3K9me3 are present in this area of the nucleus, rather then clearly 







Figure 1.10. Representation of the repressive chromatin environment of LADs.  
Chromatin associated with the nuclear lamina is mostly decorated with repressive marks (H3K9me2 and 
H3K27me3) and HDACs are very often present and ensure the establishment of a repressive chromatin 
environment. DNA binding proteins ensure the close association of DNA and the nuclear lamina (Lap2B, EMD, 
BAF) and the maintenance of a closed chromatin state (HP1). The presence of protein complexes as PRC2 helps 
keeping a closed chromatin structure and an environment of low gene expression. Cell receptors as LBR anchor 
heterochromatin at the nuclear lamina, whereas receptor MAN1 can release the chromatin from the nuclear 
lamina in case of growth factor signaling and induce, by a cascade of reactions, gene expression (the bigger red 
dots in the picture represent the interactions) (adapted from: Kind & van Steensel, 2010).  
 
Briefly, in the context of higher order chromatin structures (chromosomes) and their relation to 
the nuclear periphery, it was shown that distinct chromosomes generally occupy a preferred 
position in the nucleus (Dekker et al, 2013). Chromosome positioning seems to correlate with 
gene density, where gene-poor chromosomes tend to localize to the nuclear periphery (e.g. 
human chromosome 18), whereas gene-dense chromosomes rather occupy inner nuclear 
positions (Rouquette et al, 2010; Ciabrelli & Cavalli, 2015).  
 
H3K9me2 chromatin mark and G9a histone methyltransferase 
 
H3K9me2 was shown to cover large genomic portions described as Large Organized Chromatin 
Domains (LOCKS) (Wen et al, 2009), and these domains where shown to mainly overlap with 
LADs (Kind & van Steensel, 2010). H3K9me1/me2 marks are important in anchoring the 
chromatin fiber to the nuclear periphery, whereas H3K9me3 is responsible for transcriptional 




Chromatin decorated with H3K9me1/me2 marks, except for its role in shaping the chromatin 
landscape of the nuclear periphery, is also found in large euchromatic regions, suggesting a 
contribution of these chromatin marks in dynamic mechanisms of gene repression or activation 
(Tachibana et al, 2002; Black et al, 2012).  
G9a histone methyltransferase (HMT) belongs to the Su(var)3-9 family mainly catalyzing 
H3K9me1 and H3K9me2. Structurally G9a is composed of a catalytic SET domain, a domain 
containing ankyrin repeats and a nuclear localization signal on the N-terminus (Esteve et al, 
2006; Nakanishi et al, 2008; Collins & Cheng, 2010) (Figure 1.11.). The SET domain is 
responsible for the addition of methyl groups on histone H3, whereas the ankyrin repeats have 
been shown to represent mono- and dimethyl lysine (K) binding regions. Accordingly, G9a is not 
only able to methylate histone tails, but also able to recognize this modification and function as a 
scaffold for the recruitment of other molecules on the chromatin (Shahbazian et al, 2005; 
Casciello et al, 2015). G9a functions mainly as a heterodimer together in a complex with GLP 
(G9a Like Protein). It has been demonstrated that if one of the two proteins is depleted, H3K9 
mono- and dimethylation levels get reduced in euchromatic regions (Tachibana et al, 2002). In 
vitro studies showed that both G9a and GLP can also form homodimers and perform H3K9 





Figure 1.11. Scheme of G9a histone methyltransferase structure.  
At the N-terminal end of the enzyme ankyrin repeats (orange) recognize (read) H3K9me1 or H3K9me2 
chromatin mark. At the C-terminus the catalytic SET domain (red) deposits mono or di-methyl H3K9. 
 
G9a mainly methylates H3K9 in euchromatic regions, which causes gene repression (Tachibana 




activity  of G9a is very important in the context of cell viability and development, respectively. In 
mammalian cells, the disruption or inhibition of G9a was shown to weaken the NL-LAD 
association (Bian et al, 2013; Chen et al, 2012; Kind et al 2013; Harr et al, 2015), which, as 
mentioned, can affect gene expression.  
In studies with murine G9a-deficient embryonic stem cells (ESC) a global loss methylation in 
chromatin was observed but surprisingly not in heterochromatic regions. While HMT function 
can generally be associated with both heterochromatin and euchromatin organization (Tachibana, 
2015), this example shows that G9a can specifically associate with euchromatin and be involved 
in the repression of active promoters (Peters et al, 2001; Rice et al, 2003; Tachibana et al, 2005). 
In addition, the repressive activity of G9a was proved to be essential in embryo-genesis in mice. 
G9a depletion resulted in embryonic lethality or severe differentiation defects in ESC, showing 
that G9a is crucial for the repression of developmental genes and necessary during development 
(Tachibana et al, 2002). Likewise, G9a was found to be involved in the development of cell 
specification as an important factor of oct-3/4 gene inhibition, a homeobox gene important for the 
maintenance of pluripotency (Feldman et al, 2006).  
In terms of T-cells (which are the main target cells for HIV-1 infection), it was shown that the 
normal functioning of G9a is important in hematopoietic cell lineage commitment, as well as 
T-cell development during inflammatory response (Lehnertzt et al, 2014; Antignano et al, 2014). 
Specifically, it was shown that G9a is a negative regulator of pathogenic T-cell differentiation as 
G9a depleted T-cells were shown to have an increased sensitivity to TGF-β1 (Transforming 
Growth Factor Beta 1) which is promoting naïve T-cell differentiation in pathogenic T-cells, 
Th17 (T-helper cells) and Treg (T-regulatory cells), in the absence of intestinal inflammation 
(Antignano et al, 2014). This finding showed that G9a is important in the maintenance of T-cell 
homeostasis. In addition, G9a was shown to be involved in T-cell differentiation, as CD4+ T cells 
fail to differentiate into Th2 cells both in vitro and in vivo in the absence of G9a. Mice carrying a 
T-cell specific G9a deletion could not develop Th2 cells in response to infection in the absence of 
interferon γ (Lehnertz et al, 2014).  
In summary, apart from mediating the establishment of H3K9me2 and shaping the chromatin 
conformation in the nuclear periphery of T cells, G9a is evidently very important for T cell 





HIV-1 in the 3D nuclear space 
 
HIV-1 tethering factors and proviral interactors 
 
One of the most important factors that influences HIV-1 integration into certain chromatin 
regions is LEDGF/p75. Binding sites of LEDGF/p75 were mapped on chromosomes making 
reference to the highly annotated ENCODE (encyclopedia of DNA elements). LEDGF/p75 
binding sites (also assigned as LEDGF islands) were described to be dominantly distributed at 
transcribed genomic regions which overlay with the observed trend for these regions to be 
favored for HIV-1 integration (De Rijck et al, 2010). In addition, LEDGF/p75 knock down was 
observed to cause increased integration in regions of higher G/C content and closer to CpG 
islands (Brady et al, 2009). The overall dataset defines a model in which LEDGF/p75 directs 
HIV-1 integration by binding to IN on one side, and on the other side to open chromatin regions 
(De Rijck et al, 2010; Craigie & Bushman, 2012). LEDGF/p75 has been described as an 
H3K36me3 chromatin mark reader (Venkatesh et al, 2012; Pradeepa et al, 2012; Demeulemester 
et al, 2015, Singh et al, 2015), and it was shown that LEDGF/p75 binds to H3K36me3 regions in 
the genome (Marini et al, 2015) supporting the notion that LEDGF/p75 binds to open chromatin.  
Apart from LEDGF/p75 and its function in IN binding and directing the process of integration 
site selection, it was shown that the interaction of the PIC with proteins of the NPC is important 
in positioning of the virus inside of the nuclear space and determining its transcriptional activity 
(Marini et al, 2015; Lelek et al, 2015). It was shown that vDNA integration sites are associated to 
transcriptionally active histone marks and several nucleoporins; as NUP62, NUP96, NUP153 and 
the inner nuclear basket protein TPR. In addition, TPR depletion was shown to reduce 
LTR-driven gene expression in HIV-1 infected cells (Lelek et al, 2015). Although the knockdown 
of TPR might inhibit the levels of HIV-1 expression, it has a minor impact integration of the 
vDNA. Knockdown of NUP153 on the other hand almost completely abolishes HIV-1 
integration, with HIV DNA signals, most probably corresponding to the non-integrated virus, can 
be observed randomly positioned in the nuclear space (Marini et al, 2015).  
Chromatin composition underneath the NPC has been shown to be composed of “open-easy 
access-transcriptionally active” chromatin (Schermelleh et al, 2008), and depletion of TPR was 




accessible chromatin environment (Lelek et al, 2015). It has also been demonstrated that the 
overexpression of TPR leads to a stabilization of LEDGF7p75 at the nuclear periphery (Lelek et 
al, 2015; Wong et al, 2015). These findings underlie the significant interplay between H3K36me3 
chromatin mark, LEDGF/p75 as a reader of that mark (Pradeepa et al, 2012) and TPR in the 
context of creating an environment for HIV-1 integration (Lusic & Siliciano, 2017).  
It has also been shown that the role of LEDGF/p75 in viral integration is more in the process of 
navigating the virus towards gene bodies, whereas the function of CA interacting factor CPSF6 
(Lee et al, 2010; Price et al, 2012; Fricke et al, 2013) is the localization of the virus into 
euchromatic regions (Sowd et al, 2016). 
On the other hand, it has also been demonstrated that CPSF6 via its interaction with CA localizes 
the virus towards euchromatic regions in the nuclear interior, away from the nuclear periphery 
and that LEDGF/p75 plays a more important role in directing the virus towards gene bodies, than 
determining its nuclear localization (Sowd et al, 2016; Achuthan et al, 2018). The consensus of 
mentioned studies is that the integrated virus preferentially resides in open chromatin regions, in 
the gene bodies of actively transcribed genes (Mitchell et al, 2004; Wang et al, 2007; Marini et al, 
2015; Achuthan et al, 2018). 
 
Spatial positioning of HIV-1 in the nucleus 
 
In respect to the spatial positioning of the virus in the nucleus, structural cell specific features 
may potentially affect the discrete proviral positioning in the nucleus, considering that opposing 
data arose from studies which analyzed viral positioning in different cell types (Albanese et al, 
2008; Di Nunzio et al, 2012; Marini et al, 2015; Lelek et al, 2015; Achuthan et al, 2018). 
However, upon knockout of HIV-1 tethering factors LEDGF/p75 and CPSF6, and HIV-1 
infection in HeLa and CD4+ T cells it was shown that genes targeted for integration by the virus 
were mostly cell type specific and had a perinuclear position in the different cell types (Achuthan 
et al, 2018). Accordingly, cell type specificity seems to be a significant determinant of HIV-1 
integration site selection and proviral spatial positioning in the nucleus.  
In addition, in the context of LEDGF/p75, knock down experiments performed in HeLa cells 




the nucleus, but rather contributes to the  directing of the virus into gene-rich regions (Quercioli 
et al, 2016; Sowd et al, 2016).  
However, in primary CD4+ T cells, which are the main target of HIV-1, the proviral genome 
predominantly resides in the nuclear periphery, in open chromatin regions which are located in 
the vicinity of the NPC and excluded from LADs (Albanese et al, 2008; Di Nunzio et al, 2012; 
Marini et al, 2015).  
Regarding chromatin features of the environment where HIV-1 positions, apart from knowing 
that the chromatin of these regions is decorated with open chromatin marks, which mark actively 
transcribed genes (Schröder et al, 2002; Wang et al, 2007; Marini et al, 2015), it was confirmed 
that the provirus occupies regions with low densities of heterochromatin specific markers (Brady 
et al, 2009; Friedman et al, 2011; Vranckx et al, 2016). Chromatin accessibility and chromatin 
features evidently play important roles in HIV-1 integration site selection and spatial positioning 
of the provirus.  
On a genome-wide scale, chromatin composition and nucleosome positioning/shuffling 
throughout the genome have a significant impact on genome regulation, by modifying the in vivo 
availability of binding sites of TFs and the general transcription machinery. Mentioned 
phenomena affect DNA-dependent processes such as transcription, DNA repair, replication and 
recombination (Radman-Livaja & Rando, 2010; Tsompana & Buck, 2014), and can therefore also 
affect HIV-1 transcriptional activity (Easley et al, 2010; Matysiak et al, 2017).  
In studies aiming to understand how nucleosomal positioning regulates gene expression it was 
shown that transcriptional activation coincides with nucleosome perturbation, whereas 
transcriptional regulation requires the repositioning of nucleosomes throughout the eukaryotic 
lineage (Wallrath et al, 1994; Boeger et al, 2003; Lee et al, 2004; Hogan et al, 2006; Buck & 
Lieb, 2006; Schones et al, 2008; Shivaswamy et al, 2008). In addition, open or accessible regions 
of the genome are very often regarded as primary positions for regulatory elements (John et al, 
2011) and have been in the very beginning characterized by nuclease hypersensitivity assays in 
vivo (Gross & Garrard, 1988). Low-throughput experiments in Drosophila using DNase I and 
MNase treatment, provided the first demonstration that active chromatin coincides with nuclease 
hypersensitivity, which is chromatin accessibility (Wu et al, 1979, Wu, 1980; Keene & Elgin, 




integration sites coincide with regions 
of DNase I hypersensitivity (Verdin, 
1991; Brady et al, 2009; Busschots et 
al, 2005; Ciuffi et al, 2005; Chen et al, 
2017a).  
In silico predictions have shown that 
HIV-1 preferentially integrates into 
nucleosomal, compared to naked 
DNA, as well as that HIV-1 integration 
sites are mainly found on outer 
portions of the major DNA groove 
which is also attributed to a preference 
in integrating into more flexible DNA 
regions (Wang et al, 2007; Michieletto 
et al, 2019).  
 
In summary, the interplay between host cell chromatin features (Marini et al, 2015; Lusic & 
Siliciano, 2017; Lucic et al, 2019), HIV-1 tethering factors, as well as host cell type specificity 
significantly impact the spatial positioning of HIV-1 provirus in the host cell nucleus (Sowd et al, 


















Figure 1.12. Scheme of HIV-1 integration. 
HIV-1 integrating into open chromatin regions (outside of 
LADs) and interacting with elements of the NPC, as well as host 





I.IX. R-loops –  DNA-RNA hybrids shaping the chromatin landscape 
 
DNA-RNA duplexes that are mainly 
occurring co-transcriptionally, in DNA 
accessible and DNase I hypersensitive 
regions, are named R-loops (Sanz et al, 
2016; Chen et al, 2017a). R-loops 
represent tri-stranded nucleic acid 
structures composed of a DNA-RNA 
hybrid and a displaced single stranded 
DNA (Figure 1.13.). These structures, 
first described in 1976 (Thomas et al, 
1976) are predominantly found in G/C 
rich genomic regions (Ginno et al, 2012; 
2013). where RNA polymerase II (Pol 
II) transcribes a C-rich template. The 
generated G-rich RNA transcript bounds 
back to C-rich DNA generating a hybrid 
of increased thermodynamic stability. 
Although it is still unclear how R-loops are really formed, the most probable seems  the “thread 
back model”, according to which the RNA/DNA hybrid is formed before the two strands of the 
DNA duplex can reanneal.  
 
R-loops have been shown to be ubiquitously present across different organisms from bacteria to 
mammals and they are believed to have numerous regulatory effects, which may also affect cell 
fitness (Skourti-Stathaki & Proudfoot, 2014). 
 
I.IX.I. Mechanisms of R-loop formation and their genome-wide distribution 
 
R-loop formation is supported by factors that provide a thermodynamic advantage to the 
DNA-RNA hybrid, which is formed during transcription, over the corresponding DNA strand 
 
 
Figure 1.13. Scheme of an R-loop and the co-transcriptional 
mechanism of its formation.  
Legend on the right indicates elements and factors included in 
the process of R-loop formation. 
The picture on the left, below the thick arrow, shows a scenario 
in which the transcribed mRNA normally exits the 
transcriptional machinery. 
The picture on the right, below the thin arrow, shows a situation 
in which an R-loop is formed as a consequence of high G/C 
content asymmetries between the leading and lagging DNA 
strands and the re-annealing of the nascent RNA (adapted from: 





Factors which are facilitating R-loop formation represent intrinsic R-loop prone DNA sequences 
which can form much more stable duplexes with RNA than DNA (Roy et al, 2008; 
Belotserovskii et al, 2010). In addition, R-loop formation is favored at genomic sites prone to 
form breaks in the non-template DNA strand, negative supercoils (positively affecting DNA 
unwinding) (Roy et al, 2010), or non-canonical DNA structures (as G4-quadruplexes and 
triplexes) (Duquette et al, 2004). R-loop formation also frequently occurs during transcription 
scenarios in which the non-template DNA strand is sequestered by a ligand (Belotserovskii & 
Hanawalt, 2015). Interestingly, factors sequestering the nascent RNA, as it is exiting the 
transcriptional complex, seem to suppress R-loop formation (Santos-Pereira et al, 2013).   
The formation of an R-loop and the maintenance of an R-loop structure seem to be two distinct 
processes. In vitro studies demonstrated that for the R-loop formation initiation, within duplex 
DNA, an R-loop initiating sequence is required. Such a sequence contains clusters of guanines 
(very high G/C skew) which have also been demonstrated to form very stable R-loops. On the 
other hand, a higher thermo-dynamic stability of an R-loop, compared to a DNA-DNA duplex, 
might be sufficient for R-loop maintenance, but not for R-loop formation initiation  (Roy & 
Lieber, 2009). However, in vivo R-loop formation depends not only on intrinsic R-loop forming 
properties of a certain DNA sequence, but also on DNA-protein interactions. It was shown that 
R-loop formation is strongly increased close to polyA stretches, even though they are not 
intrinsically R-loop prone sequences. An explanation for the observed phenomenon might be that 
polyA stretches disfavor nucleosome binding and offer more “space” for the occurrence of 
R-loops in terminal gene regions (Wahba et al, 2016; Sanz et al, 2016). 
It was also shown that R-loop formation predominantly occurs in genomic regions transcribed by 
Pol II and that R-loop turnover is a very dynamic and controlled process. Co-transcriptionally 
formed R-loops are resolved with a half-life of ~10-20 minutes (Sanz et al, 2016). The observed 
phenomenon is in correlation with estimates of the paused promoter-proximal Pol II half-life 
(Jonkers et al, 2014), suggesting that R-loop formation is compatible with the normal dynamics 
of transcription. Accordingly, R-loop formation is a process most probably regulated in terms of 
frequency and residence time (Sanz et al, 2016). 
 




DNA strand (Ginno et al, 2012, 2013) (Figure 1.13.), other R-loop features have recently been 
described. The size of an average R-loop ranges from 150 to 500 bp, as directly visualized by 
electron microscopy (EM) (Duguette et al, 2004), but their size can range up to 2000 bp as shown 
by molecular R-loop mapping approaches (reviewed in: Santos-Pereira & Aguilera, 2015). In 
addition, it was estimated that R-loops occupy 5-8 % of the genome (Sanz et al, 2016; Halasz et 
al, 2017).  
The detection of R-loops is based on the use of the S9.6 monoclonal antibody which specifically 
detects DNA-RNA hybrids (Boguslawski et al, 1986). Most R-loop studies combine the use of 
the S9.6 antibody for R-loop pull-down, deep sequencing and genome-wide R-loop mapping in 
different species, from yeast (Chan et al, 2014; El Hage et al, 2014; Wahba et al, 2016) to plants 
(Xu et al, 2017) and mammals (Ginno et al, 2012; 2013; Nadel et al, 2015; Sanz et al, 2016; 
Stork et al, 2016; Halasz et al, 2017). 
R-loop peaks have been mapped close to gene promoters (Chen et al, 2015), but they have also 
been found being more spread in gene bodies (Ginno et al, 2012; 2013; Stork et al, 2016) or 
downstream of transcription start sites (TSS) (Sanz et al, 2016). The observed differences my 
also possibly be attributed to slight differences in R-loop mapping approaches. Although most 
R-loop studies show a clear link between R-loops and G/C skew, in yeast R-loops, could be 
detected even an A/T skew (Wahba et al, 2016).  
In a recent study where R-loops where captured in a method called R-ChIP (based on R-loop 
binding via a catalytically dead RNase H1 followed by strand-specific amplification of 
immunoprecipitated DNA) it was shown that R-loops have a predominant distribution in 
promoter proximal regions (59,3%), whereas additional R-loops were mapped across various 
locations within gene bodies (17,2%), close to gene terminal (6,6%), or in intergenic regions 
(16,9%). In addition, most detected R-loop peaks were overlapping with open chromatin, which 
suggests that active gene promoters are hotspots for R-loop formation in the genome (Chen et al, 
2017a).  
 
The interplay of R-loops and chromatin composition 
 
R-loops are involved in all stages of gene expression, but are also implicated in almost all the 




chromatin composition, while on the other hand R-loops also influence chromatin patterning at 
genomic regions. Several studies, including those with genome-wide mapping of R-loops  
showed an association of R-loop peaks with open chromatin marks and an overall chromatin 
accessibility in R-loop rich regions occurring at gene promoters or gene bodies  (Nadel et al, 
2015; Zeller et al, 2016, Sanz et al, 2016, Chen et al, 2017).  
At promoter regions, R-loops were proposed to negatively regulate DNA methylation levels and 
to facilitate transcription (Gino et al, 2012). R-loop destabilization at the human VIM promoter 
causes a shift from an open, non-methylated chromatin state to a closed and methylated 
chromatin (Boque-Sastre et al, 2015). R-loops in promoter regions were shown to associate with 
high levels of histone marks of active transcription, such as mono and trimethylation of lysine 4 
of histone H3 (H3K4me1 and H3K4me3), histone acetylation as well as transcription elongation 
mark H3K36me3. H3K4me1 was also found at terminal R-loops, implying that this is a common 
mark of R-loops (Chen et al, 2015; Sanz et al, 2016; Chedin, 2016).   
In addition,  R-loops may affect the chromatin environment by recruiting chromatin-modifying 
complexes,  Genes with R-loop(+) promoters show high amounts of H3K36me3 over the R-loop 
formation peak (Sanz et al, 2016). This might be further connected with recruitment of other 
chromatin factors such as SETD2. Elongation factor Spt6 responsible for Pol II escape from 
promoter pausing (Vos et al, 2018) and elongation plays a role in maintaining the transcription 
within protein-coding gene transcription units. In the absence of this factor, H3K36me3 
redistributes on intergenic regions, causing increased long non-coding RNA (lncRNA) 
transcription. These aberrant lncRNAs transcripts can anneal to DNA templates and cause 
formation of damaging levels of  R-loops (Nojima et al, 2018).  
H3K4-methylation is also enriched over R-loop(+) promoters - H3K4me3 shows a predominant 
transcription start site (TSS) distribution, whereas H3K4me1 distributes 1-2 kb downstream of 
TSS (Sanz et al, 2016), Accordingly, it is proposed that R-loops may have a more direct role in 
recruitment of H3K4me1, but the mechanism still needs to be elucidated. Interestingly, PAF1 
complex which contributes to both H3K4me1 and H3K36me3 methylations, is enriched over 
R-loop regions (Sanz et al, 2016; Chedin, 2016). 
Loss of histone chaperone complex FACT, which functions in chromatin reassembly, leads to 
R-loop accumulation (Herrera-Moyano et al, 2014). This finding suggests that not only R-loops 




accumulation. Assuming that R-loops are similarly inhibitory for nucleosome formation through 
the genome, R-loops formation likely alters the kinetics of nucleosome turnover, and 
consequently contributes to regulation of transcription (Dion et al, 2007).  
R-loops were also connected to H3S10P, a histone modification associated mainly with mitotic 
chromatin condensation. It has been shown that H3S10P levels could be suppressed by 
expression of RNase H1 enzyme, suggesting a link to R-loops (Castellano-Pozo et al, 2013) but it 
remains unclear in which context is this histone modification related to R-loops .  
Interestingly, R-loop formation has also been linked to increased deposition of marks of 
repressive chromatin. In one such example, R-loop formation has been linked to H3K9me2/me3 
and heterochromatin formation on expanded triplet repeats in Friedrichs’s ataxia and Fragile X 
syndrome, (Colak et al, 2014; Groh et al, 2014).  
In C. elegans knockout  of MET-2 and SET-25, the only two HMTs placing H3K9-methylation  
results in the frequent accumulation of R-loops  behind replication forks, causing genomic 
instability due to occurring torsional stress. DRIP-Seq (DNA-RNA immunoprecipitation 
followed by deep sequencing revealed that DNA transposons, usually repressed genomic 
sequences, show higher levels of R-loops compared to RNA transposons  and that loss of H3K9 
methylations resulted in  de-repression of those sequences. It was thus proposed that H3K9me2 
or H3K9me3 chromatin marks stabilize and protect repeat-rich genomes and sequences by 
suppressing transcription-induced replication stress (Zeller et al, 2016).  
Accumulation of H3K9me2 marks and increased R-loop formation was observed in the 
transcription termination regions in a subset of genes in mammalian cells. This seems to be a 
consequence antisense transcription, localized dsRNA accumulation and RNAi factor 
recruitment, as well as the recruitment of heterochromatin protein 1 (HP1) (Skourti-Stathaki et al, 
2014). 
Interestingly, R-loops were also shown to be negatively correlated with transcription of several 
developmental genes in murine embryonic stem cells. There, formed R-loops are responsible for 
the increased binding of Polycomb Repressive Complex 1 and 2, strong epigenetic regulators of 
transcriptional repression. Conversely, R-loop removal resulted in decreased recruitment of 
PRC1 and PRC2 and increased Pol II activation (Skourti-Stathaki et al, 2019).  
 




dependent function. It needs to be taken into account that R-loops can both facilitate, or terminate 
DNA transcription depending on their genomic position and interaction with other factors. 
Hence, the effects of chromatin regulatory factor binding may vary at genes according to the 
extent of R-loop accumulation (Fazzio, 2016).  
 
Factors interacting with R-loops 
 
It is well established that R-loop forming regions can also be associated to DNA damage 
(Skourti-Stathaki et al, 2011; Chan et al, 2014; El Hage et al, 2014).  
R-loops formed after the transcribing Pol II can block further elongation (Huertas & Aguilera, 
2003), while the ones  formed after replication forks can block the DNA replicating machinery 
(Tudori et al, 2009), induce torsional stress, transcription and replication conflicts and contribute 
to genomic instability (Zeller et al, 2016; Hamperl et al, 2017).  
Consequently, cells have evolved multiple mechanisms to control R-loop accumulation and avoid 
DNA damage and genomic instability, which are crucial in monitoring and keeping cell 
homeostasis since molecular approaches showed a clear correlation between R-loops and certain 
diseases (Groh et al, 2014; Lim et al, 2015; Garcia-Rubio et al, 2015; Grunseich et al, 2018).  
 
All regulators of R-loops 
have a negative effect on 
them, either resulting in 
their removal or by 
preventing their 
formation (Santos-Pereira 
& Aguilera, 2015) 
(Figure 1.14.). One 
prominent example is the 
DNA-RNA helicase 
SETX (Sen1 in yeast). 
SETX causes the 
degradation of the 
 
 
Figure 1.14. Schematic representation of the activity of certain R-loop 
removing factors. 
The removal of co-transcriptionally formed R-loops can occur by the interplay 
of distinct enzymes.  
The RNA moiety of an R-loop can be degraded by RNase H enzymatic 
activity. R-loops can also be removed by unwinding mechanisms of cellular 
helicases (for example Rho in bacteria, Sen1 in yeast and SETX in mammalian 
cells). The human helicase aquarius (AQR) is possibly also involved in the 




DNA-RNA duplex of R-loops (Kim et al, 1999), which can be followed by the degradation of the 
RNA transcript by the RNA exonuclease, Xrn2 (Skourti-Stathaki et al, 2011).  
R-loop removal occurs also via the activity of RNase H enzymes (RNase H1 and RNase H2 in 
eukaryotes), which degrade the RNA strand of the R-loop through their endonuclease activity 
(Cerritelli & Crouch, 2009). RNase H enzymes represent a family of non-sequence-specific 
endonucleases that catalyze the cleavage of RNA in a DNA-RNA hybrid via a hydrolytic 
mechanism (Figure 1.15.). Two main types of RNase H enzymes exist and at least one of them is 
present in most organisms (Cerritelli & Crouch, 2009). 
Early studies on RNase H1 enzymes demonstrated that the N-terminal domain of the protein is 
responsible for binding of RNA-RNA and DNA-RNA duplexes (Cerritelli et al, 2003; 
Gaidamakov et al, 2005). This domain is known as the Hybrid Binding Domain (HBD). The 
HBD shows a 25-fold higher preference for DNA-RNA hybrid binding compared to the same 
sequence of dsRNA (Nowotny et al, 2005). In addition, it was shown that type 1 RNase H 
enzymes require at least a four ribonucleotide substrate for cleavage to occur (Cerritelli & 
Crouch, 2009). 
RNase H2 was shown to be clearly different from RNase H1 regarding DNA-RNA hybrid 
hydrolysis. RNase H2 displays higher affinity in recognizing and cleaving a single ribonucleotide 
embedded in a DNA duplex.  This implies that the function of RNase H2 resembles that of a 
repair enzyme, since it is cleaving DNA at sites where DNA polymerases mistakenly 
incorporates a ribo- instead of a deoxyribonucleotide (Cerritelli & Crouch, 2009). 
 
Apart from RNase H enzymes and helicases, Topoisomerase I (Top I) is also involved in the 
removal of R-loops. Top I is responsible for the relaxation of supercoiled DNA, especially during 
transcription and DNA replication. For example, depletion of Top I in HEK293T cells results in 
both R-loop loss and R-loop gain at thousands of transcribed loci. R-loop gains were observed in 
highly transcribed genes located in gene-poor regions associated to LADs, in close proximity to 
H3K9me3 enriched regions. On the other hand, R-loop loss in response to Top I depletion was 
observed in regions repressed by Polycomb group complexes and marked with H3K27me3 mark. 
In addition, Top I depletion and rearrangement of R-loops throughout the genome resulted in cell 
cycle arrest in G0/G1 phase, which indicates that Top I function and R-loop regulation is just 




Also, by applying a very broad approach in mapping R-loop interacting partners in a human B 
cell line, 803 new R-loop interacting partners have been identified. Most identified proteins can 
be classified into groups of proteins involved in RNA processing as splicing or RNA strand 
unwinding. Interestingly, among the identified R-loop interacting proteins, nuclear pore complex 
proteins have also been identified too (Wang et al, 2018). So far, it is not known whether there 
are proteins that specifically promote R-loop stability, either directly or by counteracting the 




























I.X. The rationale of studying HIV-1 integration site selection in a chromatin 
and R-loop dependent context   
 
HIV-1 integration, as well as the completion of the viral life cycle and viral activity, significantly 
depend on host cell chromatin organization (Le Douce et al, 2012; Maldarelli et al, 2014; Cohn et 
al, 2015; Matsuda et al, 2015; Laskey et al, 2016; Lusic & Siliciano, 2017). Several studies have 
demonstrated an association between the distribution of certain chromatin marks and HIV-1 
integration sites (Benkirane et al, 1998; Lusic et al, 2003; Ikeda et al, 2007; Wang, 2007; Brady 
et al, 2009; Marini et al, 2015; Goncalves et al, 2016; Turner & Margolis, 2017). 
On the other hand, R-loops, interestingly, expose features that have already been described for 
HIV-1 integration sites, as DNase I hypersensitivity (Verdin, 1991; Sanz et al, 2016; Chen et al, 
2017a) and occurrence in G/C rich genomic regions (Brady et al, 2009; Roy & Lieber, 2009; 
Ginno et al 2012; Sanz et al, 2016). In addition, R-loop rich regions are frequently associated to 
open chromatin marks (Sanz et al, 2016; Chedin, 2016) which are also distributed over HIV-1 
integration sites (Brady et al, 2009; Marini et al, 2015; Turner & Margolis, 2017).  
Finally, HIV-1 RT has a known RNase H function (Davies et al, 1991; Beilhartz & Götte, 2010) 
and HIV-1 IN exposes features that can be attributed to RNase H enzymes; enzymes that 
specifically recognize and resolve R-loops (Majorek et al, 2014). The following section will 
provide further insight into putative RNase H functions of HIV-1 IN.  
 
I.X.I.  HIV-1 IN is an RNase H-like enzyme 
 
HIV-1 IN is composed of three independent functional and structural domains, as previously 
mentioned. In the context of putative RNase H properties of HIV-1 IN the CCD stands out. Also, 
as mentioned before, the CCD of IN shows an RNase H folding pattern and HIV-1 IN is 
accordingly classified into the group of Ribonuclease H-like (RNHL) superfamily of enzymes 




Still, the two most important 
functions of the CCD, and IN in 
general, are performing the 3’ 
processing and strand transfer 
reaction. IN order to successfully 
perform its function, IN activity 
highly depends on the efficiency 
of host cell DNA binding. In 
addition, of significant 
importance is the fact that IN 
activity is also highly regulated 
by the structure of the viral and host DNA substrates which can be influenced by protein 
interactions. It was shown that the structure of target host DNA greatly influences the site of viral 
integration as well as that DNA curvature and flexibility influence the frequency of integration 
(Pruss et al, 1994a; Pruss et al, 1994b; Wang et al, 1999). 
Apart from DNA binding properties, it was also shown that IN exhibits properties of binding 
highly structured RNA elements. 
It was demonstrated that HIV-1 
IN in virions shows RNA 
binding properties where 95% of 
the bound RNA was derived 
from viral RNAs, whereas the 
other 5% were of cellular origin. 
In addition, it was shown that IN 
shows preference for binding 
selected structural viral RNA 
elements (RNA-TAR). In this 
context, three lysine residues in 
the CTD of HIV-1 IN were 
identified to be important for IN 
RNA binding properties (K264, 
 
 
Figure 1.15. Scheme of HIV-1 IN structural domains.  
The active residues of the CCD are indicated in red. This region of IN 
has a demonstrated RNase H conformation.  
Three lysine residues that have been described to have RNA binding 
properties (K264, K266, K273) are highlighted in the CTD of IN.  
 
 
Figure 1.16. Structural superimposition of crystal structures of 
HIV-1 IN CCD and B. halodurans RNase H in complex with an 
RNADNA-RNA hybrid. 
The CCD of HIV-1 IN is represented in yellow, whereas the bacterial 
RNase H enzyme is represented in turquoise. The red and black regions 
represent the structurally aligned protein residues of IN (red) and RNase 




K266, K273) (Kessl et al, 2016) (Figure 1.15.).   
 
Supporting evidence for potential RNase H function, as well as R-loop binding properties of IN 
come from an in silico study in which the crystal structures of HIV-1 IN CCD (Goldgur et al, 
1999) and an averaged crystal structure of RNase H from Bacillus halodurans in the complex 
with an R-loop (Nowotny et al, 2005) were superimposed (Figure 1.16.). The structural 
alignment involved 45 amino acids surrounding D71 and D132 of the bacterial RNase H and D64 
and D116 of IN (Savarino, 2007).  
Considering that the viral RT has a known RNase H function (Kati et al, 1992), and that both 
enzymes are  derived by proteolytic cleavage of the Gag-Pol polyprotein, it seems plausible  that 
























I.X.II. Questions and objectives 
 
The integrated HIV-1 genome can still not be eradicated from infected cells in patients. 
Accordingly, it is very important to understand how HIV-1 selects sites in the genome where it 
integrates and what is the contribution of certain epi-genomic features that could possibly affect 
this process.  
In respect to the fact that HIV-1 integration could potentially occur anywhere in the host cell 
genome, but still does not, it is worthwhile to further investigate and describe in more detail 
where and how HIV-1 selects certain genomic sites for integration.  
Considering that the virus shows certain preferences for integration site selection and that these 
integration sites expose similar epi-genomic features, it would be interesting to assess HIV-1 
integration patterns once the chromatin composition of HIV-1 target cells is changed.  
Apart from understanding and analyzing HIV-1 integration profiles, it would also be important to 
further explore the 3D positioning of the virus in the nuclear environment and its consequences 
on viral activity, since previous studies (Albanese et al, 2008; Di Nunzio et al, 2013; Marini et al, 
2015) indicate that the nuclear position of the virus is also not random and that the virus 
preferentially positions in open chromatin regions of the nuclear periphery which are underlying 
the NPC.  
In the context of HIV-1 integration site selection and viral positioning in the genome, the aim 
would be to focus the attention on the importance and effects of H3K9me2 chromatin mark 
composition. Mainly because previous studies showed a significant influence of this chromatin 
mark in shaping the nuclear landscape (Wen et al, 2009; Kind et al, 2013), as well as the 
importance of H3K9me2 depositing HMT G9a in T cell life cycle and functioning (Lehnertz et 
al, 2014; Antignano et al, 2014), which represent the main cells targeted for HIV-1 infection. 
Another reason why the focus of this work is directed to this particular chromatin mark is the fact 
that it was shown that genes targeted for HIV-1 integration have a slightly different distribution 
of H3K9me2 chromatin mark throughout their gene body, compared to non-HIV-1 target genes 
(Lucic et al, 2019).  
 
Taking into account that the host cell chromatin under the NPC is the first open chromatin 
structure the incoming virus encounters on its way to the nucleus, and that the surrounding closed 




further explore the dynamics of HIV-1 integration from a chromatin perspective. 
Questions that have to be addressed in this context and that will be pursued in the scope of this 
work are: 
1. Is the virus positioning in open chromatin regions in close proximity to the NPC, just 
because it is the first accessible chromatin domain on its way to the nucleus? 
2. How does chromatin composition affect HIV-1 integration? 
3. Are some other genomic features also affecting HIV-1 integration site selection and its 
positioning in the 3D nuclear environment? 
 
In addition, in order to have a broader insight into HIV-1 integration site selection this work aims 
to implement questions on HIV-1 integration site selection from a viral perspective too, but still 
integrating the possible importance of R-loops (as a genomic feature) as targets for HIV-1 
integration.  
The main reasoning to implement such a perspective on HIV-1 integration site selection into this 
work arises from HIV-1 IN properties, as well as R-loop properties that can be associated to viral 
integration sites.  
 
Respectively, HIV-1 IN is classified into the enzymatic family of Ribonuclease H-like enzymes 
and its CCD shows an RNase H folding pattern which can also in silico be superimposed to the 
structure of a bacterial RNase H enzyme in complex with a DNA-RNA hybrid (Savarino, 2007). 
This finding from a computational approach already demonstrates that HIV-1 IN has potential 
RNase H function and could potentially  bind to a DNA-RNA hybrid.  
Apart from computational approaches demonstrating DNA-RNA hybrid binding properties of 
HIV-1 IN, clear RNA binding properties of the CTD of HIV-1 IN have been shown (Kessl et al, 
2016) which represents supporting evidence that HIV-1 IN could bind to an R-loop, and 
particularly to its RNA part.  
In addition, when comparing certain features of HIV-1 integration sites with features of R-loop 
forming regions certain similarities seem to be evident; 
Most R-loops are formed during transcription in G/C rich genomic regions (Ginno et al, 2012; 
2013), whereas HIV-1 preferentially integrates into gene bodies of highly transcribed genes with 




R-loop forming regions as well as HIV-1 integration sites show features of DNase I 
hypersensitivity (Verdin, 1991; Chen et al, 2017a), and both R-loops and HIV-1 integration sites 
are mostly associated to regions of active chromatin marks (Wang et al, 2007; Marini et al, 2015; 
Sanz et al, 2016).  
 
Finally, with respect to all described features of HIV-1 IN, R-loops as specific genomic features 
and their similarities to sites targeted for HIV-1 integration, questions that can be raised and that 
will be addressed in this work are: 
1. Do HIV-1 target genes contain R-loops? 
2. Do R-loops represent genomic features recognized by HIV-1 IN?  
3. Does HIV-1 integrate into or in the close proximity of R-loops? 
 
The main objective of this work is to contribute to a better and more detailed understanding, and 
description of sites targeted for HIV-1 integration.  
In addition, by trying to answer all set questions, this work will try to unreel potential novel 
features of HIV-1 IN, as well as try to contribute to a better understanding of the importance of 




















II. I. Chromatin structure disruption affects HIV-1 integration in primary 
CD4+ T cells  
 
Primary CD4+ T cells, isolated from healthy blood donors, were pretreated with several drugs 
affecting the activity of different chromatin modifying enzymes and subsequently infected with 




Figure 2.1. Scheme of the experimental procedure of primary CD4+ T isolation, activation and infection. 
Primary CD4+ T cells were isolated from whole blood of healthy blood donors and activated for 48 h with 
CD3/CD28 activation beads and IL-2. After activation cells were treated with selected drugs for 7 h and 
subsequently infected with HIV-1. The cells were collected 72 h post infection and processed for Alu PCR 
analysis.  
 
HDAC inhibitor SAHA (also known as Vorinostat) is a pan- histone deacetyltransferase (HDAC) 
inhibitor expected to increase global histone acetylation patterns (Bradner et al, 2010; Kim et al, 
2013; Seto & Yoshida, 2014). BET inhibitor JQ1 was described to cause the unloading of 
super-enhancers and thereby cause an overall chromatin remodeling (Filippakopoulos et al, 
2010). HMT inhibitor BIX01294 is known to specifically inhibit the activity of G9a, cause a 
reduction of H3K9me2 repressive chromatin mark and modify an overall chromatin structure 




potential effects on HIV-1 integration levels were assessed by Alu PCR (Figure 2.2. A). All 
tested drugs caused an increase in HIV-1 integration, but the effect of G9a inhibitor BIX01294 
was consistently the most prominent, by causing an overall increase of integration by 2,8-5 fold 
compared to HIV-1 integration in untreated conditions. 
 
In addition, the effect of UNC0642 on HIV-1 integration, which is another G9a inhibitor with 
improved biochemical properties (more specificity and improved Pharmacokinetic properties in 
comparison to other HMT inhibitors) (Liu et al, 2013b) was also tested. Still, the effect of 
BIX01294 causing an increase in HIV-1 integration by 2-4,6 fold was always more pronounced, 
since UNC0642 was only able to cause an increase in HIV-1 integration by maximum of 1,6 fold 
(Figure 2.2. B). Based on these results, we opted to use BIX01294 in all further experiments with 




Figure 2.2. Alu PCR results of HIV-1 integration levels upon drug treatments.  
A. HIV-1 integration levels were determined in at least 3 independent donors upon primary CD4+ T cell 
pretreatment with SAHA, JQ1 and BIX0124. The untreated infected control is set to 1, and is used as a reference 
for the integration efficiency, as measured by Alu PCR, under different treatment conditions. Integrated vDNA 
(Alu Ct values) is normalized over total genomic DNA levels amplified with primers for the lamin B2 gene (B13 
region). The graphs represent a summary of 3 experiments, B. HIV-1 integration levels determined in 3 
independent donors upon primary CD4+ T cell pretreatment with 2 different G9a inhibitors; UNC0642 and 
BIX0124. The untreated infected control is set to 1, and is used as a reference for the integration efficiency, as 
measured by Alu PCR, under different treatment conditions. Integrated vDNA (Alu Ct values) is normalized over 






II. II. Determining the kinetics and effects of BIX01294 in primary CD4+ T 
cells 
 
In the first instance, cells were treated 6-7 h with BIX01294. The effect of BIX01294 after 6-7 h 
treatment of primary CD4+ T cells was first tested and confirmed by western blot, where a 




Figure 2.3. Effect of BIX01294 on H3K9me2 chromatin mark depletion.   
A. Western blot results upon 6-7 h 7 µM BIX01294 treatment. As a readout for drug treatment efficiency 
H3K9me2 chromatin mark levels are shown, as BIX01294 inhibits G9a activity which deposits H3K9me2 
chromatin mark. As protein loading control total levels of ß-Actin are presented. B. Schematic representation of 
the effect of BIX01294 on G9a activity and deposition of H3K9me2 chromatin mark. In untreated conditions G9a 
is depositing H3K9me2 chromatin mark, creating an environment of condensed chromatin primarily in the 
nuclear periphery. During BIX01294 treatment the catalytic activity of G9a is inhibited which causes a decrease 





In addition, the reduction of H3K9me2 
could also be appreciated by IF 
(Immunofluorescence) staining and STED 
(Stimulated Emission Depleted) 
microscopy, where a clear global reduction 
of H3K9me2 chromatin mark was 
determined in cell nuclei (Figure 2.4.). 
Interestingly, two different H3K9me2 
staining patterns have been detected among 
cells of the same donor (Figure 2.4. upper 
panels). One staining pattern shows a global 
nuclear distribution of H3K9me2 which 
upon BIX01294 treatment also gets reduced 
on a global nuclear level. The other 
observed staining pattern of H3K9me2 
shows a more peripheral distribution of the 
chromatin mark which upon BIX01294 
treatment also gets reduced in the nuclear 
periphery.  
In addition, a control staining of related 
chromatin mark H3K9me3 was performed 
in untreated and BIX01294 treated 
conditions, since BIX01294 is expected to 
specifically inhibit the activity of HMT G9a 
and respectively only affect the deposition 
of H3K9me2 chromatin mark. As expected, 
and as seen by IF and immunoblot, H3K9me3 was not affected by BIX01294 treatment (Figure 






Figure 2.4. Specific reduction of H3K9me2 upon 
BIX01294 treatment.   
IF staining for H3K9me2 chromatin mark followed by 
STED microscopy of control (untreated) or cells treated 
with BIX01294 is shown in the upper panels.  Staining of 
related H3K9me3 chromatin mark under same conditions 
represents a control for the specificity of the drug treatment 
(lower panels) (scale bars: 1 µm) (imaged with the help of 




Cell viability assessment upon BIX01294 treatment and HIV-1 infection 
 
In order to assess cell viability upon BIX01294 treatment, HIV-1 infection as well as 
simultaneous drug treatment and infection, the MTT assay (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromidefor assay) was performed.  
The MTT assay is used to determine cell metabolic activity by assessing the presence of 
NAD(P)H dependent oxidoreductases in the sample. Oxidoreductases can reduce the tetrazolium 
dye MTT to its insoluble form - formazan which turns the sample into a purple color. The more 
oxidoreductases are present in the sample, the more formazan will be produced indicating that the 
sample contains less viable cells. 
Upon BIX01294 treatment no significant 
difference in cell viability was observed. On 
average 92% of the cells are still viable in 
comparison to untreated conditions where 
assumed that 100% of cells are viable. Cells 
upon HIV-1 infection on average do not show 
any difference in viability compared to 
untreated conditions, whereas upon BIX01294 
treatment and HIV-1 infection, on average, 
64% of cells are still viable (Figure 2.5). 
However, some cell death upon HIV-1 
infection was expected (Costin, 2007), and 
especially upon drug treatment and infection. 
Accordingly, the observed MTT results 
indicate that 7 µM BIX01294 treatment does 
not have any harmful effect on cell viability, 
which is also confirmed by one-way ANOVA 
statistical analysis which gave a p value of 
0,073 (the value is higher than 0,0001 and 





Figure 2.5. CD4+ T cell viability test upon BIX01294 
treatment and HIV-1 infection.  
MTT assay results of 4 independent donors upon 
BIX01294 treatment, upon HIV-1 infection and 
simultaneous  BIX01294 treatment and HIV-1 infection. 
The untreated control is set to 1 and used as a reference 
to assess cell viability in the analyzed conditions. The 
difference in cell viability between analyzed conditions is 
not statistically significant as assessed by one-way 




The timeline of BIX01294 effect on H3K9me2 chromatin mark 
 
In order to further assess the kinetics of BIX01294 treatment and its effects, levels of H3K9me2 
were assessed at different time points post drug treatment and drug release by western blot 
(Figure 2.6. A). Blot quantifications showed that after 6 h of treatment H3K9me2 levels were 
reduced to 62,33%; 12 h post drug release to 40,33%; 24 h post drug release to 33,67%; 48 h post 
drug release to 57,67% and 72 h post drug release to 69,67% of initial H3K9me2 levels. The 
strongest effect regarding H3K9me2 reduction was appreciated between 12 and 24 h post drug 
release. After 24 h post drug release H3K9me2 levels start getting reconstituted back to initial 
levels (Figure 2.6. B). 
Observing the strongest reduction of H3K9me2 between 12 and 24 h post drug release is also in 
accordance with the timing of occurred HIV-1 integration (Mohammadi et al, 2015). Obtained 
results are compatible with increased levels of HIV-1 integration upon BIX01294 treatment 
observed by Alu PCR (Figure 2.2). 
In addition, it can also be appreciated that H3K9me3 levels are not changing over time, which 
also shows that the drug treatment specifically targets only G9a and H3K9me2 chromatin mark 




Figure 2.6. The kinetics of BIX01294 treatment followed by the assessment of H3K9me2 levels at different 
time points post drug treatment and drug release.  




assessed by immunoblot. At each time point,  levels of H3 core histones and H3K9me3 control chromatin mark, 
which are not changed upon BIX01294 treatment, were also assessed.  ß-Actin  served as a loading control. B. 
Quantification of optical density of 3 independent immunoblots for H3K9me2 chromatin mark upon BIX01294 
treatment and drug release. Optical density values of H3K9me2 chromatin mark at each time point are 
normalized over protein loading control ß-Actin values. Time point 0 h of the drug treatment is set to 1 and used 
as a reference to assess optical density values of H3K9me2 chromatin mark at different time points post drug 
treatment initiation and drug release.  
 
Assessment of potential DNA damage upon BIX01294 treatment 
 
In order to exclude the possibility that the observed increase in HIV-1 integration might be 
caused by increased levels of DNA damage upon drug treatment, immunofluorescence (IF) 
staining of Gamma H2AX, DNA damage marker, which stains DNA double strand breaks was 
performed in untreated and drug treated conditions. 
By confocal microscopy it could be observed that primary CD4+ T cells in untreated conditions 
and upon 6-7 h of 7 µM BIX01294 treatment have similar numbers of cells positive for Gamma 
H2AX signals. In untreated conditions 32% cells contained Gamma H2AX signals, whereas in 
BIX01294 treated conditions 28% cells contained Gamma H2AX signals (Figure 2.7. B).  
In addition, the total amount of Gamma H2AX signals was also quantified by measuring total 
immunofluorescence intensity in both conditions. In both cases, no difference in total 
immunofluorescence intensity of Gamma H2AX could be detected. Accordingly, any DNA 
damage occurring upon BIX01294 treatment could be excluded (Figure 2.7. B and C). 
The obtained results indicate that increased levels of HIV-1 integration upon BIX01294 treatment 








Figure 2.7. Assessment of Gamma H2AX DNA double-strand break marker occurrence upon BIX01294 
treatment.  
A. Confocal images of primary CD4+ T cells stained for Gamma H2AX (green) and lamin B1 (red) in untreated 
conditions and upon BIX01294 treatment (scale bars: 2 µm). B. Graph shows results of absolute cell counts 
containing Gamma H2AX signals in untreated conditions and upon BIX01294 treatment, expressed in 
percentages. Numbers above the bars show total cell counts for 2 independent donors. C. Graph shows results of 
total IF intensity signals quantified in untreated conditions and upon BIX01294 treatment in 2 independent 
donors. The IF intensity values in untreated conditions are set to 1 and used as a reference to assess IF intensity 
values upon BIX01294 treatment.  
 
Cell activation status upon BIX01294 treatment 
 
Considering the observed increase in HIV-1 integration upon BIX01294 treatment and the fact 
that HIV-1 can only infect activated CD4+ T cells, the activation status of resting primary CD4 T 
cells upon BIX01294 treatment was tested by staining for CD38 and CD69 cell surface marker 
and subsequent FACS (Fluorescence-activated cell sorting) assay. This experiment was 
performed in order to verify whether the observed increase in HIV-1 integration upon BIX01294 





   
 
 
Figure 2.8. Determination of CD38 and CD69 cell surface marker expression upon BIX01294 treatment.  
A. Representative FACS profiles of resting primary CD4+ T cells for CD38 and CD69 cell surface marker in 
untreated conditions and upon BIX01294 treatment. The unstained condition is given as a negative control, and 
shows the gating of only live cells which are occupying forward and side scatter scales of up to 102. CD38 positive 
cells appear in the upper left quadrant of the FACS plot (FITC stained) (y-axis). CD69 positive cells appear in the 
lower right quadrant of the FACS plot (APC-Cy7 stained) (x-axis). The given p value of two-way ANOVA analysis 
is given in the graph. B. The graph shows CD38 and CD69 cell surface marker expression levels summarized for 4 
independent donors expressed in percentages. The legend in the upper right corner indicates that the black bars 
correspond to cell surface marker expression results in untreated conditions, whereas the white bars correspond to 
results upon BIX01294 treatment.  
 
Levels of CD38 expression vary during lymphocyte development, activation and differentiation, 




marker. In untreated conditions 32,26% cells are expressing CD38, whereas upon BIX01294 
treatment 29,37% cells express CD38. In case of CD69, in untreated conditions 0,42% cells 
express CD69, whereas upon BIX01294 treatment 1,11% cells express CD69 (Figure 2.8.). 
The obtained FACS results, performed statistical analysis and given p value of p=0,1739 
(p>0,0001) indicate that there is no significant change in cell activation status upon BIX01294 
treatment of resting primary CD4 T cells. The results indicating that the observed increase in 
HIV-1 integration levels upon BIX01294 treatment are not due to increased cell activation status, 
but rather due to a general more open and permissive chromatin structure. 
 
II.III. G9a knock down has the same effect on HIV-1 integration as BIX01294 
treatment 
 
To verify whether BIX01294 treatment and G9a depletion  have the same increasing effect on 
HIV-1 integration, G9a was directly knocked down (KD) by using a lentivirus containing a 
siRNA (small interfering RNA) sequence against this histone methyltransferase in Jurkat T cell 
line.  
The lentivirus additionally contained a puromycin resistance gene, which enabled selection of 
cells containing the successfully integrated viral vector harboring  G9a shRNA.  
Consistent with an observed reduction of G9a (Figure 2.9. A) and decreased H3K9me2 levels, a 
~3-fold increase in HIV-1 integration upon infection of Jurkat cells was measured by Alu PCR 
(Figure 2.9. B). 
Obtained results indicate that BIX01294 treatment, as well as direct KD of G9a induce a global 








Figure 2.9. G9a knock down and its effect on HIV-1 integration in Jurkat T cell line.    
A. Efficiency of G9a KD, as well as consequent H3K9me2 depletion measured by immunoblot. G9a levels were 
assessed upon lentiviral KD of the protein, followed by the assessment oh H3K9me2 levels upon G9a KD. As 
protein loading controls total levels of ß-Actin are presented. B. Alu PCR results showing HIV-1 integration 
levels upon G9a KD, summarized for 2 individual experiments. HIV-1 integration in untreated conditions is set to 
1 and used as a reference to assess HIV-1 integration levels upon G9a KD. Integrated vDNA (Alu Ct values) is 
normalized over total genomic DNA levels amplified with primers for the lamin B2 gene (B13 region). 
 
II. IV. H3K9me2 depletion has an increasing effect on HIV-1 integration, viral 
RNA expression and viral activity 
 
Considering  that BIX01294 treatment results showed increased HIV-1 integration (Figure 2.10 
A), we asked if these integrations read to productive or aberrant viral transcription. We therefore 
assessed the levels of HIV-1 transcription and viral mRNA production. For this purpose, RNA 
was extracted upon BIX01294 treated and HIV-1 infected cells, and viral transcripts were 
quantified by RT-PCR followed by qPCR (quantitative PCR) using primer and probes for short, 
mostly (NUC1B) aberrant and long (U1A) viral transcripts from the gag gene (Lusic et al, 2003). 
Indeed, the increase in HIV-1 integration upon H3K9me2 depletion was followed by increased 
viral mRNA levels in both, early and late viral transcripts, 72 h post infection, compared to 
untreated and infected samples. Short aberrant viral transcripts were 1,57 fold increased, whereas 
long viral transcripts, corresponding to the mature forms of the gag gene were 2,54 fold 
increased, following the increase in HIV-1 integration of 2,5 fold in comparison to untreated 




Viral activity upon BIX01294 treatment was assessed by FACS assay, by measuring the 
production of viral p24 protein. Obtained FACS results show an increase in p24 levels upon 
BIX01294 treatment and viral infection up to 2,59 fold compared to untreated conditions (Figure 
2.10. C). The obtained FACS results are in correlation with the previously observed increase in 
HIV-1 integration upon BIX01294 treatment of 2,5 fold and the increase in detected mature 



























Figure 2.10. Assessment of HIV-1 integration levels, viral RNA expression and viral activity upon 
BIX01294 treatment and H3K9me2 depletion.     
A. HIV-1 integration in untreated conditions and upon BIX01294 treatment, summarized for 3 independent 
donors, as measured by Alu PCR. HIV-1 integration in untreated conditions is set to 1 and used as a reference to 
assess HIV-1 integration upon BIX01294 treatment. Integrated vDNA (Alu Ct values) is normalized over total 




levels upon BIX01294 treatment, summarized for 3 independent donors. Graph on the left shows mRNA 
expression of early viral transcripts, where the values in untreated conditions are set to 1 and used as a reference 
to assess the expression of early viral transcripts upon BIX01294 treatment. The graph on the right shows mRNA 
expression levels of late viral transcripts, where the values in untreated conditions are set to 1 and used as a 
reference to assess the expression of early viral transcripts upon BIX01294 treatment. Viral gene expression 
levels are normalized over host cell housekeeping gene GAPDH. C. Representative FACS profiles of primary 
CD4+ T cells infected with HIV-1 in untreated and BIX01294 treated conditions and stained for viral protein p24. 
Unstained cells in both conditions are represented as a negative control, and show the gating of only live cells 
which are represented in the orange window and occupy forward and side scatter scales of up to 102. Live p24 
positive cells are marked in respect to the cells marked as live in the unstained control, but shifted to forward 
scatter values up to 105, caused by the presence of the p24 protein. The graph on the right represents a summary 
of p24 positive cells upon HIV-1 infection in untreated and BIX01294 treated conditions for 3 independent 
donors expressed in percentages. Results from 3 independent donors shown in panel A correspond to the same 
donors and results shown in panel B and C. 
 
Apart from increased HIV-1 integration upon H3K9me2 depletion, which is followed by 
increased viral activity, assessed by measuring  viral RNA and p24 production (Figure 2.10. A, B 
and C), we also observed a decrease in non-integrated viral DNA. This decrease, as measured by 
PCR for 2LTR circles (Figure 2.11. A and B), suggests that following nuclear entry all copies of 
HIV-1 viral DNA get integrated into the cellular genome, probably due to more open chromatin 











Figure 2.11. Quantification of non-integrated HIV-1 DNA (2LTR circles) upon H3K9me2 depletion.  
A. Graph shows the quantification of 2LTR circles upon HIV-1 infection following BIX01294 treatment, as 
normalized over levels of total vDNA (graph in panel B). A summary of 3 independent donors is shown B. 
Quantification of total vDNA upon HIV-1 infection in untreated and BIX01294 treated conditions, summarized 
for 3 independent donors. Total vDNA was quantified by plotting the amounts of total vDNA qPCR Ct values 
(y-axis) over the values obtained by serial dilutions of DNA (represented as ng/μl) from latent HIV-1 clone J-Lat 
9.2 cell DNA (x-axis). 3 independent donors, same as the ones shown in Figure 2.10., were used for 
quantification.   
 
II.V. H3K9me2 depletion affects 3D nuclear position of HIV-1  
 
The 3D positioning of HIV-1 in CD4+ T cell nuclei was determined by immuno-DNA FISH 
(Fluorescent in situ Hybridization) followed by confocal microscopy in untreated and BIX01294 
treated conditions. In untreated conditions, the virus preferentially positions in the outer shell of 
the nucleus (occupying nuclear zone 1), as previously described (Marini et al, 2015). Upon drug 
treatment, due to the modification of histone methylation patterns, more HIV-1 DNA FISH 
signals per nucleus (cell) were observed, consistent with the detected increase in HIV-1 
integration upon BIX01294 treatment, as seen by Alu PCR. 
Interestingly, upon BIX01294 treatment, we observed changes in the distribution patterns of the 
virus, as it is positioned in the interior zones of the nucleus, occupying predominantly nuclear 
zone 2 (Figure 2.12. A and B). In untreated conditions 68,87% HIV-1 DNA FISH signals occupy 
nuclear zone 1, 28,12% occupy nuclear zone 2 and 3,01% nuclear zone 3. In BIX01294 treated 




zone 2 and 6,94% nuclear zone 3. This finding was quantified by radial measurements of nuclei 
and determination of relative distances of HIV-1 signals to the nuclear lamina as previously 




Figure 2.12. 3D nuclear position of HIV-1 upon H3K9me2 depletion and BIX01294 treatment.      
A. Schematic representation of the nuclear zones and the 3D nuclear distribution of HIV-1 in untreated vs. 
BIX01294 treated conditions. Legend on the right indicates nuclear zones and division of the nucleus into areas 
of equal volume according to their distance to the nuclear lamina. B. FISH results of HIV-1 3D nuclear position 
in untreated conditions and upon BIX01294 treatment. Numbers under the images indicate the number of infected 
cells in which the distance of HIV-1 FISH signals to the nuclear lamina was measured (scale bars: 2 µm). Graph 
below shows the cumulative distribution of HIV-1 proviral signals by the Kolmogorov-Smirnov test in relation to 







II.VI. HIV-1 RIGs follow the pattern of HIV-1 positioning in the 3D nuclear 
space 
 
As for HIV-1, the nuclear position of selected HIV-1 RIGs and HIV-1 non-target genes in 
untreated and BIX01294 treated conditions was determined by immuno-DNA FISH and confocal 
microscopy.  
In total, 15 genes were analyzed (BACH2, NPLOC4, STAT5B, MKL2, DNMT1, RPTOR, 
SMG1, GRB2, GNB1, NFATC3, PACS2, KDM2B, ACTN1, RNF157, CNTN4). Genes as 
BACH2, NPLOC4, STAT5B, MKL2, DNMT1, RPTOR, SMG1, GRB2, GNB1, RNF157 and 
NFATC3 were chosen among RIGs, whereas PACS2, KDM2B, ACTN1, CNTN4 where chosen 
as HIV-1 non-target genes. RIGs BACH2, NPLOC4, STAT5B, MKL2, DNMT1, RPTOR, 
SMG1 GRB2 and RNF157 clearly change their nuclear position upon BIX01294 treatment and 
H3K9me2 depletion (Figure 2.13.), whereas GNB1& NFATC3 did not change their 3D nuclear 





















treatment.      
Numbers under the images indicate the total cell count in which the distance of the gene FISH signals to the 
nuclear lamina was measured. Graphs below the images show the cumulative distribution of alleles by the 
Kolmogorov-Smirnov test in relation to their relative distance to the nuclear lamina, with the corresponding 






Figure 2.14. 3D nuclear position of RIGs that do not change their nuclear position upon H3K9me2 
depletion and BIX01294 treatment.      
Numbers under the images indicate the total cell counts in which the distance of the gene FISH signals to the 
nuclear lamina was measured. Graphs below the images show the cumulative distribution of alleles by the 
Kolmogorov-Smirnov test in relation to their relative distance to the nuclear lamina, with the corresponding 
p  value above the x-axis of the graph (scale bars: 2 µm). 
 
Chosen HIV-1 non-target genes PACS2, KDM2B, ACTN1, CNTN4 do not move from their 
initially occupied nuclear zone, which is zone 2 for PACS2 and KDM2B. For CNTN4 gene 
locus, which is inside a LAD, we observed a slight, statistically significant (p<0,0001) shift 
towards the nuclear periphery upon BIX0124 treatment. In the case of ACTN1 the opposite 
phenomenon can be appreciated, where a minor, although statistically significant (p=0,0014) shift 








Figure 2.15. 3D nuclear position of HIV-1 non-target genes. 
Numbers under the images indicate the total cell counts in which the distance of the gene FISH signals to the 
nuclear lamina was measured. Graphs below the images show the cumulative distribution of alleles by the 
Kolmogorov-Smirnov test in relation to their relative distance to the nuclear lamina, with the corresponding 
p  value above the x-axis of the graph (scale bars: 2 µm). 
 
In summary, out of 11 analyzed RIGs, 9 genes change their nuclear position and move more 
towards the nuclear center, following the example of HIV-1 upon BIX01294 treatment and 
H3K9me2 depletion. Out of 4 analyzed non-HIV-1 target genes, 2 do not change their nuclear 




the nuclear center (ACTN1). In total, out of 15 analyzed genes 12 change their nuclear position 





Figure 2.16. Summarized representation of 3D nuclear position of HIV-1, RIGs and non-RIGs in untreated 
and BIX01294 treated conditions.   
Graph shows the cumulative distribution of all analyzed alleles and vDNA signals  by the Kolmogorov-Smirnov 
test in relation to their relative distance to the nuclear lamina. The black line on the histogram indicates the 
position of HIV-1 and RIGs in untreated conditions. The red line shows the repositioning of HIV-1 upon 
BIX01294 treatment. The green line shows the repositioning of RIGs upon BIX01294 treatment. The blue line 
shows the nuclear position of not moving RIGs and non-RIGs in the nucleus upon BIX01294 treatment.   
 
II.VII. Changed nuclear position does not affect transcriptional activity of 
HIV-1 RIGs 
 
Given that BIX01294 treatment causes a reduction of facultative heterochromatin mark 
H3K9me2 and that it also has an effect on gene positioning, we reasoned that there might be also 
a change of global gene expression levels.  
In order to assess potential changes in gene expression levels, RNA microarray analysis, of 
untreated and BIX01294 treated primary CD4+ T cells 6-7 hours post treatment was performed, 




BeadChip kit. Interestingly, RNA expression profiles of most genes were not affected by the 
treatment. Still, we observed that certain portion of genes were either downregulated or 
upregulated (Figure 2.17. A). In addition, we performed the Gene Ontology (GO) term analysis 
and among the downregulated genes we find genes involved in membrane trafficking, protein and 
ion binding. In the group of upregulated genes, genes involved in iron metabolism and 
inflammatory response are dominating (Figure 2.17. B). It is known that G9a function is pivotal 
in cell proliferation and differentiation (Lehnertz et al, 2010; Rao et al, 2016). In addition, it has 
been shown that G9a impairment by BIX01294 treatment can reduce cellular proliferation rates 
or cause cell cycle arrest (Shankar et al, 2013). On the other hand, iron is vital for T cell 
proliferation and is involved in pathways protecting cells from cytotoxicity, oxidative stress and 
DNA damage (Bowlus, 2003; Ruttkay-Nedecky et al, 2013). Thus,  it might be plausible that 
there is  an ongoing compensatory effect, where iron and inflammatory pathways are activated in 










Figure 2.17. RNA microarray results of global gene expression profiles upon BIX01294 treatment.   
A. Volcano plot shows the global change in gene expression profiles upon BIX01294 treatment. The plot shows a 
clear diversification between downregulated genes (genes on the left of the x-axis, showing an expressional log 
fold change bellow the value 0) and upregulated genes (genes on the right of the x-axis, showing an expressional 
log fold change above the value 0) upon drug treatment, summarized for 2 independent donors (data analysis 
performed by Constantin Ahlmann-Eltze). B. Heatmap shows the top 50 genes with changed expression profiles 
upon BIX01294 treatment. The color code in the upper left corner indicates log fold changes of gene expression 
levels. The top upregulated genes are indicated on the box on the right. The top upregulated genes are members 
of metalloproteases and chemokine receptors involved in iron metabolism and inflammatory response (data 
analysis performed by Constantin Ahlmann-Eltze).  
 
We then analyzed the expression profiles of HIV-1 targeted genes (RIGs) and observed again that 




We compared f RIGs to a random set of 424 genes (Figure 2.18. panel A; blue lines) a clear shift 
towards lower p-values could be noticed, suggesting  that overall, RIGs change their expression 
profiles in BIX01294 treatment (Figure 2.18. A), although this seems to be a rather mild change. 
The only significant change could be appreciated for BACH2, with a log fold change of 2, which 












Figure 2.18. RIGs expression profiles upon BIX01294 treatment.  
A. The barcode plot shows, in red, the distribution of p-values for each RIG expression change. A maximum 




performed by Constantin Ahlmann-Eltze). B. The heatmap shows the top 50 RIGs with changed expression 
profiles upon BIX01294 treatment, with BACH2 being the most significantly upregulated RIG. The color code in 
the upper left corner indicates log fold changes of gene expression levels (data analysis performed by Constantin 
Ahlmann-Eltze). C. Bar plots show RT-qPCR results of mRNA expression levels of BACH2 and STAT5B at 
different time points post BIX01294 treatment. The values in untreated conditions for each time point are set to 1 
and used as a reference to assess mRNA expression changes upon BIX01294 treatment at each analyzed time 
point. Gene mRNA expression is normalized over expression profiles of housekeeping gene 18.  
 
In conclusion, the obtained results show that BIX01294 treatment affects gene expression 
profiles. However, RIGs expression was not dramatically impacted by the treatment, whereas 
groups of genes involved in iron metabolism and inflammatory response showed clear 
overexpression. This result might also indicate that increased HIV-1 integration upon BIX01294 
treatment is not due to increased RIGs expression, but rather due to a more loose and accessible 
chromatin composition.   
 
Cell cycle profiles upon BIX01294 treatment 
 
Considering that BIX01294 treatment causes a global reduction in H3K9me2 chromatin mark, 
opening of chromatin structure and change in gene expression levels, testing potential changes in 
cell cycle profiles of untreated activated primary CD4+ T cells and BIX01294 treated cells was 
also performed.  
The cell cycle analysis was performed by propidium iodide staining of cells, followed by FACS 
analysis 7 h post BIX01294 treatment. Upon BIX01294 treatment, no significant change in the 
cell cycle profile was observed. Cells were predominantly in G1 phase (on average 67,32% of 
untreated cells; 72,75% of BIX01294 treated cells), a portion was  also found  in G2 (on average 
25,54 % of untreated cells; 22,11 % of BIX01294 treated cells) phase and late G2 or M phase (on 
average 5,06% of untreated cells; 314% of BIX01294 treated cells) (Figure 2.19. A and B).  
In untreated conditions 2,08% of cells were not gated as live, whereas in BIX01294 treated 
conditions 2% of cells were not gated as live. 
Obtained results indicate that BIX01294 treatment does not cause any changes in cell cycle 




of G9a KD, where cell cycle profiles and cell proliferation were not affected after G9a KD 




Figure 2.19. Cell cycle profiles upon BIX01294 treatment.   
A. Histogram of cell FACS profiles upon BIX01294 treatment (orange line) compared to untreated conditions 
(black line). Results represent an output of the BD Biosciences FACS analysis software where peaks occurring 
before 103 PE-A density represent cells in G1 phase of the cell cycle, peaks occurring at 103 PE-A density 
represent cells in G2 phase of the cell cycle and peaks occurring after 103 PE-A density represent cells in the late 
G2 or M  phase of the cell cycle. B. The graph shows a summary of total amounts of cells in G1, G2 and M phase 














II. VIII. Chromatin composition of HIV-1 target genes upon H3K9me2 
depletion  
 
Assessment of RIGs chromatin composition by ChIP-qPCR 
 
BIX01294 treatment and H3K9me2 depletion did not cause a significant change in transcription 
profiles of HIV-1 target genes, but significantly affected their position in CD4+ T cell nuclei. We 
therefore sought to understand how H3K9me2 depletion affects the surrounding chromatin 
composition and LEDGF/p75 binding at selected RIGs.   
ChIP-qPCR (Chromatin Immunoprecipitation followed by quantitative PCR) was performed for 
selected chromatin marks (H3K9me2, H3K9me3, H3K36me3), as well as for host cell factor 
LEDGF/p75. In total, 9 genes were analyzed by ChIP-qPCR, 5 of which were RIGs (BACH2, 
STAT5B, MKL2, RPTOR, NPLOC4) and 4 were non-RIGs (KDM2B, PACS2, ACTN1, 
CNTN4). For all the genes, primers for the first intron region, gene body and exon/intron junction 
at the gene end were designed in order to follow possible changes along selected genes. 
H3K9me2 chromatin mark served as a readout for efficient BIX01294 treatment, and was 
expected to decrease in regions where it otherwise binds. H3K9me3 served as a control for the 
treatment, since the binding of this chromatin mark should not be significantly affected by 
BIX01294 treatment. H3K36me3 was probed in ChIP as it is expected that this chromatin mark is 
deposited on HIV-1 target genes (Marini et al, 2015; Lucic et al, 2019), and might also be 
affected by BIX01294 treatment. Host cell factor LEDGF/p75 was included into the analysis 
considering its important role in HIV-1 integration site selection (De Rijck et al, 2010; Craigie & 
Bushman, 2012; Achuthan et al, 2018) as well as its know feature to act as H3K36me3 chromatin 








Figure 2.20. ChIP-qPCR results of the first intron region of selected genes. 
Distribution of H3K9me2, H3K9me3 and H3K36me3 chromatin marks, as well as of LEDGF/p75 in the first 
intron region of selected RIGs and non-RIGs in untreated conditions and upon BIX01294 treatment. The graphs 
represent summarized results for 3 independent donors, normalized over input DNA levels. The legend in the 





H3K9me2 distribution in 
untreated and BIX01294 treated 
conditions showed an overall 
decrease in H3K9me2 levels upon 
BIX01294 treatment. This trend 
could be observed in the first 
intron region in almost all of the 
analyzed genes (except for 
ACTN1) (Figure 2.20.), as well as 
in gene bodies and gene ends 
(Figure 2.21. and 2.22.). When the 
enrichment of H3K9me3 was 
analyzed, as expected, and as 
previously seen by immunoblot 
and IF (Figure 2.4. and 2.6.), the 
levels of this chromatin mark 
mainly remained unchanged upon 
BIX01294 treatment. H3K9me3 
levels do not change in the first intron region and gene ends of analyzed genes (Figure 2.20. and 
2.22.). However, a slight decrease of H3K9me3 binding can be appreciated in the gene bodies of 
analyzed genes (Figure 2.21.), which is not surprising considering the very strong effect of 
BIX01294 on related H3K9me2 chromatin mark and the high sensitivity of the used antibodies 
(Rothbart et al, 2015).  
H3K36me3 distribution showed an overall increase in the first intron region of all analyzed genes 
upon BIX01294 treatment (Figure 2.20.), whereas it’s levels in gene bodies seemed not affected 
by the treatment. Interestingly, in the gene ends of MKL2 and CNTN4 an increased binding of 
H3K36me3 could be detected. As a mark of elongating Pol II transcription, H3K36me3 is usually 
found in gene bodies and transcribed  
 
 
Figure 2.21. ChIP-qPCR of the gene body region of selected genes. 
Same as in Figure 2.20., assays in PCR with primers designed for the 




genomic regions (Venkatesh 
et al, 2012), but it can  also 
be linked to alternative 
splicing, dosage 
compensation, DNA 
replication and repair 
(Wagner & Carpenter, 2012; 
Suzuki et al, 2016). We did 
not observe an increased 
deposition of H3K36me3 in 
gene bodies of analyzed 
genes (Figure 2.21.) upon 
BIX01294 treatment, 
consistent with the 
unchanged expression 
profiles of RIGs upon 
H3K9me2 depletion and 
BIX01294 treatment. 
Interestingly, increased 
deposition  of H3K36me3 was observed in gene ends of MKL2 and CNTN4, and might  possibly 
be associated to some alternative implications of this chromatin mark.  
Analyzing ChIP-qPCR profiles of LEDGF/p75, which is also a known H3K36me3 chromatin 
reader (Pradeepa et al, 2012), revealed that LEDGF/p75 binding was enriched only in the first 
intron of RIGs upon BIX01294 treatment (Figure 2.20.), whereas it remained unchanged on non-
RIGs, similarly to the observed H3K36me3 distribution. When looking into gene bodies and gene 
ends, levels of LEDGF/p75 did not change upon BIX01294 treatment (Figure 2.21. and 2.22.). 
Only in the gene bodies of BACH2 and MKL2 a certain reduction of LEDGF/p75 binding could 
be observed, which might be justified by almost 50% more binding in the first intron region of 
these genes and the repositioning of LEDGF/p75 binding along these genes. In addition, the 
observed enrichment of H3K36me3 and LEDGF/p75 in the first intron regions of RIGs could be 
associated to the observed increased integration of HIV-1 upon BIX0124 treatment and the fact 
 
 
Figure 2.22. ChIP-qPCR results of the gene end region of selected genes. 
Same as in Figure 2.20., assays in PCR with primers designed for the gene 





that HIV-1 preferentially integrates into introns of expressed genes (Craigie & Bushman, 2012; 
Han et al, 2014; Cohn et al, 2015). 
 
Global H3K36me3 and LEDGF/p75 protein levels remain unchanged upon H3K9me2 depletion 
 
Given that H3K36me3 and LEDGF/p75 showed some differences in their deposition profiles 
along analyzed genes upon BIX01294 treatment, we assessed their overall levels in BIX01294 
treatment. Immunoblot analysis showed that global levels of H3K36me3 remain unchanged upon 
BIX01294 treatment (2.23. A and B). This result indicates that, while the global levels of 
H3K36me3 do not change, some probably local changes in its distribution occur upon BIX01294 




Figure 2.23. Quantification of H3K36me3 levels upon BIX01294 treatment.  
A. Immunoblot assessment of H3K36me3 levels upon BIX01294 treatment. As a readout for the treatment 
efficiency, H3K9me2 levels were probed. ß-Actin served as a loading control  B. Optical density quantification of 
H3K36me3 chromatin mark of western blot results of 3 independent donors upon BIX01294 treatment. Optical 
density values of H3K36me3 are normalized over optical density values of ß-Actin loading control and in 
untreated conditions set to 1 and used as a reference to assess optical density changes in H3K36me3 chromatin 







Global levels of LEDGF/p75 were assessed by western blot and IF staining in two additional 
conditions; untreated, BIX01294 treated, HIV-1 infected only and BIX01294 treated and HIV-1 
infected. Levels of LEDGF/p75 remain unchanged upon BIX01294 treatment, HIV-1 infection or 
under both, treated and infected conditions, as seen and quantified by western blot as well as 
quantified by microscopy and total immunofluorescence intensity (2.24. A, B, C and D).  
Similarly, as in the case of H3K36me3, this result indicates that only the binding profile of 
LEDGF/p75 is affected upon BIX01294 treatment and H3K9me2 depletion, whereas total protein 






















Figure 2.24. Quantification of total LEDGF/p75 levels upon BIX01294 treatment.  
A. IF staining results of LEDGF/p75 upon BIX01294 treatment. The images show maximum projection of taken 
Z-stacks. The dashed line indicates the nuclear rim, and was marked in relation to Hoechst nuclear staining (scale 
bars: 1 µm). B. Total IF intensity quantification of LEDGF/p75 upon BIX01294 treatment (31 cells in total). IF 
intensity values in untreated conditions are set to 1 and used as a reference to assess  IF intensity changes upon 
BIX01294 treatment. C. Western blot results show the assessment of LEDGF/p75 levels upon BIX01294 
treatment, HIV-1 infection and BIX01294 treatment and infection. The efficiency of BIX01294 treatment is 
demonstrated by the assessment of H3K9me2 chromatin mark levels. As protein loading controls total levels of 
ß-Actin are presented. D. Optical density quantification of LEDGF/p75 levels of western blot results of 2 
independent donors upon BIX01294 treatment and HIV-1 infection. Optical density values of LEDGF/p75 are 
normalized over optical density values of the ß-Actin loading controls and in untreated conditions set to 1 and 






 II. IX. Determining HIV-1 integration sites upon H3K9me2 depletion 
 
Finally, we wanted to address HIV-1 
integration profiles by directly 
sequencing the integration sites. As 
BIX01294 treatment and H3K9me2 
depletion resulted in alterations of 
spatial distribution of HIV-1 in the 
nuclear space (Figure 2.12. B), we 
wanted to test if  HIV-1 integration 
profiles changed as well. Therefore, 
we sought to directly sequence HIV-1 
integration upon drug treatment.  
HIV-1 integration sites have been 
sequenced in untreated and BIX01294 
treated conditions by LAM-PCR 
(Schmidt et al, 2007). In addition, a 
comparison of HIV-1 integration 
profiles in both conditions has been 
conducted, as well as a comparison of 
our dataset to other HIV-1 integration 
sites lists (Ikeda et al, 2007; Brady et 
al, 2009; Wagner et al, 2014; 
Maldarelli et al, 2014; Kok et al, 2016) 
(Figure 2.25.). This was done in 
collaboration with the group of 
Manfred Schmidt (previously NCT, 
now Genewerk) and the data analysis 




Figure 2.25. Cluster dendrogram of HIV-1 integration sites 
from untreated and BIX1294 treated conditions compared to 
other HIV-1 integration site lists.  
The obtained cluster dendrogram shows that HIV-1 integration 
sites obtained upon BIX01294 treatment produce a distribution 
pattern similar to integration sites obtained in untreated 
conditions, and similar to integration sites from other studies 
(indicated on the height scale of the dendrogram) (data analysis 




The obtained results show that HIV-1 integration patterns in untreated and BIX01294 treated 
conditions cluster together, and are clearly separated from other HIV-1 integration site datasets. 
This indicates  that a high degree of similarity between the two conditions we analyzed is 
probably due to the sequencing method used.  
 
The obtained result shows that even with a 
small dataset (in total 910 integration sites; 
413 in untreated conditions and 497 in 
BIX01294 treated conditions from 2 donors) 
an increase of 1,2 fold more integration sites 
upon BIX01294 treatment can be appreciated 
(Table 2.1.).  
However, the increase in HIV-1 integration 
upon BIX01294 treatment observed by 
Alu PCR, which was always in the range of a 
2,8-5 fold increase (Figure 2.2), does not 
correspond to the increase observed by 
integration site sequencing. This discrepancy 
might be explained by underestimating 
capacities of integration site sequencing 
approaches (Cui et al, 2016; Hughes & Coffin, 
2017).   
In addition, the results indicate that H3K9me2 
depletion does not cause a change in HIV-1 integration site selection, but rather causes an 
increase in integration into the proximal genomic regions due to increased chromatin 
accessibility. This possibility will be tested in the future experiments, where the same donors in 
which HIV-1 integration sites were sequenced, will be tested for chromatin profiles of 




Table 2.1. Summary statistics of retrieved  HIV-1 








Our results so far show that chromatin composition, in particular that related to H3K9me2 
deposition, has an effect on HIV-1 integration levels. The obtained results indicate that a global 
increase in chromatin accessibility induced by G9a inhibitor BIX01294 increases HIV-1 
integration and changes the localization of the viral genome in the 3D nuclear space.  
In addition, the results show that the drug treatment specifically targets H3K9me2 chromatin 
mark, without affecting related H3K9me3 chromatin mark. It can also be excluded that the 
observed increase in HIV-1 integration occurs due to any DNA damage, changes in cell cycle 
profiles or activation status of the cells caused by drug treatment, indicating that the observed 
increase in HIV-1 integration is related to increased chromatin accessibility.  
Analyzed gene expression profiles upon BIX01294 treatment show that RIGs expression levels 
are not significantly impacted by the drug treatment and that potentially increased HIV-1 target 
gene expression profiles can not be correlated to the observed increase in HIV-1 integration upon 
BIX01294 treatment. On the other hand, gene expression profiles of genes involved in iron 
metabolism, inflammatory response or membrane trafficking were significantly affected by the 
drug treatment.  
Finally, the detailed analysis of chromatin composition of RIGs and non-RIGs upon BIX01294 
treatment and H3K9me2 depletion revealed increased binding of H3K36me3 chromatin mark in 
the first intron region of analyzed genes, which was followed by increased binding of host cell 
factor LEDGF/p75 only on RIGs. This results might give a certain explanation for the observed 
increase in HIV-1 integration upon BIX01294 treatment, which might be connected to a global 
increase in chromatin accessibility.  
The observed increase in HIV-1 integration could additionally be observed by the analysis of 
viral integration sites upon BIX01294 treatment and H3K9me2 depletion. The integration site 
data demonstrated no change in the distribution of HIV-1 integration sites upon H3K9me2 
depletion, indicating that still the same genomic sites are targeted for HIV-1 integration, but they 
become even more targeted due to a global increase in chromatin accessibility upon BIX01294 
treatment. This finding also indicated that the observed nuclear re-distribution of the proviral 
genome upon BIX01294 treatment, as seen by FISH analysis, could not be connected to a 




In the following results section, a more viral perspective on HIV-1 integration will be given, 
integrating the interplay of viral IN and its catalytic and chromatin binding properties with 
































II. X. R-loops show strong association with HIV-1 RIGs 
 
Our results so far show that chromatin composition related to H3K9me2 levels has a significant 
impact on HIV-1 integration levels. The global increase in chromatin accessibility induced by 
G9a inhibitor BIX01294 increases significantly HIV-1 integration and changes the localization of 
the viral genome in the 3D nuclear space. In order to understand if there are other genomic 
features related to H3K9me2 chromatin mark and to viral integration, we performed a 
computational analysis in which we analyzed the presence of DNA-RNA hybrids or R-loops on 
HIV-1 integration sites (genes). For the analysis, we used HIV-1 integration sites from two 
studies (Cohn et al, 2015; Kok et al, 2016) reporting patient derived integration sites from the two 
major HIV-1 target cell types (T cells and macrophages). The  R-loop profiles were derived from 
the study by the Chedin lab, where K562 myelogenous leukemia cell line and Nt2 human 
embryonic carcinoma cell line were assayed by DRIP-Seq (DNA-RNA Immunoprecipitation 
followed by genome wide sequencing (Sanz et al, 2016). By using a cut-off of at least 3 hybrids 
per gene, we observed that genes targeted by HIV-1 have an increased incidence of R-loop 
forming structures.  (Figure 2.26. A). We then analyzed the presence of R-loops (as mapped in 
K562 myelogenous leukemia cell line by Sanz et al, 2016) in HIV-1 RIGs (Lucic et al, 2019) and 
observed that a striking 83% of HIV-1 RIGs have 3 or more R-loops (Figure 2.26. B). The same 
graph shows the control analysis of HIV-1 RIGs with the LAD regions, retrieved from human 
fibroblasts and Jurkat T cell line (Guelen et al, 2008; Robson et al, 2017), from which HIV-1 












Figure 2.26. Computational overlap of HIV-1 integration site lists and R-loop maps.   
A. Heatmap shows an overlap of HIV-1 integration sites (Cohn et al, 2015; Kok et al, 2016) and R-loop maps 
(Sanz et al, 2016). The color code on the right indicates levels the overrepresentation of R-loop forming sites in 
HIV-1 integration sites (data analysis performed by Constantin Ahlmann-Eltze). B. Heatmap shows an overlap of 
RIGs (listed in the upper part of the heatmap) and an R-loop map from K562 cells (Sanz et al, 2016), by 
including genomic LAD regions retrieved from human fibroblasts and Jurkat T cell line (Guelen et al, 2008; 
Robson et al, 2017), as outliers, into the analysis (data analysis performed by Maja Kuzman).  
 
This in silico retrieved dataset represented the first indication that R-loop forming sites might be 
associated to HIV-1 integration sites.  
 
II. XI. HIV-1 Preintegration Complexes (PICs) colocalize with R-loops 
 
In order to gain the experimental support for our hypothesis that R-loops represent the necessary  
genomic feature for HIV-1 integration, we first set up to visualize at the cellular level a possible  
colocalization of HIV-1 PICs and R-loops in primary macrophages as well as primary CD4+ T 
cells was performed.  
Cells were infected with an engineered wt HIV-1 virus containing a GFP-tag on the viral IN 
protein, produced by the Vpr-trans incorporation strategy (Albanese et al, 2008). The cells were 
collected at early time points post infection (36 h in macrophages and 18 h in CD4+ T cells) in 
order to capture the PICs before the integration step is completed. IF staining of R-loops was 
performed using the S9.6 antibody, followed by microscopy and PIC/R-loop colocalization 
analysis.  
A striking colocalization pattern between R-loop structures and HIV-1 PICs could be observed at 
early time points post HIV-1 infection in primary human CD4+ T cells and macrophages,  in both 
confocal and super-resolution microscopy. In CD4+ T cells 75% of HIV-1 PICs in the nucleus 
colocalized with R-loops (Figure 2.27. A). In macrophages a similar trend of 72% of colocalizing 







Figure 2.27. HIV-1 IN.eGFP colocalization with R-loops.  
A. IF R-loop staining with S9.6 antibody in primary CD4+ T cells upon RNase H1 pretreatment of fixed cells, 
followed by confocal microscopy. The cell on the left shows R-loop staining patterns in untreated conditions. The 
cell on the right shows the reduction of R-loop signals upon RNase H1 pretreatment of the cells, confirming the 




performed by the help of Dr. Bojana Lucic) (scale bars: 2 µm). B. Primary human CD4+ T cells  infected with 
HIV-1 INeGFP (18 h post infection) stained with S9.6 antibody - representative STED images, with the 
quantification of colocalizing PICs and R-loops, shown in the graph below (expressed in percentages) - 75% of 
PICs colocalize with R-loops. The number next to the graph indicates the number of analyzed cells in 6 
independent donors. C. Macrophages infected with HIV-1 IN.eGFP (36 h post infection) stained with S9.6 
antibody - a representative STED image, with the quantification of colocalizing PICs and R-loops, shown in the 
graph below (expressed in percentages) - 72% of PICs colocalize with R-loops. The number next to the graph 






























These obtained results could be confirmed by HIV-1 DNA FISH in primary macrophages at 
different time points post infection (36 h, 48 h & 60 h) (Figure 2.28. A and B). 
   
 
Figure 2.28. HIV-1 DNA immuno-FISH and R-loop staining in macrophages.   
A. The images show viral DNA colocalizing with R-loop signals at different time points post infection assessed 
by IF staining of R-loops (S9.6 antibody) and performed HIV-1 DNA FISH. Macrophages were infected with 
HIV-1 IN.eGFP and collected at early time points post infection for DNA immuno-FISH, followed by confocal 
microscopy. The red channel represents the R-loop IF signal. The green channel represents the HIV-1 DNA FISH 
signal. In the merged view the blue channel represents the DNA-Hoechst staining. The white arrows indicate a 
colocalizing HIV-1 FISH and R-loop signal (scale bars: 2 µm). B. Graph shows the quantification of HIV-1 FISH 
signals colocalizing with R-loop signals summarized for all analyzed time points, expressed in percentages (total 





Obtained results show that HIV-1 PICs colocalize with R-loops, thus suggesting that  HIV-1 
PICs by docking to R-loop structures, could integrate the viral genome into these  genomic 
structures (as seen by HIV-1 DNA FISH).   
 
II. XII. Functionally impaired HIV-1 IN contributes to less PIC and R-loop 
colocalization in macrophages 
 
In order to verify that the initially observed colocalization between HIV-1 PICs and R-loops does 
not represent an artifact or a phenomenon occurring just by chance, the same set of experiments 
was performed on macrophages, as already described, but with PICs containing a functionally 
impaired IN (CCD mutant D116N). As an additional control, we used Raltegravir (Markowitz et 
al, 2007),  which impairs HIV-1 integration by acting as an Integrase strand transfer inhibitor.  
All viruses used in this set of experiments were produced by the Vpr-trans incorporation strategy 
(Albanese et al, 2008) and contained a IN.eGFP.  
 
HIV-1 IN CCD mutant  
 
We used a CCD mutant containing a point mutation at position 116 (D116N) of HIV-1 IN, which 
renders the virus catalytically inactive for integration (Engelman et al, 1995). With this mutant 
we infected macrophages to test for R-loop colocalization in the absence of integration. 
Upon infection of primary macrophages a significant reduction of PICs colocalizing with R-loops 
could be observed. Only 30,1% of the PICs were detected to colocalize with R-loops, which 
represents a drop of 41,45 % compared to the wt virus (Figure 2.29.).  
 
HIV-1 wt IN in the presence of Raltegravir 
 
Upon the assessment of a drop in HIV-1 D116N IN PICs and R-loop colocalization, the 
following question to answer was whether a chemical inhibitor of wt IN would contribute to a 
similar drop in PIC and R-loop colocalization. The colocalization of wt IN PICs and R-loops was 




Raltegravir contains Mg2+ chelating groups and is supposed to bind the two metal ions in the 
catalytic site of IN and block the binding of host DNA (Mouscadet & Tchertanov, 2009).  
Upon infection of macrophages with HIV-1 and the addition of Raltegravir at the moment of 
infection and after 24 h of infection, a drop in the number of PICs colocalizing with R-loops at 60 
h post infection could be appreciated. Only 21,45% of the PICs were colocalizing with R-loops, 
which represents a drop in colocalization of 50,1%, compared to the colocalization of wt IN 






Figure 2.29. Comparison of wt IN.eGFP HIV-1, D116N IN.eGFP HIV-1 and wt IN.eGFP HIV-1 in the 
presence of Raltegravir and their colocalization with R-loops.  
A. Representative confocal images of HIV-1 PIC colocalization with R-loops in all analyzed conditions. White 
arrows indicate PICs colocalizing with R-loops, whereas yellow arrows indicate PICs not colocalizing with 
R-loops. The blue channel represents IF staining of Lamin B1. The red channel represents IF staining of R-loops. 
The green signals represent the GFP signals from the IN.eGFP. The very pronounced R-loop signals correspond 
to cellular nucleoli which are composed of ribosomal genes and nucleolar organizer regions known to be very R-
loop rich (Wahba et al, 2016; Kuznetsov et al, 2018) (scale bars: 2 µm). B. Graph shows a summary of quantified 
PIC colocalization with R-loops for all analyzed conditions. The numbers above the bars indicate numbers of 
analyzed donors. Showed results were generated 60 h post infection.  
 
The obtained results suggest that catalytically active HIV-1 IN is required for high occurrence of 
PIC and R-loop colocalization. In addition, the results point to a scenario in which PICs 
containing wt IN do not just by chance colocalize with R-loops, but that this colocalization 
represents a non-random process that is observed in the case of 75% of PIC signals in primary 



















II.XIII. Assessment of IN C-terminal mutant and replication deficient HIV-1 
colocalization with R-loops  
 
We further reasoned that 3 residues in the  C-terminal region of HIV-1 IN, which have previously 
been shown to decrease the DNA binding activity of the viral enzyme (Cereseto et al, 2005) 
could contribute to the R-loop binding capacity of HIV-1 PIC. The same 3 residues (K264,K266 
and K273) were also shown to have RNA binding properties (Kessl et al, 2016), and could 
therefore indeed be important for the recognition of RNA-DNA hybrids. Accordingly, cells were 
infected with a virus containing mutations in those 3 lysine residues (K264,K266,K273) in the 
C-terminal domain of IN.  
We also used a tat deficient, replication incompetent HIV-1, in order to verify if the  
colocalization between PICs and R-loops is due to the recognition and of viral docking to R-loop 
sites, or if it is a consquence of of  R-loop formation at the replicating viral genome.  
All virus variants used in this set of experiments were produced by the Vpr-trans incorporation 
strategy (Albanese et al, 2008) and contained a IN.eGFP.  
 
HIV-1 IN C-terminal mutant (K264,266,273Q) 
 
Viral infectivity of the C-terminus IN mutant was assessed by infecting primary CD4+ T cells and 
Jurkat cells. The virus showed a severe drop in integration capacity, which is followed by the 
absence of viral RNA production (Figure 2.30. B and C). In addition, the assessment of early and 
late viral cDNA transcripts was performed, in order to exclude any other deficiency in the viral 
life cycle and to prove that only integration is affected by the C-terminal domain mutations of IN 
(K264,266,273Q) (Figure 3.30. B and D). The results show that the reverse transcription is not 


















Figure 2.30. Features of HIV-1 IN (K264,266,273Q) C-terminal mutant.   
A. Quantification of total vDNA levels upon CD4+ T cell and Jurkat cell infection with HIV-1 K264,266,273Q IN. 
Total vDNA was quantified by plotting sample total vDNA qPCR Ct values over a graph of total vDNA qPCR Ct 
values (y-axis) of serial dilutions of latent HIV-1 clone J-Lat9.2 cell DNA (x-axis). B. Graphs show integration 
levels of HIV-1 K264,266,273Q IN compared to wt HIV-1 levels in CD4+ T cells and Jurkat cells. HIV-1 integration 
levels in wt HIV-1 infection are set to 1 and used as a reference to assess integration levels upon cell infection with 
HIV-1 K264,266,273Q IN mutant. Integrated vDNA (Alu Ct values) is normalized over total genomic DNA levels 
amplified with primers for the lamin B2 gene (B13 region). C. Graph shows RNA expression levels of the gag gene 
upon HIV-1 K264,266,273Q IN infection. Viral gag  mRNA expression levels in wt HIV-1 infection are set to 1 and 
used as a reference to assess gag mRNA expression levels upon cell infection with HIV-1 K264,266,273Q IN 
mutant. Viral gag mRNA expression is normalized over expression profiles of housekeeping gene GAPDH. D. 
Graphs show the production of early and late viral DNA transcripts of wt HIV-1 and HIV-1 K264,266,273Q IN, 
normalized over the levels of total vDNA. The levels of early and late viral DNA transcripts of wt HIV-1 are set to 1 
and used as a reference to assess the amount of early and late viral DNA transcripts upon cell infection with HIV-1 
K264,266,273Q IN mutant. Panels A-D represent the results of the same material from 2 independent donors and 2 





















Further on, the colocalization between PICs of HIV-1 K264,266,273Q IN.eGFP and R-loops was 




Figure 2.31. HIV-1 IN (K264,266,273Q) C-terminal mutant colocalization with R-loops.   
A. Representative confocal images of HIV-1 K264,266,273Q IN,eGFP PICs colocalization with R-loops in 
primary CD4+ T cells. Images were acquired 72 h post infection. The blue channel represents IF staining of 
Lamin B1. The magenta channel represents IF staining of R-loops. The green signals represent the GFP signals 
from the IN.eGFP. Graph below corresponds to the analysis of the nuclear position of IN.eGFP signals in relation 
to the nuclear lamina or nuclear interior, analyzed in 25 cells of 2 donors. B. Representative confocal images of 
HIV-1 K264,266,273Q IN.eGFP PICs colocalization with R-loops in primary macrophages. The blue channel 
represents IF staining of Lamin B1. The magenta channel represents IF staining of R-loops. The green signals 
represent the GFP signals from the IN.eGFP. The R-loop channel is shown separately and the white arrows are 
pointing to the spots where HIV-1 PICs are positioned. Images were acquired 60 h post infection. Graph below 
corresponds to the analysis of the nuclear position of IN.eGFP signals in relation to the nuclear lamina or nuclear 






The obtained results show that HIV-1 K264,266,273Q IN.eGFP PICs either remain trapped in the 
nuclear lamina, or once inside the nucleus, do not colocalize with R-loops. Based on the analysis 
performed on primary CD4+ T cells, 88% of HIV-1 K264,266,273Q IN.eGFP PICs are found in 
the nuclear lamina, whereas 12% of the signals can be detected inside of the nucleus (Figure 2.31. 
A). A very similar scenario was observed for macrophages in which 71% of HIV-1 
K264,266,273Q IN.eGFP PICs were detected in the nuclear lamina, and 29% inside the nucleus 
(Figure 2.33. B). It remains elusive at this point why HIV-1 K264,266,273Q IN.eGFP PICs are 
being trapped in the nuclear lamina. However, the PICs of the analyzed C-terminal mutant of IN 
are not docked to R-loop forming genomic regions, which represents another indication that only 







II. XIV. R-loops are enriched in HIV-1 RIGs 
 
The initial bioinformatic analysis of HIV-1 RIGs 
and R-loops (Sanz et al, 2016) (Figure 2.26. B) 
indicated that RIGs are enriched in R-loops. To 
experimentally verify the presence of  DNA-RNA 
hybrids on selected RIGs, immunoprecipitation 
followed by qPCR (DRIP-qPCR)  was performed in 
primary CD4+ T cells, according to the method from 
Chedin’s lab (Ginno et al, 2012, 2013; Sanz et al, 
2016 and personal communication). DRIP-qPCR 
represents an approach in which R-loops can be 
mapped by using the R-loop specific antibody S9.6 
(Boguslawski et al, 1986) (Figure 2.32.).   
Genomic DNA, isolated from primary CD4+ T 
cells, was sheared to fragment sizes around or 
below 500 bp to enable efficient S9.6 antibody 
binding and final DNA pull down. After shearing, 
the initial material was split in two different tubes, 
which were treated as a positive (only RNase A 
treated) and negative control sample (RNase A and 
RNase H1 treated). Upon shearing and enzymatic digestion both samples were incubated with the 
S9.6 antibody overnight which was followed by DNA pull down with agarose beads and DNA 
extraction. After DNA extraction, qPCR was performed for selected control genes known to be 
either R-loop rich or R-loop poor genomic sites (Gino et al, 2012; Sanz et al, 2016), as well as for 
selected RIGs (BACH2 and STAT5B) (Figure 2.33.). 
 
 
Figure 2.32. Schematic representation of 




     
 
Figure 2.33. DRIP-qPCR results of control genes and selected RIGs.   
A. S9.6 immunoprecipitation of DNA-RNA hybrids on selected positive control gene APOE and negative control 
gene MYADM in the presence of RNase A (control treatment) or RNase A+ RNase H1 treatment, which removes 
the formed RNA-DNA Hybrids. All samples were normalized over R-loop negative gene SNRPN. The qPCR results 
of positive and negative R-loop genes represent a control and readout for the efficiency of the DRIP procedure. B. 
Graph shows the enrichment of R-loops in BACH2 and STAT5B gene in primary CD4+ T cells, normalized over R-
loop negative gene SNRPN. The black bars in the graphs correspond to the positive portion  of the samples (only 
RNase A treated) which should contain R-loops, whereas the gray bars corresponds to the negative control samples 
(RNase A and RNAse H1 treated) in which R-loops should be depleted. The graphs represent a summarized results 
of the same 3 independent donors.   
 
According to the results of  DRIP-qPCR on primary CD4+ T cells, a clear enrichment in R-loop 
signals could be appreciated on two most prominent RIGs, BACH2 and STAT5B (Figure 2.33. 
B). The results represent a confirmation of the metadata analysis (Figure 2.26.) which indicated 
that RIGs are enriched in R-loops. The detection of R-loops in RIGs was also somewhere 
expected, considering that HIV-1 integration genes usually have high G/C skew and are highly 
expressed (Schröder et al, 2002; Brady et al, 2009; Marini et al, 2015) and that R-loops mainly 
occur co-transcriptionally in G/C rich genomic regions (Gino et al, 2012; Sanz et al, 2016; 






II. XV. Integrated HIV-1 is detected  in R-loop rich regions  
 
We aimed to confirm that 
the integrated HIV-1 
genome can be found in 
genomic regions where 
DNA-RNA hybrids are 
formed.  For this purpose, 
the DRIP procedure was 
performed on HIV-1 
infected primary CD4+ T 
cells, and was modified to 
specifically amplify the 
genomic regions containing 
HIV-1 by applying the  Alu 
PCR protocol  to detect the 
integrated viral DNA in the 
precipitated fraction  
(Figure 2.34. A).  
Upon performing this 
modified approach on 
infected primary CD4+ T 
cells, we observed that   the 
integrated HIV-1 DNA is  
enriched in R-loop rich 
genomic sites (Figure 2.34. B). This result represents a direct proof that HIV-1 integration can 
occur in R-loop regions, thus confirming the meta data analysis (Figure 2.26.), as well as the 






Figure 2.34. Assessment of the presence of integrated vDNA in R-loop rich 
genomic DNA.  
A. Schematic representation of the DRIP-Alu PCR in which upon the classical 
DRIP approach on infected primary CD4+ T cells Alu PCR is performed. B. 
Graph shows results of the DRIP-Alu PCR in HIV-1 infected primary CD4+ T 
cells. HIV-1 integration levels in the actual sample are set to 1 and used as a 
reference to assess HIV-1 integration levels in the RNase H1 treated, negative 
control sample.  DRIP-Alu PCR are normalized over R-loop negative gene 






II. XVI. In vitro assessment of the interaction between HIV-1 IN and R-loops 
 
Upon making the observation that HIV-1 PICs colocalize with R-loops with high occurrence 
(more than 72% of PIC signals) in primary CD4+ T cells and macrophages, and that a 
functionally active HIV-1 IN is required for this colocalization, the following questions to answer 
were whether HIV-1 IN indeed has R-loop binding properties, whether it can perform the strand 
transfer reaction on an R-loop, and whether it eventually has RNase H1 properties and can  thus 
resolve an R-loop. The need to answer those questions was even more strengthened  by the 
observation that according to the DRIP-Alu PCR in HIV-1 infected primary CD4+ T cells the 
integrated viral DNA can be detected at R-loop forming sites.  
In order to get a more detailed insight into the catalytic features of HIV-1 IN in the context of 
R-loops, in vitro binding and strand transfer assays were performed in the presence of HIV-1 IN 
and R-loop and non-R-loop nucleic acid substrates. 
The main part of the following results were generated by our collaborator from the University of 
Bordeaux, Dr. Vincent Parissi. 
 
HIV-1 IN binds R-loops 
 
The assessment of R-loop binding by HIV-1 IN was performed in an assay in which an in vitro 
formed R-loop on the pFC53 plasmid (provided by the Chedin Lab), as well as the pFC53 
plasmid only (without R-loop) were offered to HIV-1 IN for binding.  
The pFC53 plasmid contains a G/C rich Airn region flanked by a T3 and T7 promoter. By in vitro 
transcription initiation from the plasmids T3 promoter, by T3 RNA polymerase, R-loop 
formation can be induced on the plasmid. R-loop formation can be monitored by agarose gel 
electrophoresis and appreciated as a shift on the gel (Figure 2.35.). In addition, the R-loop 
forming region of the plasmid is flanked by recognition sites of restriction enzymes and can be 
cut from the plasmid, which enables the monitoring of the R-loop and non-R-loop fragments of 






Figure 2.35. Monitoring of in vitro R-loop formation on the pFC53 plasmid.   
In lane 1 a shift and a smear on the gel can be detected upon transcription initiation on the pFC53 plasmid, 
indicating successful R-loop formation. In lane 2 the recognizable profile of the transcribed and RNase H1 treated 
plasmid can be appreciated. In line 3 a clear shift on the gel can be appreciated, indicating successful R-loop 
formation, as well as a release of all plasmid fragments upon HpaI digestion. Lane 4 represents a control 
digestion of the pFC53 plasmid with HpaI, confirming that the plasmid can be successfully cut into its 2 main 
fragments; the R-loop fragment and non-R-loop fragment.  
 
Upon in vitro R-loop formation and preparation of nucleic acid substrates, HIV-1 IN was added 
to the reaction. The binding of IN to the different substrates was monitored by gel shift assays. IN 
was also added in different concentrations to the substrates, ranging from 0,2-1,6 µM, in order to 
monitor binding affinity and efficiency (Figure 2.36. A). The results show that HIV-1 IN can 
bind to R-loops (shifted high molecular complexes that can be detected in the gel pockets). In 
addition, upon this initial observation, IN binding to R-loops was further monitored by using 
lower concentrations of IN (below 0,4 µM) to assess binding efficiency (Figure 2.36. B). The 
results show that IN can efficiently bind to R-loops, even when low concentrations of IN are 










Figure 2.36. In vitro binding of HIV-1 IN to nucleic acid substrates which contain or not contain formed 
R-loop structures.   
A. Comparison of HIV-1 IN binding affinity to nucleic acid substrates containing R-loops and not containing 
R-loops via gel shift assay and by the addition of increasing amounts of recombinant IN enzyme (indicated in the 
upper part of the gel). R-loop formation was performed via transcription initiation on the pFC53 plasmid which 
was used as the nucleic acid of the binding assay. The marks on the right part of the gel indicate the generated 
plasmid fragments upon HpaI enzymatic digestion of the pFC53 plasmid which either contained formed R-loops 
or did not. B. Assessment of HIV-1 IN binding efficiency on R-loops by providing low concentrations of IN to 
the nucleic acid substrate (pFC53 plasmid) via gel shift assay (indicated in the upper part of the gel). The marks 
on the right part of the gel indicate the generated plasmid fragments upon HpaI enzymatic digestion of the offered 
nucleic acid substrate. C. Graph shows quantified optical density values of shifted R-loop/IN and non-R-loop/IN 
complexes from the gel shift assays (data obtained by Dr. Vincent Parissi).  
 
In addition, optical density quantification of shifted R-loop/IN and non-R-loop/IN complexes 
from the gel shift assays indicated that HIV-1 IN showed more affinity for the binding of R-loops 
in comparison to nucleic acid substrates without containing an R-loop structure (Figure 2.36. C).  
The obtained results represent proof that HIV-1 IN can efficiently bind R-loops. 
 
HIV-1 IN performs the strand transfer on R-loop templates 
 
Upon defining that HIV-1 IN has the property of binding R-loop containing nucleic acid 
substrates, the assessment of IN strand transfer reaction on R-loop templates was performed. As 
previously mentioned, nucleic acid substrates were generated from the pFC53 plasmid and 
offered to HIV-1 IN in the context of a strand transfer reaction. After the integration assay was 
performed, the generated integration products were treated with either RNase A or RNase A and 
RNase H1 and HpaI in order to release the integration products. Upon enzymatic digestion, the 







Figure 2.37. Monitoring the HIV-1 IN strand transfer reaction on R-loop containing and non-R-loop 
containing nucleic acid substrates.  
A. Gel shift assay results of the performed strand transfer reaction on R-loop and non-R-loop containing DNA 
templates generated on the pFC53 plasmid. Different smears on the gel represent the generated and shifted 
integration products. The arrows on the right indicate the positions of the R-loop forming and non-R-loop 
forming part of the pFC53 plasmid upon HpaI enzymatic digestion, which was used as the nucleic acid template 
for the strand transfer reaction. The first lane shows the result of the integration assay performed on the pFC53 
plasmid containing an in vitro formed R-loop, whereas the second line shows the result of the integration assay 
performed on the naked pFC53 plasmid. B. Graph shows quantified optical density values of integration products 
generated R-loop and non-R-loop containing DNA templates (data obtained by Dr. Vincent Parissi). 
 
The obtained results show that HIV-1 IN can perform the strand transfer reaction with equal 
efficiency on nucleic acid substrates containing R-loops or not containing R-loops. A slightly 
higher efficiency towards the R-loop containing substrate was, however, not statistically 
significant (Figure 2.37.).   
In addition, in a very similar experimental setup in which RNase H1 was added to the strand 
transfer reaction in the presence of HIV-1 IN and nucleic acid substrates, it was observed that the 
strand transfer reaction is performed more efficiently on R-loop templates once the R-loop is 




functions, and is not capable to solve an R-loop independently. The obtained result suggests that  
HIV-1 IN might require a binding partner with helicase activity, possibly similar to RNase H1, in 
order to efficiently perform integration of the viral genome into R-loop forming regions.  
 
 
Figure 2.38. HIV-1 IN strand transfer reaction results with nucleic acid substrates with and without R-loop 
structures in the presence of RNase H1.   
A. Gel shift assay results of the performed strand transfer reaction on R-loop and non-R-loop containing DNA 
templates in the presence of RNase H1. The pFC53 plasmid was used as  the nucleic acid template for the strand 
transfer reaction. B. Graph shows quantified optical density values of integration products generated R-loop and 
non-R-loop containing DNA templates in the presence of RNase H1. The legend on the right shows the 
comparison of integration product amounts between nucleic acid templates and RNase H1 treated and untreated 
templates.  Blue bars indicate the amount of circular half and full side integration products, the red bar shows the 
amount of linear full side integration products, the gray bar shows the amount of present donor DNA (viral 
genome) and the yellow bar represents the total activity of the recombinant IN enzyme measured by the presence 









II. XVII. R-loop depletion affects HIV-1 integration  
 
Considering the datasets  obtained so far, which strongly supports HIV-1 integration into 
R-loops, it was important to understand how and if HIV-1 integration is affected once R-loops 
are depleted in cells. In order to test whether HIV-1 integration is affected by R-loop removal, 
different cell lines (HEK293T, HeLa and Jurkat cells) as well as primary cells (CD4+ T cells and 
macrophages) were transfected with the pMMM-FLST plasmid construct coding for human 
RNase H1 and containing a M27 nuclear localization signal (to ensure RNase H1 expression and 
R-loop depletion in the cell nucleus), as well as a GFP tag (to control for plasmid transfection 
efficiency) (Suzuki et al, 2010). Upon transfection and RNase H1 overexpression, cells were 





Figure 2.39. Scheme of experimental workflow of R-loop depletion and HIV-1 infection.    
The image on the left shows successful transfection and expression of the pMMM-FLST construct in HEK293T 
cell nuclei. The timeline on the right shows the experimental procedure at certain time points. First, cells are 
transfected with the pMMM-FLST plasmid construct containing an NLS and expressing an GFP-RNase H1. 24 h 
post transfection, transfection efficiency is assessed by FACS analysis or microscopy approaches. Cells are left 
for another 24 h in culture to reach a peak of GFP expression (estimated to occur 48 h post plasmid construct 
transfection). 48 h post transfection cells are infected with HIV-1 and collected 72 h post infection for Alu PCR 









Apart from Alu PCR, PCRs in which we controlled for the presence of total vDNA and the 











Figure 2.40. Assessment of HIV-1 integration upon RNase H1 overexpression in human cell lines and 
primary cells.     
Alu PCR results of HIV-1 integration upon RNase H1 overexpression are shown, as well as the assessment of 
2LTR circles upon RNase H1 overexpression and HIV-1 infection. Alu PCR values in untreated conditions are 
set to 1 and used as a reference to assess HIV-1 integration levels upon RNase H1 overexpression. Integrated 
vDNA (Alu Ct values) is normalized over total genomic DNA levels amplified with primers for the lamin B2 
gene (B13 region). The amounts of 2LTR circles were normalized over total vDNA values and 2LTR circle levels 
in untreated conditions are set to 1 and used as a reference to assess 2LTR circle levels upon RNase H1 
overexpression. Total vDNA was quantified by plotting sample total vDNA qPCR Ct values over a graph of total 
vDNA qPCR Ct values (y-axis) of serial dilutions of latent HIV-1 clone J-Lat9.2 cell DNA (x-axis). The numbers 
below or next to the graphs indicate the number of independently performed repetitions.  
 
According to the Alu PCR results, HIV-1 integration is significantly decreased after 
overexpression of RNase H1 and depletion of R-loops in different human cell lines (HeLa, 
HEK293T, Jurkat), as well as primary CD4+ T cells and macrophages.  
The remaining HIV-1 integration in HeLa cells compared to untreated conditions upon infection 
was 16,67%, in HEK293T cells 46,67% and in Jurkat cells almost fully abrogated (0,79%). 
In primary CD4+ T cells integration levels of 25,5% could still be observed, whereas in 
macrophages integration was almost fully abrogated (0,4%), as seen in Jurkat cells. 
The observed decrease in HIV-1 integration upon RNase H1 overexpression, was followed by 
increased levels of 2LTR circles measured in cell lines. In HeLa cells an increase in 2LTR circles 
of 2,89 fold was observed, in HEK293T cells 2,45 and in Jurkat cells 1,76. 
In addition, total vDNA levels were assessed by direct comparison of real time PCR Ct values of 
amplified total vDNA (Apolonia et al, 2007) and real time PCR Ct values of serial dilutions of 




In HeLa and HEK293T cells in untreated conditions and upon RNase H1 overexpression 
identical amounts of total vDNA were detected, whereas in Jurkat cells in RNase H1 treated 
conditions 3 times more total vDNA was detected, and still less integrated HIV-1 DNA.   
Obtained results suggest that the depletion of R-loops in cell lines, as well as primary cells affects 
efficient HIV-1 integration.  
 
In order to claim that the observed decrease in HIV-1 integration upon RNase H1 overexpression 
is a consequence of R-loop removal, and not due to potential degradation of viral RT products by 
the presence of RNase H1, we controlled for the presence of early (short DNA reverse transcripts 
from the 5’ LTR) and late (reverse transcripts from the gag gene) viral RT-products, as well as 
2LTR circle formation upon RNase H1 overexpression and infection at different time points post 
infection in primary CD4+ T cells. For this purpose the digital droplet PCR (ddPCR) was 
performed, which enables an absolute quantification of selected targets in the sample, by using 
specifically designed primer probes for early and late HIV-1 RT products, as previously 
described by Bejarano et al, 2018. In addition, we controlled for successful R-loop removal upon 
RNase H1 overexpression by dot blot assay as previously described by Wahba et al, 2013 (Figure 









Figure 2.41. RNase H1 overexpression in primary CD4+ T cells and quantification of early and late HIV-1 
RT-products, as well as 2LTR circles at different time points post infection. 
A. Overexpression of RNase H1 in primary CD4+ T cells was performed by transfecting the pMMM-FLST 
plasmid construct containing a GFP-RNase H1 gene sequence. Plasmid transfection efficiency as well as 
GFP-RNase H1 expression was verified by microscopy approaches 24 h post transfection. The R-loop 




R-loops were assessed by the incubation of 500 µg loaded total genomic DNA  with the S9.6 antibody. Optical 
density quantification of R-loop levels are shown below the dot blot. 24 h upon plasmid transfection, cells were 
infected with HIV-1 and collected at different time points post infection for ddPCR analysis of early and late viral 
RT products, as well as the presence of 2LTR circles. B. The quantification of early and late viral RT products, as 
well as 2LTR circles was performed by ddPCR. The obtained values for early and late viral RT products, as well 
as 2LTR circles were normalized over housekeeping gene RPP30 values. The obtained values were subsequently 
normalized to the highest detected absolute number. The black lines correspond to untreated condition, whereas 
the green lines correspond to RNase H1 overexpression. The graphs represent summarized results of 3 
independent donors.  
 
The obtained results show that the production of early and late viral RT-products is not affected 
by RNase H1 overexpression, indicating that the previously observed decrease in HIV-1 
integration is a consequence of R-loop removal (Figure 2.41. B). In addition, the quantification of 
2LTR circles showed an increasing trend in samples where RNase H1 was overexpressed (Figure 
2.42. B), which is in correlation with the previously observed decrease in successful vDNA 




















RNase H1 mutants do not affect HIV-1 integration 
 
The observation that RNase H1 overexpression strongly reduces HIV-1 integration in cell lines 
and primary cells prompted us to better characterize this effect of the transfected enzyme. In 
particular, we wanted to understand if the observed effect is indeed due to the R-loop removal, or 
if it can be caused by the inability of HIV-1 IN to bind the R-loops in the presence of the 
functional RNase H1 helicase.    
In order to answer this question, HEK293T and HeLa cells were transfected with plasmid 
constructs defective in R-loop binding (D210N), or RNase H1 mutants defective in both R-loop 
binding, as well as in the catalytic activity (WKKD). The cells were then infected with HIV-1, as 




Figure 2.42. Scheme of experimental workflow of RNase H1 mutant D210N and WKKD overexpression 
and HIV-1 infection.     
Cells transfected with either D210N or WKKD RNase H1 mutant plasmid constructs, both containing a GFP 
reporter gene (used to assess the transfection efficiency) were infected with HIV-1 48 h post transfection, and 
collected 72 h post infection to determine HIV-1 integration levels via Alu PCR.  
 
Measuring HIV-1 integration upon cell transfection with RNase H1 mutants revealed that HIV-1 








Figure 2.43. Estimation of HIV-1 integration levels upon overexpression of RNAse H1 mutants D210 and 
WKKD in HEK293T and HeLa cells.       
A. HIV-1 Alu PCR results of HEK293T and HeLa cells upon RNase H1 binding mutant D210N overexpression. 
Alu PCR values in untreated conditions are set to 1 and used as a reference to assess HIV-1 integration upon 
D210N RNase H1 mutant overexpression. B. HIV-1 Alu PCR results of HEK293T and HeLa cells upon RNase 
H1 binding and catalytic mutant WKKD overexpression. Alu PCR values in untreated conditions are set to 1 and 
used as a reference to assess HIV-1 integration upon WKKD RNase H1 mutant overexpression. Integrated vDNA 
(Alu Ct values) is normalized over total genomic DNA levels amplified with primers for the lamin B2 gene (B13 
region). The numbers next to the graphs represent numbers of performed repetitions.  
 
The results obtained with the mutant forms of RNase H1 together with the results with the wild 
type enzyme strongly support the findings that HIV-1 integration depends on the presence of 
R-loops and that their removal, mediated by the catalytic activity of RNase H1, has a very 













II. XVIII. HIV-1 RIGs expression is not affected by R-loop depletion 
 
Taking into account that most 
R-loops are formed 
co-transcriptionally (Sanz et al, 
2016, Chedin, 2016), and that HIV-1 
RIGs have been described as 
transcriptionally highly active genes 
(Marini et al, 2015, Lucic et al, 
2019), the next question to ask was 
R-loop depletion by RNase H1 can 
affect expression profiles of HIV-1 
RIGs. In addition, the assessment of 
RIGs expression profiles upon 
RNase H1 overexpression might 
provide an additional explanation to 
the observed decrease in HIV-1 
integration upon R-loop depletion. 
Mainly because a potential decrease 
in RIGs expression levels would 
argue for a scenario in which HIV-1 
integration is decreased because of 
decreased gene expression activity of 
HIV-1 target genes and not because 
of the removal of R-loops.  
 
To tackle these questions, RNase H1 was overexpressed in primary CD4+ T cells and the RNA 
expression profiles of selected HIV-1 RIGs (BACH2, STAT5B and MKL2) and HIV-1 non-RIGs 
(GPC5 and PACS2) were analyzed by RT-qPCR.  
The obtained results show that HIV-1 RIGs, as well as non-RIGs RNA expression profiles are 
not affected by RNase H1 overexpression and R-loop removal (Figure 2.44.).  
 
 
Figure 2.44. Gene expression profiles of selected HIV-1 RIGs and 
non-RIGs upon RNase H1 overexpression.       
Gene expression profiles are generated by RNA extraction upon RNase 
H1 overexpression, following RT-qPCR analysis. Gene expression 
levels in untreated conditions are set to 1 and used as a reference to 
assess gene expression levels upon RNase H1 overexpression. Gene 
expression levels are normalized over expression profiles of 
housekeeping gene Tubulin. The slight differences observed in the 
height of the bars, which are indicating RNA expression levels, are not 
statistically significant as determined by one-way ANOVA statistical 
analysis (p value is given in the graph legend). The number next to the 
graph represents the number of independent donors. The legend in the 
right upper part of the graph indicates bars corresponding to untreated 
and RNase H1 overexpressed conditions, as well as which analyzed 





The result might be in line with previously reported data stating that high R-loop occurrence does 
not necessarily mean high transcriptional output (Stork et al, 2016), considering that R-loops also 
have many regulatory functions and are not exclusively associated to gene expression (Ginno et 
al, 2012; Chen et al, 2015; Zeller et al, 2016).  
However, the obtained result argues for a scenario in which HIV-1 integration is more affected 
by the presence of R-loops on genes which are highly targeted for HIV-1 integration, than by 
their expression levels. Such a result is in correlation with, yet unpublished data from our lab, 
which show that the spatial organization of super-enhancers is more important in the 
determination of HIV-1 integration sites, than gene expression activity of genes selected for 
HIV-1 integration (Lucic et al, 2019). These data indicate that the presence of a structure as 
R-loops, or the spatial conformation of T-cell nuclei has significant impact on HIV-1 integration 

























III. I. Chromatin accessibility and HIV-1 integration 
 
Integration of HIV-1 vDNA into the host genome represents an important step in the life cycle of 
the virus. Without the successful completion of this process, the virus is not able to replicate and 
produce viral progeny. At the same time, the viral integration site selection and underlying 
genomic features of those selected sites can contribute to our understanding on how HIV-1 
integration sites contribute to viral transcriptional activity or silencing, which results in latent 
infection. In addition, a more detailed definition and understanding of the genomic features 
HIV-1 integration sites can provide a potential platform for future drug treatment strategies 
contributing to viral eradication from infected cells.  
 
HIV-1 integration can potentially occur anywhere in the host genome. However, the virus shows 
certain preferences in integration site selection. HIV-1 preferentially integrates into gene bodies 
of actively transcribed genes (Schröder et al, 2002), especially into introns (Cohn et al, 2015), 
which are closely associated to Alu elements of the host genome (Stevens & Griffith, 1994). In 
addition, it has been shown that HIV-1 integration sites are decorated with marks of open/active 
chromatin (Wang et al, 2007) and delineated with super-enhancers (Lucic et al, 2019), which is in 
accordance with HIV-1 integration into actively transcribed genomic regions. It has also been 
shown that the integrated viral genome positions in the nuclear space in a non-random fashion, 
predominantly in the outer shell of the nucleus, in open chromatin regions, where it also interacts 
with elements of the NPC, as well as host cell factor LEDGF/p75 (Albanese et al, 2008; Di 
nunzio et al, 2013; Marini et al, 2015). Considering that the chromatin organization in HIV-1 
target cell nuclei has an evident effect on viral integration site selection and viral replication 
(Lusic & Siliciano, 2017), the first aim of this study was to understand how chromatin 
composition affects HIV-1 integration? Does integration into open chromatin regions represent a 
phenomenon occurring just by chance, considering that this is the first chromatin environment the 
incoming virus encounters when entering the nucleus through the nuclear pore (Schermelleh et al, 




feature involved in HIV-1 integration site selection in such a nuclear and chromatin surrounding?  
 
To start tackling these questions, primary CD4+ T cells were first treated with drugs affecting the 
activity of different types of chromatin modifying enzymes, infected with HIV-1 and further on 
HIV-1 integration levels were assessed by Alu PCR in order to measure eventual changes in 
HIV-1 integration after changing the chromatin structure. The results showed that all used drugs, 
SAHA, JQ1 and BIX01294, had an increasing effect on HIV-1 integration levels.  
SAHA, as an HDAC inhibitor was expected to cause a global opening of the chromatin structure 
(Kim et al, 2013; Frank et al, 2016), BET inhibitor JQ1 was expected to cause the unloading of 
super-enhancers and thereby cause a general chromatin reshuffling (Filippakopoulos et al, 2010; 
Kumar Bid & Kerk, 2016; Brown et al, 2018; Lucic et al, 2019), and BIX01294 as HMT G9a 
inhibitor was expected to cause a drop in H3K9me2 facultative heterochromatin mark deposition 
and increase global chromatin accessibility (Kubicek et al, 2007; Ciechomska et al, 2016).  
The results of this experiment already gave an indication that chromatin structure, especially 
chromatin accessibility, can affect HIV-1 integration. The effect on HIV-1integration of HDAC 
inhibitor SAHA was very modest and could almost be neglected, and so was that of BET 
inhibitor JQ1. That JQ1 has no effect on HIV-1 integration profiles was also shown in our recent 
study, where we sequenced the integration sites using this drug (Lucic et al, 2019). On the other 
hand, G9a inhibitor BIX01294 had consistently in all the experiments an increasing effect on 
HIV-1 integration. HMT G9a and with it H3K9me2 chromatin mark, have a well-documented 
role in T-cell development and differentiation, as they regulate expression of genes important for 
T cell metabolism (Tachibana et al, 2002; Lehnertz et al, 2014). In addition, the previously 
described impact of H3K9me2 in chromatin structure and organization (Wen et al, 2009; Kind & 
van Steensel, 2010; Kind et al, 2013) could be confirmed here through the observed effect of 
BIX01294 on HIV-1 integration. 
  
According to the assessed kinetics of BIX01294 in primary CD4+ T cells after 6-7 h of 7µM 
BIX01294 treatment, primary CD4+ T cells are still viable, which is in accordance to previously 
reported IC50 values of BIX01294 (Dhayalan et al, 2009; Ho et al, 2017), and the decrease in 
H3K9me2 chromatin mark can be appreciated in both immunoblot and immunofluorescence 




different staining patterns of H3K9me2 chromatin mark in the same population of primary CD4+ 
T cells from the same donor. One staining pattern showed a global nuclear distribution of the 
chromatin mark, whereas the other staining pattern showed a clear peripheral distribution of the 
chromatin mark. The peripheral staining pattern of H3K9me2 is more in line with previous 
findings showing that this chromatin mark is mainly deposited in the nuclear periphery where it 
also contributes to the organization of LOCKs and LADs (Wen et al, 2009; Kim & van Steensel, 
2010; Harr et al, 2015). However, the observation of different chromatin states or patterns in 
single cells of the same population is not a novel phenomenon (Lieberman-Aiden et al, 2009; 
Nagano et al, 2013). In addition, it is also well known that different cellular phenotypes or 
chromatin patterns in the same population of cells represent a consequence of distinct gene 
expression differences (Elowitz et al, 2002; Blake et al, 2003; Golkaram et al, 2017).  
H3K9me2 levels, which showed the strongest drop 12-24 hours post BIX01294 release (after 
initial 6-7 hours of drug treatment), correlated well with the timing of HIV-1 integration post 
viral infection in T cells (Mohammadi et al, 2015) when also the increase in HIV-1 integration 
was observed. 24 hours post drug release H3K9me2 levels start reconstituting back to initial 
levels, which is underlining the importance of G9a activity in T cells, as well as the establishment 
of H3K9me2 chromatin mark (Tachibana et al, 2002; Lehnertz et al, 2014). Finally, BIX01294 
treatment does not have any detectable effect on related H3K9me3 chromatin mark, as seen by 
immunoblot and immunofluorescence staining. This result indicates that BIX01294 treatment 
specifically affects G9a and the deposition of H3K9me2 chromatin mark.  
Additionally, cell viability and proliferative potential, assessed by MTT test upon BIX01294 
treatment only, or followed by HIV-1 infection showed that upon BIX01294 treatment no 
significant change in cell viability could be observed, whereas cells upon BIX01294 treatment 
and HIV-1 infection on average showed a drop of 36% in cell viability. This increased cell death, 
as detected with the MTT test (determines cellular metabolic activity through the presence of 
NAD(P)H dependent oxidoreductases) was expected upon HIV-1 infection (Costin, 2007), as 
well as upon drug treatment and infection (Ivanov et al, 2017; Shytaj et al, 2019).   
 
G9a inhibitor UNC0642, which is supposed to have improved biochemical properties as 
compared to BIX01294 (Liu et al, 2013b) did not have a reproducibly significant effect on HIV-1 






To confirm that the observed increase in HIV-1 integration is a consequence of the drug 
treatment and its effect on H3K9me2 chromatin mark only, we tested if the drug has any 
damaging effect on the cells. The assessment of DNA double strand break marker Gamma H2AX 
upon BIX01294 treatment by IF staining revealed that the drug treatment does not have DNA 
damaging effects in primary CD4+ T cells, and gave more supporting evidence to the fact that the 
observed increase in HIV-1 integration upon BIX01294 treatment can be attributed to the 
changes in chromatin structure and organization mediated my G9a.  
The activation status of cells represents an important aspect in HIV-1 infection. As HIV-1 
preferentially infects and replicates in activated CD4+ T cells (Margolick et al, 1987), even 
though integrated HIV-1 DNA can also be detected in resting CD4+ T cells (Chun et al, 1995; 
Chun et al, 1997). However, activated CD4+ T cells are highly permissive for HIV-1 infection. 
The process of cell activation has major repercussions on cellular function, gene expression, 
metabolism, affecting also chromatin organization. Activated CD4+ T cells, as compared to the 
resting ones, undergo a global increase in chromatin accessibility, such as an increase in 
H3K27ac levels (Gate et al, 2018; Lucic et al, 2019). Considering the importance of cellular 
activation on chromatin organization and on HIV-1 infection, it was important to assess whether 
BIX01294 treatment can eventually influence the activation status of cells, which would 
consequently affect HIV-1 integration levels. The expression levels of cell surface markers CD38 
and CD69 were assessed in primary resting CD4 T cellswhich were treated with BIX01294. Cell 
surface marker CD38 has a known tight regulation during T cell activation and differentiation 
(Sandoval-Montes & Santos-Argumedo, 2005; Quarona et al, 2013); CD69 is known as another 
marker of T cell activation status (Simms & Ellis, 1996). The obtained results show that 
BIX01294 treatment does not cause a change in cell activation status of resting T cells. Thus, the 
observed increase in HIV-1 integration upon BIX01204 treatment can not be attributed to 
enhanced  cellular activation status of the cells. High permissiveness to HIV-1 integration can 
solely be attributed to the changes in chromatin structure. Finally, to control the effect of 
BIX01294 and exclude possible pleiotropic effects of the drug treatment, a direct knock down of 
G9a, histone methyltransferase that deposits H3K9me2 was performed followed by HIV-1 




depleted H3K9me2 chromatin mark, as expected. Similarly, an increasing effect on HIV-1 
integration was observed, providing an important control and supporting the use of BIX01294 in 
the following study.  
In conclusion, all performed controls regarding the effect of BIX01294 treatment on primary 
CD4+ T cells contribute to a very detailed understanding of the drug’s effect on CD4+ T cells. The 
results provide strong evidence that the observed phenomenon of increased HIV-1 integration 
levels upon drug treatment can only be attributed to the changes in H3K9me2 chromatin levels 
and represent a consequence of increased global chromatin accessibility.  
The effect of BIX01294 on increased HIV-1 integration was also followed by increased viral 
activity, as assessed by  the production of viral RNAs and viral p24 protein. This finding was not 
surprising considering that more viral DNA was successfully integrated into the host genome due 
to a generally more open chromatin structure upon BIX01294 treatment, which might also have a 
stimulating effect on viral RNA production. It is in fact well established that the chromatin 
environment can influence basal HIV gene transcription (Jordan et al, 2001; Lusic & Giacca, 
2014; Turner & Margolis, 2017). In addition, the assessment of total vDNA levels upon 
BIX01294 treatment and HIV-1 infection showed that viral entry into cells is not affected by the 
treatment and that identical levels of total viral DNA are found in cells upon drug treatment. 
Moreover, a decrease in 2LTR circles, episomal viral forms formed due to inefficient integration, 
and a concomitant increase in HIV-1 integration suggest that nuclear entry is not affected by 
BIX01294 treatment. Still, more copies of the viral genome integrated into the cellular chromatin 
due to its increased accessibility.  
 
HIV-1 provirus positions non-randomly in primary CD4+ T cell nuclei in respect to structural 
elements of the cellular chromatin and the NPC (Albanese et al, 2008; Guelen et al, 2008: Di 
Nunzio et al, 2012; Di Nunzio et al, 2013; Marini et al, 2015). It was therefore important to 
assess the effect of BIX01294 treatment and H3K9me2 depletion on HIV-1 provirus spatial 
positioning in primary CD4+ T cell nuclei, especially considering that H3K9me2 represents a 
chromatin mark which mainly decorates chromatin in the nuclear periphery (Kind & van 
Steensel, 2010). The performed immuno-DNA FISH results in this context showed a clear 
repositioning of the provirus from the nuclear periphery towards the nuclear center. Apart from 




the increase in HIV-1 integration levels upon drug treatment could also be visually appreciated 
(Figure 2.12.). 
Considering that HIV-1 integration genes occupy certain nuclear areas which are excluded from 
LADs, but still in the outer shell of the nucleus (Marini et al, 2015; Lucic et al, 2019), it became 
relevant to assess their nuclear position upon BIX01294 treatment. Obtained immuno-DNA FISH 
results of HIV-1 RIGs upon BIX01294 treatment clearly indicate that the majority of analyzed 
genes follow the behavior of the provirus and change their nuclear position, from peripheral 
towards inner nuclear zones. In addition, considering chromosomal positions of RIGs, this result 
indicates that RIGs are not just clustering together on chromosomes (Marini et al, 2015), but 
could also potentially move in clusters upon H3K9me2 depletion, as recently observed in the 
case of transition from resting to activated T cell status (Lucic et al, 2019).  
Focusing only on HIV-1 provirus spatial positioning in untreated conditions, results from 
previous studies could be confirmed, demonstrating that the provirus predominantly positions in 
the nuclear periphery (Albanese et al, 2008; Di Nunzio et al, 2012; Di Nunzio et al, 2013; Marini 
et al, 2015; Lucic et al, 2019). However, a recent study suggested a different scenario, according 
to which integrated HIV-1 preferably occupies central areas of cell nuclei (Achuthan et al, 2018). 
The study however differs in several points from here presented results. First of all, the amounts 
of the virus the authors used in their study exceeds significantly the more physiological 
conditions which we aimed in maintaining in this and in a parallel study by Lucic et al, 2019. 
Second, most of their analysis was performed on HeLa and U20S cells, which are not primary 
targets of HIV-1. This could account for the observed differences in integration patterning and 
gene position, as HIV-1 integration sites are delineated with super-enhancers which mainly 
control the expression of cell identity genes (Whyte et al, 2013; Lucic et al, 2019). Mentioned 
findings indicate that cell type specificity seems to be another significant determinant of HIV-1 
integration site selection and proviral spatial positioning in the nucleus apart from chromatin 
composition, as demonstrated by the results of this work.  
 
The analysis of RIGs expression levels upon BIX01294 treatment was performed in order to test 
if changed chromatin composition and changed nuclear position could affect their expression 
levels. A potential increase in RIGs expression could give an additional explanation for increased 




HIV-1 predominantly integrates into active transcription units (Han et al, 2014; Cohn et al, 
2015).  
However, RNA microarray profiling upon BIX01294 treatment showed that RIGs transcriptional 
profiles are not significantly affected upon drug treatment. Possibly because these genes are 
already highly expressed in T cells (Marini et al, 2015; Lucic et al, 2019). However, two groups, 
one of downregulated and the other of upregulated genes could be distinguished upon BIX01294 
treatment. According to the performed GO term analysis, in the group of downregulated genes, 
genes involved in membrane trafficking, protein and ion binding are dominating, whereas in the 
group of upregulated genes, genes involved in iron metabolism and inflammatory response are 
overrepresented. It is known that G9a activity (which is inhibited by BIX01294 treatment) is 
pivotal in cell proliferation and differentiation (Lehnertz et al, 2010; Rao et al, 2016). In addition, 
it has been shown that G9a impairment by BIX01294 treatment can reduce cellular proliferation 
rates or cause cell cycle arrest (Shankar et al, 2013), whereas iron is vital for cell proliferation in 
T cells and is involved in pathways protecting cells from cytotoxicity, oxidative stress and DNA 
damage (Bowlus, 2003; Ruttkay-Nedecky et al, 2013). The results might indicate an ongoing 
compensatory effect, where iron and inflammatory pathways are activated in order to prevent cell 
cycle arrest.  
In order to prove whether BIX01294 treatment causes cell cycle arrest in primary CD4+ T cells, 
cell cycle analysis was performed. The obtained FACS profiles upon propidium iodide staining 
of cells show that BIX01294 treatment does not cause any changes in cell cycle profiles of 
primary CD4+ T cells. This result is in accordance with previous findings in which H3K9me2 
depletion caused by direct G9a knock down did not affect cell cycle profiles and cell proliferation 
(Yokochia et al, 2009). 
 
In respect to the fact that BIX01294 is a drug that affects the activity of HMT G9a, and 
consequently changes the deposition of H3K9me2 chromatin mark, which might alter the 
distribution of other histone marks or chromatin binding factors, ChIP-qPCR was performed in 
order to verify whether any type of changes can be appreciated in that regard. The results show 
that upon BIX01294 treatment the most prominent changes, in the context of chromatin mark 
binding, can be detected in the first intron region of analyzed genes. However, a general drop 




considering the known effect of BIX01294. Also, H3K9me3 chromatin mark distribution was not 
significantly affected by the treatment, which is in line with previously obtained immunoblot and 
IF results. However, a slight decrease of H3K9me3 binding was appreciated in the gene bodies of 
analyzed genes, which is not surprising considering the very strong effect of BIX01294 on 
related H3K9me2 chromatin mark and the high sensitivity of the used antibodies (Rothbart et al, 
2015). The distribution of H3K36me3 and LEDGF/p75 upon BIX01294 treatment was not 
significantly affected in regions of gene bodies or gene ends. Main differences were observed for 
H3K36me3 and LEDGF/p75 binding in the first intron region of analyzed genes, but this requires 
further confirmation at the global genome-wide level. H3K36me3 is a chromatin mark which is 
mainly associated to gene bodies and represents a signal of elongating Pol II transcription 
(Venkatesh et al, 2012). However, a slight increase in H3K36me3 binding was detected in gene 
ends of MKL2 and CNTN4. This finding might be connected to some alternative implications of 
this chromatin mark, considering that it can also be linked alternative splicing, dosage 
compensation, DNA replication and repair (Wagner & Carpenter, 2012; Suzuki et al, 2016). 
Interestingly, an increased LEDGF/p75 binding was detected only on RIGs upon BIX01294 
treatment, and could not be detected on non-RIGs. One can presume that LEDGF/p75 cannot 
bind to non-RIGs in the first intron region due to the presence of H3K9me3, which was detected 
in first introns of analyzed genes. Considering that H3K9me3 is a repressive chromatin mark that 
induces the compaction of chromatin it might also prevent LEDGF/p75 binding. LEDGF/p75 is a 
transcriptional mediator protein that promotes activator-dependent transcription and is binding to 
active transcription units (Ge et al, 1998a; De Rijck et al, 2010; Craigie & Bushman, 2012). 
However, the fact that LEDGF/p75 binding is following H3K36me3 enrichment on RIGs is not 
very surprising considering that LEDGF/p75 is a known reader of this particular chromatin mark 
(Pradeepa et al, 2012).  
Furthermore, the observed enrichment of H3K36me3 and LEDGF/p75 in the first intron regions 
of RIGs can possibly be associated to the observed increased integration of HIV-1 upon BIX0124 
treatment and the fact that HIV-1 preferentially integrates into introns of expressed genes 
(Craigie & Bushman, 2012; Han et al, 2014; Cohn et al, 2015). 
In addition, taking into account the obtained RNA microarray results which suggest that RIGs 
gene expressions are not affected by the drug treatment, meaning that RIGs are under all 




LEDGF/p75 binding is always facilitated on RIGs. This possibility might be explained by the 
fact that LEDGF/p75 is known to bind active transcription units, located downstream of 
transcription start sites (De Rick et al, 2010).  
Interpretation of increased HIV-1 integration in the context of the obtained ChIP-qPCR results 
points further to the necessity of performing a global, genome-wide analysis of chromatin 
features upon BIX01294 treatment.   
 
HIV-1 immuno-DNA FISH results upon BIX01294 treatment revealed a changed proviral 
nuclear position and gave a visual proof of increased HIV-1 integration upon drug treatment. 
These data also pointed to the possibility that HIV-1 might target alternative genomic sites for 
integration upon H3K9me2 removal. Consequently, HIV-1 integration site sequencing was 
performed. The initial statistical analysis of retrieved HIV-1 integration sites upon BIX01294 
treatment, compared to integrations obtained after infection of CD4+ T cells from the same donor 
under non-treated conditions confirmed a slight increase in HIV-1 integration. However, the 
number of retrieved integration sites did not fully correlate to HIV-1 integration levels measured 
by Alu PCR. This discrepancy might be explained by general underestimating capacities of 
integration site sequencing approaches (Cui et al, 2016; Hughes & Coffin, 2017).  
The analysis of HIV-1 integration patterns showed that HIV-1 still maintains its integration 
patterns into active genes, probably marked by H3K36me3 and bound by LEDGF/p75. In 
addition, the analysis revealed that the in vitro generated dataset of HIV-1 integration sites from 
this study can be separated from other HIV-1 integration site datasets where different sequencing 
methods were used (Ikeda et al, 2007; Brady et al, 2009; Wagner et al, 2014; Maldarelli et al, 
2014; Kok et al, 2016). This could be due to different library preparation methods, as well as 
different sequencing methods used in our and different studies to retrieve HIV-1 integration sites. 
However, based on a prediction that was recently made, HIV-1 integrations seem to be non 
saturating, meaning that as many times as integration site sequencing is performed, new 
integrations can always be detected (Lucic et al, 2019). It is of course worth noting that some 
genomic regions, which can be defined as hot spots or recurrent integration genes do appear in 
both, untreated and treated conditions.  
Although we did not detect a clear change in the integration patterns, it has to be pointed out that 




BIX01294 integration sites with the respective chromatin profiles can one be absolutely sure that 
there are no differences in integration patterns between control and treated conditions. Similarly, 
the mentioned analysis will be crucial in making a final conclusion about the relevance of 
chromatin for HIV-1 integration. One can also take into account the possibility that there are 
other, yet undefined genomic features that contribute to the constant targeting of identical 
integration sites by the virus. This possibility was investigated in the second part of this study. 
 
 
Overall, the results of the first part of this study show that chromatin composition and 
accessibility significantly affect HIV-1 integration levels. In the obtained dataset, G9a inhibition 
by BIX01294, and the consequent H3K9me2 depletion had the most prominent effect on HIV-1 
integration levels. How the manipulation of other chromatin patterns might influence HIV-1 
integration and integration site selection remains to be explored. Still, this part of the work 
underlines the importance of the chromatin state in target cells determining the fate of the 
invading virus, as well as infected cells, as already proven by other studies (Archin et al, 2009; du 
Chene et al, 2007; Gijsbers et al, 2011; Wagner et al, 2014; Cohn et al, 2015; Marini et al, 2015; 


















III. II. R-loops as genomic sites of HIV-1 integration 
 
The investigation of HIV-1 integration from a chromatin related perspective, especially 
determining the effects of HMT G9a activity and deposition of H3K9me2 chromatin mark, 
revealed that chromatin accessibility significantly affects HIV-1 integration levels. 
However, in this work, HIV-1 integration, or more precisely, HIV-1 integration site selection was 
also investigated from a different perspective, taking into account the intrinsic and poorly 
explored property of HIV-1 integrase, which is responsible for HIV-1 integration into the cellular 
chromatin. Hence, the second part of this thesis focuses on the viral IN and its catalytic and 
chromatin binding properties to R‑ loops, as special genomic features selected for HIV-1 
integration.  
 
The reasoning for this perspective on HIV-1 integration site selection arises from the fact that the 
CCD of HIV-1 IN exposes an RNase H folding pattern, and when in silico superimposed to the 
RNase H1 enzyme of Bacillus halodurans in complex with a DNA-RNA hybrid, a perfect match 
of the active residues of both enzymes can be appreciated (Goldgur et al, 1999; Nowotny et al, 
2005; Savarino, 2007). Respectively, RNase H enzymes specifically resolve DNA-RNA hybrid 
structures (Eder et al, 1993; Cerritelli & Crouch, 2009). In addition, it has been shown that the 
CTD of HIV-1 has the ability of binding structured RNA elements (Kessl, 2016). Moreover, 
when comparing the known features defining HIV-1 integration sites with R-loop forming 
regions, a clear overlap can be observed. HIV-1 integration sites have been described as sites of 
transcriptionally active genes with increased DNaseI hypersensitivity (Verdin, 1991; Brady et al, 
2009; Busschots et al, 2005; Ciuffi et al, 2005; Chen et al, 2017a), and with high G/C content 
and. On the other hand, R-loop regions represent sites of DNaseI hypersensitivity (Ginno et al, 
2012, 2013; Sanz et al, 2016) and are formed mainly co-transcriptionally in highly transcribed 
G/C rich genomic regions (Ginno et al, 2012, 2013; Sanz et al, 2016). Intriguingly, another 
finding which might possibly connect R-loops to the first part of the study, is the fact that the 
distribution of H3K9me2 also seems to affect the formation of R-loops (Zeller et al, 2015; 
Skourti-Stathaki et al, 2014). However, in the second part of this work, the focus was exclusively 
directed to R‑ loops, as genomic structures, and their possible importance in HIV-1 integration.  




from computational metadata analysis in which R-loop maps (Sanz et al, 2016) were overlapped 
with lists of HIV-1 integration sites (Cohn et al, 2015; Kok et al, 2016), showing that R-loop 
forming regions tend to be overrepresented at sites of viral integration. Further analysis, in which 
R-loop maps from K562 cells (Sanz et al, 2016) and HIV-1 RIGs (Lucic et al, 2019) were 
overlapped, showed that 83% of HIV-1 integration genes (RIGs) had 3 or more R-loops on them. 
This feature clearly distinguishes HIV-1 integration genes from HIV-1 non-target regions. 
According to these preliminary analysis, we reasoned that studying R-loops as potential target 
sites for HIV-1 integration could provide a more detailed insight into HIV-1 integration site 
selection and lead to a more detailed description of HIV-1 integration sites.  
 
In the first experimental analysis, we tested the colocalization between HIV-1 PICs and R-loops 
using an engineered viral construct carrying an eGFP tag on the C-terminus of viral IN, which 
enabled the detection of viral PICs (Albanese et al, 2008). Cells were collected at early time 
points post infection to increase the possibility to observe PIC docking to certain nuclear areas. 
According to this analysis in primary CD4+ T cells 75% of analyzed PICs colocalized with 
R-loops, which was followed by the observation of a similar trend in macrophages where 72% of 
analyzed PICs colocalized with R-loops. This finding suggests that the vast majority of PICs in 
HIV-1 target cells are docked to R-loop forming sites. This colocalization was also confirmed by 
HIV-1 DNA immuno-FISH in macrophages at different time points post infection.  
To further address the observed colocalization and to verify whether the high occurrence in PICs 
colocalizing with R-loops represents an active process and not just a stochastic observation, 
macrophages were either infected with the same viral construct in the presence of IN strand 
transfer inhibitor Raltegravir, or with a construct containing a mutation at the active residue 
D116N of the CCD of IN. The obtained colocalization results show that in the case of HIV-1 
D116N mutant, only 31,1% of PICs colocalize with R-loops, which represents a drop of over 
41%. In the presence of Raltegravir the effect is even more pronounced, and only 21,45% of PICs 
colocalize with R-loops representing a drop of more than 50%. Raltegravir is known to inhibit the 
strand transfer activity of HIV-1 integrase. The observed drop in colocalization with R-loops 
after Raltegravir treatment points to the fact that strand transfer reaction might be important to 
keep HIV-1 IN docked to R-loops. The results indicate that for a high occurrence of PIC and R-




provide evidence that colocalization between HIV-1PICs and R‑ loops is not a randomly 
occurring process.  
Considering previous reports that the CTD of HIV-1 has RNA binding properties and that lysine 
residues 264, 266 and 273 have been defined as key players in that process (Kessl et al, 2016), 
assessing colocalization between R-loops and a HIV-1 variant containing mutations in those 
residues would possibly strengthen the hypothesis of HIV-1 IN binding to R-loops. Before 
performing the colocalization assessment, the activity and the behavior of such a virus had to be 
determined, considering that such a viral construct represented a newly obtained tool in the lab. 
Viral cDNA production, integration and RNA production capacities were determined in primary 
CD4+ T cells and Jurkat cells. The obtained results show that the HIV-1 K264,266,273Q virus is 
able to produce viral DNA, but incapable of integrating its genome into the host cell genome, and 
accordingly does not produce viral RNA, as seen upon infection of both cell types. The results 
regarding viral integration are in accordance with previous findings showing that the acetylation 
of these three lysine residues by p300 histone acetyltransferase contributes to more efficient viral 
integration, and once these residues are mutated there is an evident drop in viral integration 
efficiency (Cereseto et al, 2005). The obtained results show that viral reverse transcription, as 
well as PIC assembly, are not affected by the presence of the three mutated residues, which 
enabled us to continue with a colocalization analysis of HIV-1 K264,266,273Q viral PICs and R-
loops. Primary CD4+ T cells and macrophages were infected with the virus and the colocalization 
with R-loops was assessed. The obtained results show that viral PICs either remain trapped in the 
nuclear lamina, or once inside the nucleus, do not colocalize with R-loops. In primary CD4+ T 
cells, 88% of PICs are found in the nuclear lamina, whereas 12% of the signals can be detected 
inside of the nucleus, but outside of R-loop forming sites. A very similar scenario was observed 
for macrophages in which 71% of PICs were detected in the nuclear lamina, and 29% inside the 
nucleus, but also away from R-loop forming regions. The results clearly show that the PICs of the 
analyzed C-terminal mutant of HIV-1 IN are not docked to R-loop forming genomic regions, 
which represents another indication that only wt HIV-1 PICs, without the impairment of IN 
activity, are successfully docked to R-loops. On the other hand, what contributes to the 
phenomenon of HIV‑ 1 K264,266,273Q PICs remaining trapped in the nuclear lamina, remains 





After obtaining microscopic evidence that HIV-1 IN and R-loops are colocalizing in HIV-1 target 
cells, that for the occurrence of this process a catalytically active IN is required, indicating that 
PICs are actively docked to genomic R-loops, further attention was directed to another result that 
arose from the initial metadata analysis. Apart from a high correlation between HIV-1 integration 
sites and genomic R-loop sites, which was predicted by the analysis, the in silico analysis also 
indicated that most HIV-1 RIGs contain more than one R-loop forming region. In order to prove 
whether RIGs are enriched in R-loops, DRIP-qPCR (Gino et al, 2012; 2013) was performed on 
primary CD4+ T cells. The results of this analysis demonstrate that selected RIGs, BACH2 and 
STAT5B, are enriched in R-loops, which confirms the in silico prediction. In addition, 
considering that BACH2 and STAT5B are highly expressed in T cells, as well as genes of high 
G/C content (Brady et al, 2009; Marini et al, 2015), such an outcome might not be surprising. 
However, those genes are found on the vast majority of HIV-1 integration site list (Maldarelli et 
al, 2014; Wagner et al, 2014; Cohn et al, 2015; Kok et al, 2016; Lucic et al, 2019), which 
supports the hypothesis of R-loops representing genomic sites of HIV-1 integration.   
 
The obtained DRIP-qPCR result raised the question whether integrated viral DNA can be situated 
in R-loop forming sites. In order to tackle this question, a modified approach of the initial DRIP-
qPCR procedure was applied on HIV-1 infected primary CD4+ T cells. Instead of directly 
performing the qPCR upon the DRIP procedure, Alu PCR was performed in order to try detecting 
integrated viral DNA (Tan et al, 2006) in R-loop rich genomic regions that have previously been 
pulled down in the DRIP procedure. The obtained DRIP-Alu PCR results show that integrated 
viral DNA can be detected in R-loop rich genomic regions. Apart from representing another 
confirmation of the initial computational prediction, this result shows that R-loops represent 
genomic sites that can accommodate the integrated viral genome. Considering evident similarities 
between HIV-1 integration sites (Verdin, 1991; Brady et al, 2009; Busschots et al, 2005; Ciuffi et 
al, 2005; Chen et al, 2017a) and R-loop forming sites (Ginno et al, 2012, 2013; Sanz et al, 2016), 
this finding provides supporting evidence to the hypothesis that R-loops represent sites of HIV-1 
integration and potential HIV-1 IN binding.  
Attempting to further strengthen this hypothesis, and prove whether HIV-1 IN can directly 
interact with R-loops, in vitro binding and strand transfer assays of HIV-1 IN in complex with 




Bordeaux). The performed in vitro binding assays show that HIV-1 IN can bind to nucleic acid 
substrates containing R-loops, even more efficiently compared to nucleic acid substrates without 
R-loops, as well as exposing higher binding affinity to nucleic acid substrates containing R-loops 
compared to non-R-loop containing DNA substrates. The obtained results might primarily not be 
very surprising considering the RNase H fold of the CCD of HIV-1 (Yang et al, 1990; Majorek et 
al, 2014). However, it represents a finding that is clearly in line with the obtained microscopy 
data showing that HIV-1 PICs are docked to R-loops and provides additional prove to the 
concept of defining R-loops as sites of HIV-1 integration. 
 
The results of the in vitro strand transfer reaction performed on R-loop and non-R-loop 
containing nucleic acid templates showed that HIV-1 IN can perform the strand transfer reaction 
on R-loops, even slightly more efficient than on non-R-loop containing DNA templates. The 
results of this set of experiments also revealed that the putative RNase H domain, still present in 
HIV-1 IN, is not enzymatically functional, and that the strand transfer reaction is even more 
efficiently completed on R-loop containing DNA templates once the R-loop is resolved in the 
presence of an RNA helicase. The finding that HIV-1 IN does not have RNase H1 function, 
although its CCD has an RNase H-like fold is not very surprising considering that a certain 
protein fold, or folding pattern of a protein domain does not necessarily imply certain enzymatic 
function. In accordance with that is the fact that HIV-1 IN is classified into the RNHL 
(ribonuclease H-like) superfamily of proteins, which is composed of a large group of 
evolutionary related, but functionally diverse group of proteins (Majorek et al, 2014). For 
instance, when performing protein sequence alignment and similarity analysis, by using NCBI’s 
BLASTp tool (Altschul et al, 1997), between HIV-1 RT, with known RNase H function, and the 
CCD of HIV-1 no sequence similarity can be found. On the other hand, the finding that HIV-1 IN 
can perform the strand transfer reaction on DNA templates containing R‑ loops is in accordance 
with previous findings showing that the structure of target host DNA greatly influences the site of 
viral integration as well as that DNA curvature and flexibility influences the frequency of 
integration (Pruss et al, 1994a; Pruss et al, 1994b; Wang et al, 1999; Michieletto et al, 2019). 
Also, the result of successful strand transfer on R-loop containing DNA templates is in line with 
previous findings showing that HIV-1 IN shows preference for binding structured RNA elements 




the R-loop has to occur.  
The finding that the strand transfer reaction is even more efficiently completed on R-loop 
containing nucleic acid templates once the R-loop is resolved can possibly be explained by the 
fact that HIV-1 IN and RNase H1 are enzymes which are interacting, and most probably 
competing for the same substrate (Lusic Lab, unpublished data). In such a scenario, most 
probably both, HIV-1 IN and RNase H1 bind to the R-loop; and while RNase H1 resolves the 
R‑ loop structure, IN performs the strand transfer reaction.  
 
Further on, upon obtaining mentioned series of molecular data indicating that RIGs are enriched 
in R-loops, that integrated viral DNA can be situated in R-loop forming regions and that HIV-1 
IN can in vitro bind to R-loops and perform the strand transfer reaction on them, the focus was 
again directed to HIV-1 integration in an R-loop dependent context. In order to investigate how 
the presence of R-loops affects HIV-1 integration, viral integration was assessed upon RNase H1 
overexpression and R-loop depletion in cell lines (HeLa, HEK293T, Jurkat), as well as primary 
cells (CD4+ T and macrophage). The results of this experiment show that HIV-1 integration is 
significantly impacted in different cell lines and primary cells. Alu PCR results show that HIV-1 
integration is decreased upon RNase H1 overexpression, throughout all analyzed groups of cells, 
and almost abrogated in Jurkat cells and primary macrophages. The observed decrease in 
integration is followed by an increasing trend of 2LTR circle formation, which is expected 
considering that integration is less efficient, or even abrogated in some cases. In addition, the 
final prove that R-loop removal is the main reason for decreased viral integration upon RNase H1 
overexpression was provided by absolute quantifications of early and late HIV-1 RT-products, as 
well as 2LTR circles by ddPCR (Bejarano et al, 2018) in primary CD4+ T cells. The obtained 
results showed that the production of both early and late RT-products is not affected by RNase 
H1 overexpression. Accordingly, the results indicate that viral reverse transcription process is not 
impaired by RNase H1 overexpression, and that the observed decrease in HIV-1 integration is an 
exclusive consequence of R-loop depletion. In addition, the absolute quantification of 2LTR 
circles in untreated conditions and upon RNase H1 overexpression showed a slight increase in the 
numbers of formed 2LTR circles upon RNase H1 overexpression, which is in correlation with the 
observed decrease in viral integration and previous quantification of 2LTR circles by qPCR. This 




integration upon R-loop depletion. Further on, this results also represents a confirmation that 
RNase H1 only gets expressed in the nucleus of the cell, considering the M27 NLS of the plasmid 
construct used for protein overexpression (Suzuki et al, 2010), and that viral RT-products cannot 
be exposed to the effect of RNase H1 since the protein seems to have a nuclear localization, an 
RT is considered to be initiated in the cytoplasm (Francis et al, 2016; Rankovic et al, 2017; Lusic 
& Siliciano, 2017). 
 
In order to further validate that only R-loop removal represents the cause of the observed 
decrease in HIV-1 integration, the same experimental setup was performed on selected cell lines 
(HeLa and HEK293T), but using mutated variants of RNase H1. An RNase H1 binding mutant 
(D210N), as well as an RNase H1 binding and catalytic mutant (WKKD) were used for this 
purpose, which have also been used in previous studies for the purpose of R-loop pull down 
approaches (Chen et al, 2017a). Obtained Alu PCR results upon overexpression of the two 
mentioned RNase H1 mutants in cell lines showed that HIV-1 integration is not affected by their 
presence, which provided proof that the previously observed decrease in HIV-1 integration 
represents a consequence of R-loop depletion.  
The results from this experiment indicate that R-loop presence is required for efficient HIV-1 
integration, which is in accordance with the in vitro data of IN binding and strand transfer activity 
on R-loops, as well as the finding of integrated viral DNA in R-loop forming regions. These 
results together argue for the possibility of describing R-loops as sites of HIV-1 integration.  
 
However, the observation that R-loop depletion causes a decrease in HIV-1 integration led to a 
question if gene expression levels are affected by RNase H1 overexpression and whether the 
decrease in viral integration could be due to a general drop in gene expression levels rather than a 
consequence of R-loop removal. These questions were especially important to respond 
considering that R-loops are mainly formed co-transcriptionally (Ginno et al, 2102; 2013) and 
that HIV-1 preferentially integrates into actively transcribed genes (Schröder et al, 2002, Lucic et 
al, 2019). In order to test for this option, RNA expression profiles of selected RIGs and non-RIGs 
were analyzed by RT-qPCR in primary CD4+ T cells upon RNAse H1 overexpression. Obtained 
results show that both RIGs (BACH2, STAT5B, MKL2) and non-RIGs (GPC5, PACS2) 




this result might not be very surprising considering that those are genes mainly poorly expressed  
in T cells (Marini et al, 2015). In the context of RIGs, this result argues for a scenario in which 
transcriptional activity of HIV-1 target genes is a less favored feature in the context of HIV-1 
integration, compared to the presence of an R-loop structure. Such an outcome would 
conceptually be in line with the finding that the nuclear organization of T cells is more important 
in dictating HIV-1 integration site selection, compared to only gene expression levels (Lucic et 
al, 2019). In this context, the obtained results indicate that the structural organization of the 
genome, together with the presence of certain genomic structural elements and their interplay 
with host cell factors impact HIV-1 integration and integration site selection more than any other 
























III. III. Perspectives and concluding remarks  
 
The first part of this study clearly shows that HIV-1 integration is significantly affected by 
chromatin accessibility. Series of experimental data show that the use of chemical G9a inhibitor 
BIX01294 and the depletion of H3K9me2 chromatin mark in primary CD4+ T cells have an 
increasing effect on HIV-1 integration, indicating that the process of HIV-1 integration and 
integration efficiency can not be separated from (epi)genomic factors such as chromatin 
composition.  
In addition, the results from this part of the study also suggest that when manipulating with the 
chromatin composition of a certain chromatin mark, in order to appreciate discrete changes in the 
chromatin distribution of other chromatin binding factors at certain genomic sites, a deeper and 
more targeted analysis of selected genes or genomic sites will provide more information, 
compared to general global scale analysis. 
 
Of note, the finding that chromatin accessibility in the context of H3K9me2 histone mark 
significantly affects HIV-1 integration becomes especially important considering that BIX01294 
is a known and very strong HIV-1 latency reversing agent (Imai et al, 2010; Bouchat et al, 2012; 
Nguyen et al, 2017). Accordingly, future studies on HIV-1 latency reversing agents which are 
manipulating chromatin structure composition and accessibility should be conducted carefully 
and include the factor of possible increase in HIV-1 integration efficiency. 
 
 
The final conclusion of the second part of this study is that the presence of R-loops, as structural 
genomic elements, in HIV-1 integration genes, is of more importance for efficient viral 
integration compared to high transcriptional activity of HIV-1 target genes.    
Nevertheless, it would still be very important to assess how RNase H1 overexpression affects 
gene expression on a global scale. Also, it would be of significant importance to understand and 
distinguish the influence of co-transcriptional R‑ loops (Ginno et al, 2012; 2013) and regulatory 
R-loops (Yu et al, 2013; Santos-Pereira & Aguilera, 2015; Grunseich et al, 2018) in the context 
of HIV-1 integration. Still, in order to further strengthen the concept of R-loop structures as sites 




presence of R-loops in the process of transcription (Skourti-Stathaki et al, 2011; Skourti-Stathaki 
et al, 2014), from the fact that R-loops are also structural genomic elements that evidently 
influence HIV-1 integration. In line with the concept of R-loops as structural genomic elements 
possibly affecting a plethora of other biological processes, are findings indicating that 
transcriptional output does not seem to be correlated to R-loop levels on individual genes (Stork 
et al, 2016; Wahba et al, 2016).  
 
Overall, the results of the second part of this work provide strong evidence that R-loops, as 
structural genomic features, represent sites of HIV-1 IN binding and, accordingly, HIV-1 
integration. The initially obtained computational results provided an accurate prediction on HIV-
1 RIGs as genomic sites enriched in R-loops, which was further on confirmed by molecular 
approaches in cells. In addition, R-loops were shown to be genomic sites having the capacity to 
accommodate integrated HIV-1 DNA. In addition, microscopic data on HIV-1 PICs 
colocalization  with R-loops provided first indication that HIV-1 IN is docked to R-loop forming 
genomic sites. In respect to the entire dataset on microscopy, it was demonstrated that for high 
occurrence of PIC and R-loop colocalization a functionally active viral IN is required, confirming 
that the observed colocalization does not represent a randomly occurring event. Further on, HIV-
1 IN binding on R-loop nucleic acid templates was confirmed in vitro, as well as the capability of 
HIV-1 IN to perform the strand transfer reaction on R-loop containing DNA templates. In line 
with that are obtained results showing that R-loop depletion in cells has a decreasing effect on 
HIV-1 integration. And finally, R-loop depletion was shown not to affect transcriptional activity 
of selected RIGs, indicating that the presence of R-loops, as structural genomic elements, on 
these genes is more important in affecting HIV-1 integration, compared to their transcriptional 
activity.  
However, the in vitro dataset also demonstrated that HIV-1 IN strand transfer is more efficient at 
R-loop forming sites once the R-loop is resolved by RNase H1. Studying the interplay between 
IN and other R-loop resolving enzymes (as Aquarius, Senataxin, Topoisomerases, etc) in the cell 
seems to be crucial in understanding HIV-1 integration in an R-loop dependent context, and gives 






Considering that the focus of the second part of this study was directed towards R-loops as 
structural genomic elements, without implying their regulatory aspects, it is important to mention 
the interplay between R-loops and chromatin, considering that the first part of this work 
predominantly deals with the importance of chromatin composition related to HIV-1 integration. 
Several studies showed the association of R-loop peaks and open chromatin marks, as well as 
overall increased chromatin accessibility in R-loop rich regions, mainly occurring at gene 
promoters or gene bodies (Zeller et al, 2016, Sanz et al, 2016, Chen et al, 2017a). Presumably, 
such findings could represent another connection between R-loops and HIV-1 integration sites 
considering that HIV-1 preferably integrates into gene bodies of actively transcribing genes, 
carrying open chromatin marks (Schröder et al, 2002; Wang et al, 2007; Cohn et al, 2015). 
However, gene terminal R-loops where shown to show features of transcription terminators (Sanz 
et al, 2016). Also, in a variety of different organisms it was shown that R-loop formation can be 
connected to RNA Pol II termination, as well as the establishment of heterochromatin 
(Castellano-Pozo et al, 2013; Skourti-Stathaki et al, 2014, Boque-Sastre et al, 2015; Sanz et al, 
2016; Skourti-Stathaki et al, 2019). In summary, what appears evident from mentioned studies is 
that the interplay between chromatin and R‑ loops, as well as its outcome in a context of 
chromatin accessibility and genomic activity significantly depends on the region of R-loop 
formation. Respectively, if R-loop formation occurs at gene TSS, TTS, gene bodies, before or 
after replication forks significantly affects chromatin accessibility and vice versa (Santos-Pereira 




In conclusion, both parts of this study provide strong evidence that chromatin composition, 
chromatin accessibility mediated by the deposition of H3K9me2 mark, as well as structural 
genomic elements - R-loops, significantly impact HIV-1 integration. Both aspects of this study 
provide more detailed description of HIV-1 integration sites, HIV-1 integration efficiency, as 
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IV. Materials and methods 
 
IV.I. Cell lines and cell culture 
 
Human lymphoblastiod cancer Jurkat cell line and latent HIV-1 clone J-Lat9.2 was kept in RPMI 
medium supplemented with heat inactivated 10% FBS and 1% Penicillin/Streptomycin.  
Human epithelial HEK293T and HeLa cell lines were kept in DMEM medium supplemented 
with 10% FBS and 1% Pen/Strep antibiotics.  
 
IV.II. Primary cell isolation 
 
CD4+ T cells  
 
Primary CD4+ T cells were purified from whole blood from healthy donors with RosetteSep™ 
Human CD4+ T Cell Enrichment Cocktail (STEMCELL TECHNOLOGIES). Cells were 
activated with Dynabeads Human T-Activator CD3/CD28 (ThermoFisher) and 5 ng/mL IL-2 for 
48 h and kept in RPMI medium supplemented with heat inactivated 10% FBS and 1% Pen/Strep 
antibiotics.  
 
Monocyte derived macrophages (MDMs) 
 
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
blood donors by Ficoll density gradient centrifugation. PBMCs were seeded in 8-well LabTek 
chamber slides (Thermo Fisher Scientific, Waltham, MA) in DMEM containing 10% heat 
inactivated FBS and incubated at 37°C for 6 h. Subsequently, floating lymphocytes were 
removed and adherent monocytes were washed followed by cultivation in DMEM containing 
10% heat inactivated FBS and 10% human AB serum (Sigma-Aldrich, St. Louis, MO) for 7 days 
to allow differentiation into macrophages. 
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IV.III. Drug treatments 
 
Primary CD4+ T cells were treated for 6-7 h with 7 µM BIX10294 (Sigma-Aldrich), 1 µM JQ1 
(Sigma-Aldrich), 7 µM SAHA (Sigma-Aldrich) and 7 µM UNC0642 (Sigma-Aldrich).  
 
IV. IV. Cell viability test 
 
Cell viability was determined by performing live cell staining and flow cytometry. For the 
purpose of this assay 2*105 cells were collected for each analyzed time point. Living cells were 
washed in PBS and stained for 30 minutes on ice with Fixable Viability Dye eFluor 450 
(eBioscience). After the staining cells were washed in PBS and fixed for 10 minutes in 4% 
PFA/PBS. Subsequently the cells were washed and resuspended in PBS. Flow cytometry was 
performed on BD FACSVerse flow cytometer and flow cytometry data was analyzed in the BD 
FACSuite software (BD Biosciences). Live cells were gated according to a negative control 
sample in which all cells were dead. The negative control sample was generated by keeping cells 
for 10 minutes in 100% ethanol, which would kill most cells in the sample. The cells were 
subsequently fixed and stained as previously described. 
 
IV. V. Cell cycle analysis 
  
Cell cycle analysis was performed on primary CD4+ T cells after 7 µM BIX01294 treatment in 
order to determine potential changes in cellular cycles upon drug treatment. For the purpose of 
this analysis 1*106 cells were collected after 7 h of drug treatment (as well as untreated control 
cells), washed in PBS and fixed in icecold methanol (methanol was added dropwise to cells while 
vortexing them). After fixation the cells were washed with PBS and treated with 1 mg/mL 
RNase A for 30 minutes at 37°C. After RNase A treatment cells were washed with PBS and 
stained with Propidium Iodide (Roche) in 1:20 ratio. Propidium Iodide is a DNA binding and 
intercalating dye and according to the amount of bound Propidium Iodide in the cells, cell cycle 
profiles can be determined, since cells contain certain DNA amounts in specific phases of the cell 
cycle.   
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Flow cytometry was performed on BD FACSVerse flow cytometer and flow cytometry data was 
analyzed in the BD FACSuite software (BD Biosciences). 
 
IV. VI. Cell proliferation assay (MTT test) 
 
The viability and proliferative potential of cells upon BIX01294 treatment was assessed through 
the CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT) assay (Promega; Madison, 
WI, USA), as previously described by Shytaj et al, 2015.  
For the MTT assay 300*105 cells of each analyzed condition were resuspended in 100 μL 
RPMI/10% FBS and transferred into a 96-well plate. To each well the MTT solution was added 
(15 μL) and, after 2-4 h, the reaction was stopped by the addition of 100 μL of the 
Solubilization/Stop Solution. Absorbance values at 570nm were acquired with an Infinite 200 
PRO (Tecan, Männedorf, Switzerland) multimode plate reader. Reactions were conducted in 
triplicate and the averages of the triplicates were normalized over the matched untreated controls 
and expressed as a percentage. 
 
IV. VII. G9a knockdown 
 
Jurkat cells were stably transduced with pGZIP-G9a lentiviral vector containing a puromycin 
resistance sequence. 48 h after transduction, cells were grown in selection medium with 
increasing amounts of puromycin reaching a final concentration of 4 µg/mL. 
 
IV. VIII. Total protein amount quantification by western blot 
 
Cell pellets were lysed 10 minutes on ice in RIPA buffer (150mM NaCl, 20mM Tris-HCl pH 7.4, 
1mM EDTA, 0.5% NP-40, 0.5% DOC, 0.1%SDS) and sonicated for 5 minutes (30 s ON, 30 s 
OFF) at 4°C in Bioruptor (diagenode). The total protein concentration of cellular extracts was 
measured by Bradford assay (BioRad). Western blot gels were loaded with 8 µg of protein lysate. 
Gels were running on 120 V and 400 mA (western blot system from Biometra) in 1X SDS 
running buffer (25 mM Tris, 192 mM Glycine, 0,1% SDS, pH 8.3). Proteins were transferred to a 
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nitrocellulose membrane with a Trans-Blot device for semi-dry transfer (BioRad). The 
nitrocellulose membrane was blocked for 1 h at room temperature in 1% skim milk in 0,1% 
PBS/Tween. Upon blocking the membrane was incubated with primary antibodies, which were 
also diluted in 1% skim milk in 0,1% PBS/Tween, rotating overnight at 4°C. Western blots were 
developed after washings in 0,1% PBS-Tween and incubation with secondary antibodies for 1 h 
at room temperature with Amersham ECL Prime Western Blotting Detection Reagent (GE 
Healthcare Life Sciences).  
Used primary antibodies: mouse monoclonal anti-β-actin (Sigma-Aldrich), mouse monoclonal 
Anti-dimethyl-Histone H3 (Lys 9) 05-1249 (Millipore), rabbit-polyclonal Anti-Histone H3 06-
755 (Millipore), rabbit polyclonal LEDGF/p75 A300-847A (Bethyl Laboratories), rabbit 
monoclonal G9a/EMT2 (C6H3) 3306 (Cell Signaling Technology). 
Used secondary antibodies: anti- mouse and anti-rabbit (Jackson immunoresearch).  
 
IV. IX. Virus production  
 
Viral particle production procedure 
 
Production of viral particles was performed as previously described in Marini et al, 2015.  
Producer HEK293T cells were seeded to reach 70% confluency in plastic round 15 cm dishes. 
The Ca-Phosphate approach for cell transfection was used (list of reagents is listed in Table 4.1.). 
6-8 h after plasmid DNA transfection into HEK293T cells, the medium was changed and cells 
were kept for another 48 h post transfection at 37°C to produce viral particles which were 
released into the medium (supernatant). After 48 h the cell medium was collected, filtered 
through 0,45 μm (Roth GmBH) filter and prepared for ultracentrifugation on a SW40 rotor 
(Beckman Coulter ultracentrifuge) through a 20% sucrose gradient at 28 000 rpm for 1,5 h. After 





Materials and methods 
158 
 
Single round infection HIV-1 viral stocks 
 
For the production of single round infection HIV-1 viral stocks a plasmid obtained from the Env- 
molecular clone pNL4-3/E-R- was used. This molecular clone contains a frameshift mutation 
introduces close to the 5’ end of the env gene (Connor et al, 1995) and performs a single-round 
infection once pseudotyped with the glycoprotein envelope from vesicular stomatitis virus (VSV-
G). This disables the virus from performing multiple rounds of infections and causing massive 
cell death.  
This virus was used in the context of monitoring levels of viral integration by Alu PCR in either 
primary cells or cell lines, as well for FISH analysis in order to monitor the exact positioning of 
single proviruses and avoid superinfection. 
 
C-terminal IN mutant HIV-1 viral stocks 
 
For the production of viral particles containing K264,266,273R mutations in the viral IN the 
construct HIV-1BRU(K264,266,273R) was used (Cereseto et al, 2005), which contains the full viral 
genome.  
This virus was used to test for its integration capacity, transcription capacity and the capacity to 
form retro-transcribed viral DNA products.  
 
IN.eGFP HIV-1 viral stocks 
 
Production of the engineered HIV-1 wt virus, HIV-1 virus with the K264,266,273R mutations in 
the C-terminus of the viral IN, the D116N CCD HIV-1 mutant, as well as the tat deficient HIV-1 
mutant having an eGFP tagged integrase was performed as previously described in Albanese et 
al, 2008, through the “trans-incorporation” technique. 
The trans-incorporation technique takes advantage of the viral protein Vpr being able to shuttle 
fused exogenous proteins inside the viral particle. In order to produce HIV-1 viruses containing a 
tagged IN protein pVpr-IN-eCFP was constructed by cloning Vpr (PCR amplified from pNL4.3) 
in frame with the codon optimized IN (Limon et al, 2002) into the peCFP-N1 vector (Clontech 
Laboratories, Inc., Saint-Germainen-Laye, France). Also, an HIV-1 protease cleavage site 
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(IRKVL), flanked at both C- and N- terminus by a flexible linker (KRIQST) which was 
introduced between Vpr and IN. pVpr-IN-eGFP was constructed by substituting the eCFP cDNA 
with eGFP. 
For viral particle production the constructs containing either the full viral genome, a mutation in 
the CCD of IN, mutations in the C-terminus of IN, or a tat deletion, as well as the belonging 
pVpr-IN-eGFP construct were transfected via the Ca-Phosphate approach into HEK293T 
producer cells as previously described. 
 
Creation of adequate Vpr constructs 
 
The K264,266,273R mutations in the C-terminus of the viral IN, as well as the CCD mutant 
D116N were constructed by a quick change PCR and introduction point mutations in the IN 
domain of the created pVpr-IN-eGFP construct.  
The tat deficient HIV-1 viral construct was made by deleting a 34 bp segment in the big tat exon 
of the pNL4-3 HIV-1 original molecular clone. This virus has also been tagged with the IN.eGFP 
fusion construct.   
The mentioned eGFP tagged viral constructs were used mainly for microscopy approaches, but 
were also successfully used to verify their integration capacity Alu PCR. 
 
Table 4.1. List of reagents for calcium phosphate transfection of HEK 293T cells. 
Reagent Amount per 15 cm dish of cells 
2.5 M CaCl2 300 μL 
2X HBS (50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.5) 2.5 mL 
pNL4-3/E-R- plasmid 25 μg 
VSV-G plasmid 5 μg 
H2O 2.5 mL 
*Procedure:  
Mix DNA and H2O. 
Add CaCl2 dropwise (incubate 10 min) 
Add mixture to 2X HBS by vortexing (incubate 20 min). 
Add to cells dropwise. 
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IV. X. SG-PERT assay 
 
The SG-PERT assay was performed for virion number quantification in viral stocks. SG-PERT 
assay was performed as previously described in Pizzato et al, 2009.  
A 5 μL aliquot of the viral stock was lysed in 5 μL 2X lysis buffer (0.25% Triton X-100, 50 mM 
KCl, 100 mM TrisHCl pH7.4, 40% glycerol). RNase inhibitor (0.4 U/μL) was added to the 
volume of buffer needed for virus disruption immediately before use. 90 μL 1X dilution (diluted 
to 1X from 10 X stock (50 mM (NH4)2SO4, 200 mM KCl and 200 mM Tris–HCl, pH 8.3) buffer 
was added to the lysed sample after 10 minutes of lysis. 10 μL of the diluted virus lysate samples 
were mixed immediately with 10 μL of 2X reaction mix (10 mM (NH4)2SO4, 40 mM KCl and 
40 mM Tris–Cl pH 0.3, 10 mM MgCl2, 0.2 mg/ml BSA, 1/10,000 SYBR Green I, 400 μM 
dNTPs, 1 μM forward primer,1 μM reverse primer, 1.2 μg/ml BMV RNA). Hotstart Taq was 
added (0.2 U/reaction) immediately before use. 
 
Used thermal cycler conditions used were: 30 min RT reaction at 37 °C, 5 min hot-start Taq 
activation at 95 °C and 45 cycles of amplification. Each amplification cycle was composed of 5 s 
denaturation at 95 °C, 5 s annealing at 55 °C, 15 s extension at 72 °C, 7 s acquisition at 83 °C, 
using the lightcycler; 5 s denaturation at 95 °C, 5 s annealing at 55 °C, 20 s extension at 72 °C, 
11 s acquisition at 83 °C, using the CFX96 Touch platform (Bio Rad). 
Data analysis was performed by using the CFX Maestro Software (Bio Rad) by comparison of 
real time Ct values of 10 fold serial dilutions of a recombinant HIV-1 RT standard which was 
prepared in parallel to the analyzed samples (activity of undiluted standard is 5,088 * 109 pUnits 
RT/μL) and the analyzed sample.  
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IV. XI. Infections 
 
Cell infections for FISH and integration analysis  
 
Cell lines and primary cells were infected with 100 ng p24 per 105 cells pNL4-3/E-R- HIV-1, and 
subsequently kept in culture and collected 72 h post infection.  For the purpose of FISH analysis, 
only MDMs were fixed and collected at different time points post infection (36, 48 and 60 h post 
infection).  
 
Cell infections for colocalization analysis  
 
Primary cells were infected with pNL4-3/E-R- HIV-1, IN.eGFP HIV-1 wt, IN.eGFP D116N, 
IN.eGFP K264, 266, 273R and  IN.eGFP 𝚫tat in a concentration of 100 ng p24 per 105 cells. 
For microscopy and colocalization analysis primary CD4+ T and macrophages were collected at 
different time points post infection (18, 36, 48, 60 or 96 h).   
 
5 uM Raltegravir (HIV-1 strand transfer inhibitor) was added to macrophages at the moment of 
infection wit IN.eGFP HIV-1 wt and sequentially added every 24 h as long as the cells were kept 
in culture. 
 
IV. XII. Genomic DNA extraction 
 
DNA was extracted with DNeasy Blood & Tissue kit (Qiagen) by following manufacturer 
instructions. DNA concentration was measured via spectrophotometry on P-class P 300 
NanoPhotometer (IMPLEN).  
 
IV. XIII. Measurement of integrated vDNA (Alu PCR) 
 
The presence of integrated viral DNA was evaluated by Alu PCR as previously described (Tan et 
al, 2006). Alu LTR sequences were amplified from 250 ng of genomic DNA in the first round 
PCR. In the second round Real Time PCR, a 1:50 dilution of the first round PCR product was 
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used as a template together with the I-specific primer λT, the internal LTR primer LR and the 
probe ZXF-P. 
As a normalizer gene for the Real Time PCR the amounts of housekeeping gene lamin B2 (B13 
region) were quantified from 10 ng genomic DNA.  
Alu PCR was normalized using the 2(-Delta Delta C(T)) method for analysis of real time 
quantitative PCR (Livak & Schmittgen, 2001).  
 




ZXF-P probe TGTGACTCTGGTAACTAGAGATCCCTCAGACCC 
Alu1 TCCCAGCTACTGGGGAGGCTGAGG 
λ-primer ATGCCACGTAAGCGAAACT 
B13 Fwd primer CCCCAGGGAGTAGGTTGTGA 
B13 Rev primer TGTTATTTGAGAAAAAGCCCAA 
B13 probe CAGCAGGAAAGGAC 
 
 
IV. XIV. Quantification of 2LTR circles and total viral DNA 
 
Quantification of 2 LTR circles and total viral DNA was performed as previously described by 
Apolonia et al, 2007. Total DNA from infected cells was extracted with DNeasy Blood & Tissue 
kit (Qiagen) as previously described. qPCR was performed by using an input of 250 ng genomic 
DNA, primers that were designed for the 5’ and 3’ LTR junction (for 2 LTR quantification) and 
primers annealing to the 5’ LTR and Gag gene (for total viral DNA quantification), as well as 
fluorescently labeled probes and TaqMan chemistry (BioRad) (Table 4.3.). 2LTR circles were 
quantified by normalization over the total viral DNA values by using the 2(-Delta Delta C(T)) 
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Table 4.3. List of used primers and probes for 2 LTR circle and total viral DNA quantification. 
Primer Sequence 
2 LTR circles Fwd primer  AACTAGAGATCCCTCAGACCCTTTT 
2 LTR circles Rev primer CTTGTCTTCGTTGGGAGTGAATT 
2 LTR circles probe CTAGAGATTTTCCACACTGAC 
Total viral DNA Fwd primer TGTGTGCCCGTCTGTTGTGT 
Total viral DNA Rev primer GAGTCCTGCGTCGAGAGAGC 
Total viral DNA probe CGCCCGAACAGGGACTTGAA 
 
 
IV. XV. Infectivity test 
 
The amount of infected primary CD4+ T cells was determined via staining of p24 marker on 
cellular surfaces cells and subsequent flow cytometry analysis. For the purpose of this assay 
2*105 cells were collected 72 h post infection, washed in PBS and fixed for 1,5 h in 4% 
PFA/PBS. Cells were stained for 30 minutes with anti-p24 antibody Coulter Clone KC57-RD1 
(Beckman Coulter) and subsequently washed and resuspended in PBS. Flow cytometry was 
performed on BD FACSVerse flow cytometer and flow cytometry data was analyzed in the BD 
FACSuite software (BD Biosciences).  
 
IV. XVI. HIV-1 integration site sequencing 
 
HIV-1 integration site analysis was performed as previously described in Schmidt et al, 2007, by 
performing linear amplification-mediated PCR (LAM-PCR). 
Upon DNA extraction of previously infected primary CD4+ T cells the material was prepared for 
the linear PCR initiated from 5′-biotinylated vector-specific primer(s) as described in the table 
below (Table 4.4. and Table 4.10.). A starting material of 500 ng was used for the initial linear 
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Table 4.4. Linear PCR setup. 
Reagent Final amount (1X reaction) 
10X Taq polymerase reaction buffer 5 μL 
dNTPs 1 μL 
Primer LTR I (0.5 pmol/μL) 0.5 μL 
Template DNA (1 ug) X μL 
Taq polymerase (2.5 U/μL) 0.5 μL 
ddH2O Up to 50 μL 
 
Linear PCR parameters are described in the table below (Table 4.5.). 
 
Table 4.5. Linear PCR. 
Temperature Time Cycle number 
95C 5 min 1 
95°C 1 min 
 
60°C 45 s 
72°C 90 s 
72°C 10 min 
4°C ∞  
 
After performing linear PCR, magnetic Dynabeads (Invitrogen) were washed twice in 0.1% 
BSA/PBS and 3 M LiCl buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 3M LiCl) and 
resuspended in 6 M LiCl buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 6 M LiCl). Beads were 
added in a 1:1 ratio to the PCR product.  To covalently link the biotinylated PCR product to the 
streptavidin-coupled magnetic beads the samples were overnight incubated at room temperature 
on a horizontal shaker at 300 rpm.  
To generate double-stranded DNA fragments a hexanucleotide priming reaction was carried out 
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Table 4.6. Hexanucleotide priming reaction. 
Reagent Amount (1X reaction) 
10X hexanucleotide mixture (Roche) 2 μL 
dNTPs (200 uM) 0.5 μL 
Klenow polymerase (2 U/μL) 1 μL 
ddH2O Up to 20 μL 
  
After the hexanucleotide priming reaction, the bead-DNA complexes were washed twice with 
ddH2O on a magnetic stand and divided in 2 separate tubes and prepared for enzymatic digestion 
with MseI and MluCI restriction enzymes for 1-2 hr at 37°C to generate restriction sites suitable 
for the annealing of DNA linker cassettes. The linker cassette fulfills the purpose of a 12 bp 
unique barcode for each sample which can be later on tracked after the sequencing is performed. 
The linker cassette ligation reaction was performed after the enzymatic digestion (Table 4.7.).  
 
Table 4.7. DNA linker cassette ligation reaction. 
Reagent Amount (1X reaction) 
*10X incubation buffer 1 μL 
*ATP (10 mM) 1 μL 
Linker cassette 2 μL 
*Fast Link DNA ligase (2 U/μL) 1 μL 
ddH2O Up to 10 μL 
*Fast Link DNA ligation kit (Biozym) 
 
After the linker cassette ligation reaction, the samples were washed twice with ddH2O on a 
magnetic stand. The bead-DNA complexes were denatured by a 10-60 min 0.1 M NaOH wash on 
a horizontal shaker at 300 rpm at room temperature (increasing denaturation times increases the 
purity of DNA). Beads were removed with a magnetic stand and the released DNA was prepared 
for the First Exponential PCR in order to amplify the amount of successfully linker-ligated DNA 
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Table 4.8. First Exponential PCR setup. 
Reagent Final amount (1X reaction) 
10X Taq polymerase reaction buffer 5 μL 
dNTPs 1 μL 
Primer LTR II (50 pmol/μL) 0.5 μL 
Primer LC I (50 pmol/ μL) 0.5 μL 
Template DNA (1 ug) 2 μL 
Taq polymerase (2.5 U/μL) 1 μL 
ddH2O Up to 50 μL 
 
Table 4.9. Linear PCR I. 
Temperature Time Cycle number 
95C 2 min 1 
95°C 45 s 
 
60°C 45 s 
72°C 1 min 
72°C 5 min 
4°C ∞  
 
PCR products of the first exponential PCR were captured with streptavidin-coupled magnetic 
beads as previously described (same procedure as after the Linear PCR). Captured DNA was 
prepared for the Second Exponential PCR. The Second Exponential PCR has the same 
temperature and cycle regime as the First Exponential PCR, as well as the same chemical regime. 
The only difference is that in this PCR setup another primer pair was used. Primer LTR III and 
LC II, in order to ensure the amplification of only successfully linker-ligated DNA on the 3’ end, 
and DNA fragments containing the viral LTR on the 5’ DNA end.  
After performing the Second Exponential PCR a control 2% agarose gel was run with the 
obtained PCR products in order to verify that the LAM-PCR procedure was successfully 
performed and to control for eventual contaminations in the H2O negative control sample. Upon 
the Second Exponential PCR, DNA purification of the PCR products was performed.  
DNA products were purified from the PCR with AMPure beads (Beckman Coulter). The beads 
were added to the PCR product in a 1:1,1 ratio and incubated 5 min at room temperature. The 
supernatant was removed by using a magnetic stand and the beads were washed twice with 80% 
EtOH. After the washing steps, the beads were resuspended in 20 μL water and the purified DNA 
 35 
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was transferred into fresh tubes by using a magnetic stand. This purified DNA was used as an 
input for the sequencing library preparation.  
  
Table 4.10. List of used primer pairs for LAM-PCR procedure. 
Primer Sequence 
LTR I GAGCTCTCTGGCTAACTAGG 
LTR II AGCTTGCCTTGAGTGCTTCA 
LTR III AGTAGTGTGTGCCCGTCTGT 
LC I GACCCGGGAGATCTGAATTC 
LC II AGTGGCACAGCAGTTAGG 
 
Sequencing library preparation 
 
For the sequencing library preparation, a 40 ng DNA input of the purified DNA from the 
LAM-PCR procedure was used and a PCR was performed to ligate the sequencing linker to the 
purified DNA (Table 4.11. and Table 4.12.). 
 
Table 4.11. Mega PCR – Library preparation. 
Reagent Final amount (1X reaction) 
10X Taq polymerase reaction buffer 5 μL 
dNTPs 1 μL 
Mega primer (5 pmol/μL) 1 μL 
*Mega Linker (CCTAACTGCTGTGCCACT) 1 μL 
Template DNA (40 ng) 2 μL 
Taq polymerase (2.5 U/μL) 1 μL 
ddH2O Up to 50 μL 
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Table 4.12. Linear PCR II. 
Temperature Time Cycle number 
95C 2 min 1 
95°C 45 s  
60°C 45 s 
72°C 1 min 
72°C 5 min 
4°C ∞  
 
The Mega primer sequence was individually chosen for each sample and was dependent on the 
ligated linker cassette. It is important that the Mega primer anneals to the unique linker cassette. 
After performing the PCR another control 2% agarose gel was run to check for successful DNA 
amplification and the amplified DNA was further purified with AMPure beads as previously 
described. The only difference in this DNA purification step is that the beads are added in a lower 
ratio to the PCR product (1:0.7) in order to amplify only PCR products above the size of 100 bp, 
since PCR products of this size most probably contain the target sequence and successfully bound 
linker cassettes and sequencing linker.  
 
Next generation sequencing 
 
The prepared sequencing libraries were sequenced on an Illumina MiSeq platform by 250 bp 
Paired End sequencing method.  
 
Integration site data analysis and comparison 
 
The pairwise comparison of the common integration site (CIS) profile was performed to evaluate 
the similarity of the samples. The CIS definition is based on an approach based on graph and 
described in Fronza et al, 2015. Each combination of the insertion site set of samples were 
analyzed in order to obtain a mixed CIS profile. Normalized entropy N between 0 and 1 was then 
computed for each CIS >2th order in the mixed profile. The normalized entropy value for the CIS 
in the mixed profile of the samples is defined as Nijl= (Sk pijlk)/log 2, where pijlk is the IS 
fraction belonging to the sample k, which represents the dataset of IS from other studies (Ikeda et 
 15 
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al, 2007; Brady et al, 2009; Wagner et al, 2014, Maldarelli et al, 2014; Kok et al, 2016). Then, all 
those CIS with Nijl > 0 were defined as shared. The fraction of shared CIS with respect to the 
total number of CIS was used as a measure of association between the two samples. The values 
together form a 9 x 9 association matrix, with values ranging from 0 (no shared CIS) to 1 (all CIS 
are shared). The matrix was then loaded into R suite and converted to a dissimilarity table. 
Briefly, for each element eij in the matrix, with i = 1, 2, … 9, a dissimilarity table was 
constructed where the dissimilarity values di,j = 1 – eij are used as a distance in order to perform 
a hierarchical clustering. The tree structure is then obtained by plotting the results returned from 
the R function hclust(). 
 
IV. XVII. RNA extraction 
 
RNA was extracted with Invitrap spin universal RNA mini kit (Stratec biomedical) by following 
manufacturer instructions. RNA concentration was measured via spectrophotometry on P-class P 
300 NanoPhotometer (IMPLEN). 
 
IV. XVIII. Quantitative reverse transcription PCR  
 
The quantitative reverse transcription PCR was performed as previously described in Marini et al, 
2015.  
For the quantification of HIV transcript levels, RNA was purified from the cells with the Invitrap 
spin universal RNA mini kit (Stratec biomedical), as previously described. The messenger RNA 
(mRNA) levels were quantified by TaqMan quantitative reverse transcription PCR (qRT-PCR) 
using HIV-1 primers and probe, and housekeeping gene 18S and GAPDH (both containing 
VIC™/TAMRA™ fluorescent probe) (Applied Biosystems) as controls. 
The RT-PCR reaction was performed using M-MLV reverse transcriptase and reagents from 
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Table 4.13. RT-PCR setup. 






- 500 ng 
- 3 ⎧g 
- 10 mM 
Incubate reaction 
 
65 °C – 5 min 
4 °C - ∞ 
Mix 2 





- 3 ⎧M 
- 40 U 
Add mix 2 to reaction and incubate 
 
37 °C – 2 min 
4 °C - ∞ 
Addition of M-MLV reverse 
transcriptase 
- 200 U Add enzyme to reaction and incubate 
 
25 °C – 10 min 
37 °C – 50 min 
70 °C – 15 min 
4 °C - ∞ 
 
Table 4.14. List of used primers and probes for HIV mRNA expression levels quantification. 
Primer Sequence Position 
U1a Fwd primer  ACATCAAGCAGCCATGCAAAA 543 
U1a Rev primer CAGAATGGGATAGATTGCATCCA 629 
U1a probe AAGAGACCATCAATGAGGAA 605 
Nuc1b Fwd primer CGTCTGTTGTGTGACTCTGGTAACT 111 
Nuc1b DNA Rev primer CACTGCTAGACATTTTCCACACTGA 158 
Nuc1b probe ATCCCTCAGACCCTTT 140 
 
For the quantification of cell gene transcription levels, the same procedure as described for HIV 
transcript levels was performed. 
 
Table 4.15. List of used gene expression assays (Applied Biosystems). 




Tubulin 1a Hs03045184_g1 
 1X 




IV. XIX. RNA expression analysis by microarray 
 
RNA expression levels were determined via BeadArray microarray Technology (Illumina) by 
using the HumanHT-12 Expression BeadChip kit.  
BeadArray data analysis was performed in GenomeStudio software (Illumina) and R statistical 
software.  
 
IV. XX. Bacterial Artificial Chromosome (BAC) DNA purification   
 
BAC DNA was purified with NucleoBond Xtra Maxi kit (Macherey-Nagel) according to 
manufacturer instructions. BAC DNA constructs containing sequences of selected RIGs and non-
RIGs were used for the generation of fluorescent DNA FISH probes.  
 
Table 4.16. List of used BAC constructs. 
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IV. XXI. Immunofluorescence (IF) 
 
Cell preparation and permeabilization  
 
Suspension cells were seeded and fixed with 4% PFA/PBS on glass cover slips which were 
previously coated with 0,5 mg/mL PEI (Polyethyleneimine), whereas adherent cells were directly 
grown on glass coverslips. 
Only for R-loop staining cells were fixed 10 minutes in methanol at -20°C and subsequently 1 
minute in Acetone at -20°C. Cells were washed with PBS and permeabilized with 0,5% 





After washing and 30 minutes blocking in 4% BSA/PBS cells were incubated with primary 
antibodies diluted in 1% BSA/PBS overnight at 4°C. After incubation with primary antibodies 
cells were washed with 0,1% PBS/Tween and incubated with secondary Alexa Fluor antibodies 
(ThermoFisher) for 1 h at room temperature. After 0,1% PBS/Tween washing cells were 
counterstained with Hoechst and mounted on glass slides with mowiol solution.  
For STED nanoscopy Anti-Rabbit IgG ATTO 647N and Anti-Mouse IgG ATTO 594 (Sigma-
Aldrich) secondary antibodies were used.  
Used primary antibodies: rabbit polyclonal lamin B1 16048 (abcam), mouse monoclonal mAb 
414 24609 (abcam) mouse monoclonal Anti-Histone H3 (di methyl K9) 1220 (abcam), rabbit 
polyclonal Anti-Histone H3 (tri methyl K9) 8898 (abcam), rabbit polyclonal LEDGF/p75 A300-





For the R-loop staining in primary CD4+T cells and macrophages different staining approaches 
had to be applied. The R-loop antibody epitopes had to be exposed via different fixation and 
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permeabilization strategies in the two cell types. 
Primary CD4+T cells were fixed with 4% PFA/1X PBS/0,1%Tween for 10 minutes at room 
temperature. During the last two minutes of fixation a few drops of PBS/0,5% TritonX-100 were 
added. Cells were subsequently washed 3 times with 0,05%TritonX-100/PBS. Cells were 
permeabilized with 0,5% TritonX-100/PBS for 10 minutes at room temperature. Permeabilization 
was followed by 3 washes of 0,05%TritonX-100/PBS. Cells were blocked for 30 minutes at room 
temperature with 4% BSA/PBS/0,1% Tween. Cells were incubated overnight at 4°C with the 
primary antibody - S9.6 (Kerafast) and other tested antibodies (lamin B1 16048 - abcam) in a 
1:500 dilution in 1% BSA/PBS/0,1% Tween. The cells were washed 3 times with PBS/0,1% 
Tween and incubated for 1 hour at room temperature with the secondary antibody Alexa Fluor 
antibodies (ThermoFisher) in a 1:1000 dilution in 1% BSA/PBS/0,1% Tween. After 3 times 
washing in PBS/0,1% Tween, cells were stained with Hoechst for 5 minutes at room temperature 
and once rinsed in PBS. Coverslips were mounted with mowiol on glass microscopy slides. 
 
For R-loop staining in primary macrophages cells were fixed 10 minutes in methanol at -20ºC 
and 1 minute Acetone at -20ºC. Cells were subsequently washed 3 times with PBS and 
permeabilized with 0,5% Triton in 0,1% PBS/Tween for 10 minutes at room temperature. After 3 
times washing with PBS/0.1% Tween and 30 minutes blocking in 4% BSA/PBS cells were 
incubated with primary antibodies (S9.6 and lain B1) diluted 1:500 in 1 % BSA/PBS overnight at 
4C. Cells were afterwards washed 3 times with PBS/0.1% Tween and incubated for 1 hour at 
room temperature with the secondary antibody Alexa Fluor antibodies (ThermoFisher) in a 
1:1000 dilution in 1% BSA/PBS/0,1% Tween. After 3 times washing in PBS/0,1% Tween 
washing cells were stained with Hoechst for 5 minutes, rinsed in PBS and coverslips were 
mounted on glass microscopy slides with mowiol solution. 
 




Cells were first prepared and permeabilized as already described in the IF section. Upon cell 
preparation, cells were first immunostained (as previously described) either with lamin B1 or 
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nuclear pore complex antibodies, which served as a landmark for the nuclear periphery. Upon 
incubation of the secondary antibodies, secondary antibodies were 10 minutes fixed with 
EGS/PBS in order to preserve their presence until completion of the entire FISH procedure. Cells 
were further permeabilized with 0.5% triton/0.5% saponin/PBS and 0.1 M HCl for 10 minutes, 
which was followed by 0,1% PBS/Tween washings between the incubation steps. Further on 
cells were equilibrated in 2X SSC buffer (Table 4.17.) and left in hybridization buffer overnight 
(Table 4.18.). Only for HIV FISH before cell equilibration in 2X SSC buffer and incubation in 
hybridization buffer, cells were treated with with 100 µg/ml RNase A (PureLink RNase A 
(Invitrogen)) in 2x SSC for 30 min at 37°C, in order to avoid possible HIV-1 FISH probe 
hybridization to viral RNA transcripts.  
 
Table 4.17. Preparation of saline-sodium citrate buffer (SSC). 
20X SSC buffer 
NaCl 175,3 g (In stock solution 3M) 
Na3Citrate x 2 H2O 88,2 g (in stock solution 300 mM) 
Dissolve chemicals in 800 ml ddH20 
Adjust pH to 7.0 with 14 N (or similar) HCl 
 
Table 4.18. Preparation of FISH hybridization buffer. 
FISH hybridization buffer 
50 ml deionized Formamide 
10 ml 20x SSC 
20 ml sterile water; adjust pH to 7.0, 
20 ml of 50% dextran sulfate 
Final volume = 100 ml 
Store at 4°C 
 
FISH probe preparation 
 
Biotinylated HIV-1 FISH probes were prepared with the Nick Translation Kit (Roche) and 
Dioxigenin labeled BAC FISH probes were prepared with the DIG-Nick Translation Mix 
(Roche) according to manufacturer instructions. Probe size was controlled by loading 1 µL of 
probe labeling reaction on a 1% agarose gel. If the prepared DNA FISH probes had the desired 
size between 200-500 bp, they were cleaned up with Illustra Microspin G-25 columns (GE-
Healthcare) according to manufacturer instructions, and precipitated in the presence of human 
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Cot-1 DNA (Roche) and DNA from herring sperm (Sigma). The presence of highly repetitive 
human sequences and fish sperm DNA in the target DNA FISH probe should facilitate specific 
binding of the FISH probe to the genomic target. Finally, after ethanol precipitation, the probes 
were resuspended in 10 µL formamide, incubated at 37°C for 15-20 min and 10 µL of 20% 
dextran in 4X SSC was added to a final volume of 20 µL. 
 
FISH probe hybridization and detection 
 
1-10 µL of the FISH probes were loaded onto glass slides which were covered with coverslips 
containing the cells, followed by sealing in a metal chamber, and heat-denatured in a water bath 
at 80°C for 7 min. Hybridization was performed for 48 h at 37°C in a water bath. Upon 
hybridization, coverslips containing the cells were washed in 2X SSC buffer (10 min each wash), 
which was followed with three washings in 0.5X SSC buffer at 56°C in order to wash away 
potential unspecific bound DNA FISH probe fragments. FISH detection, for Dig-labelled BAC 
probes, was performed by using FITC-labelled anti-digoxigenin antibody (Roche), whereas 
biotin-labelled HIV-1 probes were detected by a TSA Plus system from Perkin Elmer, allowing 
signal amplification, by using an anti-biotin antibody (SA-HRP) and a secondary antibody with a 
fluorescent dye (usually FITC for HIV). 
Upon FISH probe detection, the cells were counterstained with Hoechst and coverslips were 
mounted with moviol solution on glass slides  
 




Confocal microscopy was performed on the confocal laser-scanning microscope Leica TCS SP8, 
by taking Z-stacks from each analyzed sample.  
Images were analyzed in ImageJ Fiji image processing package and Volocity imaging software 
(Perkin Elmer).  
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Measurements and FISH data analysis 
 
Distance measurements between the FISH signals and the nuclear envelope were measured using 
ImageJ Fiji image processing package and Volocity imaging software (Perkin Elmer). Distance 
measurements were normalized over nuclear radius (defined as half of the middle of the 
mAb414-TRITC or lamin B1 ring), and then binned into three classes of equal surface area 
(FISH signals positioned in the area of 1-19% of nuclear radius length occupied nuclear zone 1, 
signals in the area of 20-43% of nuclear radius length occupied nuclear zone 2 and signals in the 
area of 44-100% of nuclear radius length occupied nuclear zone 3). 
In addition, movement and redistribution of alleles upon distance measurements was assessed by 
performing the Kolmogorov-Smirnov test and p value definition in Prism Graphpad software. 
Images of representative cells containing FISH signals were adjusted in ImageJ Fiji image 
processing package by adjusting brightness and contrast ratio in order to increase signal to noise 
ratio and highlight the visibility of the FISH signal. Gaussian Blur filter was applied to the 




The colocalization analysis between R-loop signals and HIV-1 IN.eGFP signals was conducted 
via visual appreciation of the analyzed signals. A colocalization between R-loop signals and 
HIV-1 IN.eGFP signals was counted as positive only in case of a total match/overlap of the 
analyzed signals (appreciated by a color-change in the colocalizing signals upon channel merge 
in Fiji image analysis software - R-loop channel set to magenta and IN.eGFP set to green; a 
merge of the channels and colocalization between analyzed signals appears as a white/yellow 
signal). Signals positioned next to each other were not counted as colocalizing signals.  
 
The position assessment of HIV-1 IN.eGFP (K264,266,273Q) mutant in primary CD4+ T cells 
and macrophages was performed via visual appreciation of the IN.eGFP signals in respect to their 
position to the nuclear lamina - stained with rabbit polyclonal lamin B1 16048 (abcam) antibody. 
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STED (Stimulated Emission Depletion) nanoscopy  
 
STED nanoscopy was performed on a gated λ=775 nm STED system containing an easy 3D 
optics module (Abberior Instruments) and the λ=640 nm excitation laser line. Additional confocal 
images of eGFP signals excited at λ=488 nm were acquired.  
Deconvolution of STED images was performed in Imspector software (Abberior Instruments) via 
the linear deconvolution tool.  
Images were further processed in ImageJ Fiji image processing package and Gaussian Blur filter 
was applied to the images by setting the gamma value to 1, in order to increase signal to noise 
ratio. 
 
IV. XXIV. Plasmid DNA purification 
 
Plasmid DNA was extracted with Plasmid Midi Kit (Qiagen) according to manufacturer 
instructions.   
 
IV. XXV. Plasmid transfections 
 
pMMM-FLST plasmid, containing RNase H1 coding sequence and NLS, as well as GFP reporter 
sequence, was transfected into Jurkat cells and primary CD4+T cells via electroporation using 
Amaxa Cell Line Nucleofector Kit V (Lonza). Again, 0,5 µg of plasmid DNA was used for 
transfection of 106 cells. 
The same plasmid was transfected into MDMs with the PromoFectin kit (PromoKine). 0,5 µg of 
plasmid DNA was used for transfection of 106 cells.  
 
pMMM-FLST, RNase H WKKD (binding and catalytic mutant) and D210N (binding mutant) 
plasmid constructs were delivered into HEK293T cells and HeLa wt cells via lipofection. 2*106 
cells were lipofected with 0,5 µg plasmid per 1*106 cells with Lipofectamine LTX with Plus 
Reagent kit (Thermo Fisher).  
The efficiency of plasmid delivery was assessed via fluorescence microscopy and detection of 
GFP expression on Olympus IX81 microscope (Olympus). 




IV. XXVI. Chromatin immunoprecipitation followed by quantitative PCR 
(ChIP-qPCR) 
 
ChIP was performed as described in Chen et al, 2012 with smaller modifications. 
CD4+T cells (10x106) were washed twice in PBS before crosslinking with 1% final formaldehyde 
for 10 min at room temperature, followed by termination of the reaction with 125 mM glycine on 
ice. The cell pellet was washed twice with PBS and was lysed in 0.5% NP-40 buffer (10 mM 
Tris-Cl pH7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM PMSF and protease inhibitors). The nuclei 
obtained were washed once in the same buffer without NP-40. Lysis of the nuclei was performed 
using a nuclear lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8) and keeping the 
cells for 30 minutes on ice. DNA was sheared by sonication (on Bioruptor sonicator Diagenode) 
to obtain fragment size of 400-200 bp. Extracts were pre-cleared by incubation with 
immunoglobulin-γ and agarose beads, followed by centrifugation at 1,200g for 5-10min. The 
lysate was then diluted to 1X in a 5X ChIP binding buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 % NP40, 0.25 % Na-DOC, 1 mM EDTA pH 8 and protease inhibitors) and incubated 
with 2-4 µg of the indicated antibody overnight at 4°C, followed by incubation for 2 h with 
MagnaChIP Protein A/GMagnetic Beads (Millipore). Beads were then washed with ChIP binding 
buffer (1X PBS, 0,1% BSA, 2 mM EDTA, pH7.4), LiCl-containing buffer (10 mM Tris-HCl, 
pH8, 250 mM LiCl, 1% IGEPAL, 1% NaDoc, 1 mM EDTA) and with TE buffer (10 mM Tris-
HCl, pH8, 50 mM NaCl, 1mM EDTA). ChIP samples were subsequently treated with RNase A 
for at least 30min at 37°C, and then treated with proteinase K for at least 2 h at 56°C. De-
crosslinking of protein-DNA complexes was performed by an overnight incubation at 65°C. 
Afterwards the DNA was pulled down by a 2 h incubation with AMPure XP magnetic beads 
(Beckman Coulter) at room temperature. The beads containing bound DNA fragments were 
washed twice with 80% ethanol and afterwards air dried for 45 min. Upon drying the beads were 
resuspended in water, and the magnetic beads were removed with a magnet, which released the 
immunoprecipitated DNA.  
Target enrichment was determined by quantitative PCR. Enrichment was calculated by using the 
2(-Delta Delta C(T)) method for analysis of real time quantitative PCR (Livak & Schmittgen, 
2001) and the results were normalized over ChIP input values.  




Used antibodies: mouse monoclonal Anti-Histone H3 (di methyl K9) 1220 (abcam), rabbit 
polyclonal Anti-Histone H3 (tri methyl K9) 8898 (abcam), rabbit polyclonal LEDGF/p75 A300-
847A Bethyl Laboratories), rabbit polyclonal Anti-Histone H3 (tri methyl 36) 9050 (abcam). 
 
Table 4.19. List of used primers for ChIP-qPCR analysis. 
Gene Region Sequence 
BACH2 First intron F: GAAGAGTGCCTAGCACAGTAAG 
R: GAGCACACAGGTTTAGGAGATG 
Gene body F: CAACTCCAAGGGCCAGAG 
R: AGAGGCTGAACCAACAAGAG 
Exon/intron junction (gene end) F: TCTGCCTCTGATCCCTATGT 
R: GGTAGCAAGTAAGGGTCCAAA 
STAT5B First intron F: TCAAACGTGGTGGAAGTGTTAG 
R: CACCCAGCCTACCATCTTATTT 
Gene body F: GGTGATGGTCATGGTTTCCT 
R: GAGACACCTGCTTCTGCTG 
Exon/intron junction (gene end) F: CTTCCTCTGAAGGGATGGTATTG 
R: TCACGCTGATGACTTGAAACT 
MKL2 First intron F: GACCCTTTGCGTACCTTCTT 
R: GTGGAGCTCAGAGTCTACATTTC 
Gene body F: TGAAACACAAGATTCGGATCG 
R: GGGAATAAACAGAAATGGTGGAAAT 
Exon/intron junction (gene end) F: AGAGGAAAGACCACTCCCTAT 
R: GGCTTTCTGTTGTGAGTTGTATG 
RPTOR First intron F: TGCTGGCAGATTGTGGTAAA 
R: GGGAAGGAAGGAAGGAAGAAAG 
Gene body - 
Exon/intron junction (gene end) - 
NPLOC4 First intron F: CCAAGGCCAACTCCAGTATT 
R: GGTCTGTCTCTTCCTGTGTATTT 
Gene body - 
Exon/intron junction (gene end) - 
KDM2B First intron F: GTTGCTTGGGTTGCAATGG 
R: AGAGAGCCCGGGACATTAT 
Gene body - 
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Exon/intron junction (gene end) - 
PACS2 First intron F: CCCAAATCTCATAGCCAGTAGG 
R: GTGAGGGAGCACAGGAAATA 
Gene body - 
Exon/intron junction (gene end) - 
ACTN1 First intron F: AGGTAGAGAGGAACCAGAAA 
R: AATGCCAGGGAAAGGTAAGG 
Gene body - 
Exon/intron junction (gene end) - 
CNTN4 First intron F: CTTACACACCCTTCACCACTAC 
R: CGCAAGACTCCCACAATAGAA 
Gene body F: CAGGAGTGATGGGTGAATATGAG 
R: TAAAGCAAAGCATTCCAGCTTC 




IV. XXVII. DNA-RNA hybrid immunoprecipitation (DRIP) 
 
DRIP was performed as previously described in Ginno et al, 2012.   
107 primary CD4+ T cells were used as starting material. After collection, cells were washed with 
PBS and used for DNA extraction with DNeasy Blood & Tissue kit (Qiagen). 4 μg of DNA was 
sheared by sonication (Bioruptor, Diagenode). After sonication the sample was split, where one 
part of the sample was treated only with RNase A (to remove possible residual RNA) and the 
other part of the sample was treated with RNAse A (PureLink RNase A, Invitrogen) and RNAse 
H1 (NEB M0297S) (to remove R-loops) overnight at 37°C. The RNAse H1 treated sample was 
used as a negative control for the R-loop pull down procedure. After RNase A and RNase H1 
digestion the samples were additionally digested with proteinase K (Proteinase K Solution, 
ThermoFisher) for 30 minutes at 37°C. After proteinase K digestion, the DNA was extracted 
from the samples by phenol/chloroform extraction. Samples are resuspended in 450 μL of TE 
buffer and 50 μL of binding buffer (10X binding buffer: 100 mM NaPO4 pH 7, 1,4 M NaCl, 0,5% 
Triton X100,) was added. To each sample 10 μL of S9.6 antibody (Kerafast) was added and the 
samples are incubated at 4ºC overnight. Agarose A/G beads (Pierce) were pre-washed 3 times 
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with 1X binding buffer (diluted in TE) before addition to the samples. The beads were added to 
DNA-S9.6 antibody complexes and left incubating on a rotisserie shaker for 2 h at 4ºC. After 
incubation, bead-antibody complexes were washed 3 times with 1X binding buffer and 
resuspended in 250 μL elution buffer (50 mM Tris, pH 8; 10 mM EDTA, 0,5% SDS). Afterwards 
another proteinase K digestion was performed for 1 h at 55ºC, by the addition of 7 μL of the 
enzyme. After digestion, the DNA was cleaned up with QIAquick PCR purification kit (Qiagen).  
 
 
The enrichment of R-loops was 
determined by qPCR using control 
primers for R-loop rich and R-loop poor 
genes (Table 4.20.). R-loop enrichment 
was also assessed for selected RIGs, and 
the results were analyzed by the 2(-Delta 
Delta C(T)) method for analysis of real 
time quantitative PCR (Livak & 
Schmittgen, 2001), and normalized over 
the R-loop poor region of the SNRPN 
gene, which turned out to be the best 
normalizer for primary CD4+ T cells, and has previously been demonstrated to be an adequate 
DRIP-qPCR normalizer gene (Garcia-Rubio et al, 2015) .  
  
To control for the efficiency of the DRIP procedure and successful R-loop pull-down, the DRIP 
was in parallel performed on an R-loop containing plasmid construct (kindly provided by the lab 
of Frederick Chedin), which was also used as a spike in control in the actual DRIP samples. 
The pFC53 plasmid, containing an R-loop forming sequence and a T3 promoter first had to be in 
vitro transcribed, which would initiate R-loop formation. For this reaction 3 μg of plasmid DNA 
was used, which was mixed with 1 M DTT, 2,5% Tween, 2,5 mM rNTPs, 5X reaction buffer 
(Promega) and T3 RNA Polymerase (Promega). The reaction was incubated for 30 minutes at 
37ºC, and the T3 RNA Polymerase was subsequently heat inactivated for 10 minutes at 65ºC. 
The reaction was afterwards split for either only RNase A treatment or RNase A and RNase H 
 
 
Figure 4.1. Scheme of the binding region of the R-loop 
specific antibody S9.6.  
The epitope of the R-loop specific S9.6 antibody is 
demonstrated to be 6 bp in size (Phillips et al, 2013).  
Materials and methods 
182 
 
treatment, as previously described for the actual DRIP samples. Upon subsequent Proteinase K 
digestion, the samples were ran on a 2% agarose gel to check for R-loop formation. The formed 
R-loop fragment can be appreciated on the gel in form of a smear and slight shift of the plasmid 
on the gel. In order to separate the R-loop fragment from the rest of the plasmid and use both 
fragments as spike in controls, only the RNase A treated sample was further digested with ApaLI 
(NEB) restriction enzyme by following manufacturer instructions. Upon digestion, the reaction 
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Table 4.20. List of used primers for DRIP-qPCR. 
Positive R-loop primer Sequence 
APOE F: CCGGTGAGAAGCGCAGTCGG 
R: CCCAAGCCCGACCCCGAGTA 
MYADM F: CGTAGGTGCCCTAGTTGGAG 
R: TCCATTCTCATTCCCAAACC 
RPL13A F: AATGTGGCATTTCCTTCTCG 
R: CCAATTCGGCCAAGACTCTA 
EGR1 F: CCAATTCGGCCAAGACTCTA 
R: CTTGTGGTGAGGGGTCACTT 
BTBD19 F: GGCTGCTCAGGAGAGCTAGA 
R: ACCAGACTGTGACCCCAAAG 
Negative R-loop primer Sequence 
SNRPN F: GCCAAATGAGTGAGGATGGT 
R: TCCTCTCTGCCTGACTCCAT 
EGR1 negative region F: GAACGTTCAGCCTCGTTCTC 
R:GGAAGGTGGAAGGAAACACA 
MYADM negative region F: TGCATCTACATCCGCAAAAG 
R: AGAGTGGACGCTGCAGAAAT 
pFC53 primer Sequence 
R-loop fragment F: TTTAGAGCTTGACGGGGAAA 
R: CAACAGTTGCGTAGCCTGAA 
Non-R-loop fragment F: TTGCCGGGAAGCTAGAGTAA 
R: GCTGCCATAAGCATGAGTGA 
RIGs primer Sequence 
BACH2 F: GAAGAGTGCCTAGCACAGTAAG 
R: 
GAGCACACAGGTTTAGGAGATG 
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IV. XXVIII. DNA-RNA hybrid immunoprecipitation (DRIP) combined with 
Alu PCR 
 
In order to verify whether integrated HIV-1 DNA can be situated in R-loop rich regions a 
combined approach of DRIP and Alu PCR was performed. 
DRIP was performed on infected material - pNL4-3/E-R- HIV-1 infected CD4+ T cells as 
previously described. DRIP was performed to the last step of DNA extraction, which was 
followed by using the extracted genomic DNA as an input for an Alu PCR reaction. Alu PCR 
was performed in 2 steps as previously described. The results were analyzed by the 2(-Delta 
Delta C(T)) method for analysis of real time quantitative PCR (Livak & Schmittgen, 2001), and 
normalized both over both, the B13 region of the lamin B2 gene or R-loop poor region of the 
SNRPN gene.  
 
IV. XXIX. Absolute quantification of early and late HIV-1 RT-products and 
2LTR circles 
 
The absolute quantification of early and late HIV-1 RT-products and 2LTR circles was 
performed by digital droplet PCR (ddPCR) as previously described by Bejarano et al, 2018. Early 
and late RT-products were detected with primers and probes annealing to the long terminal repeat 
(LTR) or to the gag gene of the HIV-1 genome. A specifically designed set of primers and probe 
were used for the detection of 2LTR circles (Table 4.21.). As a housekeeping control gene of the 
host genome ribonuclease P protein subunit p30 (RPP30) was also quantified and used for the 
normalization of really and late RT-product values, as well as 2LTR circles. In addition, 20 µL 
reactions, containing 2-4 µL of the diluted DNA, 900 nM of each primer, 200 nM probe, 1x 
ddPCR Supermix for probes (no dUTP) (Bio Rad) and water were prepared for each sample and 
analyzed target. The droplets were generated by using the droplet generation oil for probes 
(BioRad). The droplets were immediately transferred to a 96-well microplate. The PCR 
amplification was performed by applying the following temperature regime: initial denaturation 
and stabilization at 95°C for 10 min, 40 cycles of denaturation at 94°C for 30 s, and 
annealing/extension at 57°C for 60 s, followed by 10 min at 98°C. Following PCR amplification, 
the droplets were sorted and analyzed in a QX200 droplet reader (BioRad) by using the 
QuantaSoft v1.6 software (BioRad) and the settings for absolute quantification. Results were 
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analyzed using the same software, and copy numbers were normalized to the copy numbers of the 
housekeeping gene. 
 
Table 4.21. List of used primers/probes for ddPCR amplification of early and late 
HIV-1 RT-products and 2LTR circles (Bejarano et al, 2018).  
Target Sequence 
5’ LTR Fwd TTAAGCCTCAATAAAGCTTGCC 
5’ LTR Rev GTTCGGGCGCCACTGCTAG 
5’ LTR probe FAM–CCAGAGTCACACAACAGACGGGCA–BHQ1 
Gag Fwd CATGTTTTCAGCATTATCAGAAGGA 
Gag Rev TGCTTGATGTCCCCCCACT 
Gag probe HEX—CCACCCCACAAGATTTAAACACCATGCTAA–BHQ1 
2LTR Fwd CTAACTAGGGAACCCACTGCT 
2LTR Rev GTAGTTCTGCCAATCAGGGAA  
2LTR probe  FAM—AGCCTCAATAAAGCTTGCCTTGAGTGC–BHQ1 
RPP30 Fwd GATTTGGACCTGCGAGCG 
RPP30 Rev GCGGCTGTCTCCACAAGT 
RPP probe FAM–CTGACCTGAAGGCTCT–BHQ1 
 
 
IV. XXX. Total quantification cellular R-loop levels by dot blot assay 
 
The dot blot assay was performed as previously described by Wahba et al, 2013.  
500 ng of genomic DNA was directly spotted on a nitrocellulose membrane (GE Healthcare Life 
Sciences) and left to dry. Afterwards, the nitrocellulose membrane was UV-crosslinked and 
blocked for 30 minutes in 5% FBS/1% Tween/1xPBS at room temperature. Further on the 
nitrocellulose membrane was incubated with the primary S9.6 antibody in a 1:500 dilution in 1% 
FBS/1% Tween/1xPBS overnight at 4°C. Afterwards the membrane was washed in 0,1% 
Tween/1xPBS and incubated with mouse secondary antibody (Jackson immunoresearch) for 1 h 
at room temperature. After secondary antibody incubation, the membrane was again washed in 
0,1% Tween/1xPBS and R-loop signals were detected with the Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare Life Sciences) and exposing the membrane on a 
western blot chemiluminescence imaging device Alliance Q9 Touch (Mandel).  




IV. XXXI. In vitro integration assays  
 
Integration assays were performed as previously described by Benleulmi et al, 2015. For the 
purpose of assay performance, recombinant purified IN was used. IN/v DNA complexes were 
pre-assembled as previously described by Lesbats et al, 2008 and Benleulmi et al, 2015. 10 ng of 
donor DNA containing the U5 viral ends was used to assemble the IN/vDNA complexes. Pre-
assembled complexes were further on incubated with 50 ng of, either transcribed (containing R-
loop) or non-transcribed pFC53 plasmid constructs (not containing R-loop) in 20 mM HEPES 
pH7, 15% DMSO, 8% PEG, 10 mM MgCl2, 20 µM ZnCl2, 100 mM NaCl, 10 mM DTT final 
concentration. After the integration reaction was performed, the reaction was further treated for 1 
h at 37ºC with HpaI restriction enzyme in order to cut the pFC53 plasmid construct into its R-
loop and non-R-loop fragment, as well as to release the formed integration products. Afterwards 
the resultant integration products were deproteinized by Proteinase K treatment and 
phenol/chloroform/isoamyl alcohol (25/24/1 v/v/v) treatment before loading onto a 1% agarose 
gel. The obtained gel was further dried and submitted to autoradiography. The bands 
corresponding to free substrate (S), donor/donor, linear FSI (FSI) and circular HSI + FSI 
(HSI + FSI) products were quantified.  
This part of the study was completed by the help and work of Dr. Vincent Parissi (University 
Bordeaux).  
 
IV. XXXII. In silico analysis of R-loops and HIV-1 integration sites 
 
The initial screen of the overlap between R-loop forming sites and HIV-1 integration sites was 
performed using the R statistical software via the application of the sequence alignment and 
analysis plugin Bioconductor, by using a cut-off window for sequence alignment of 50 kb. HIV-1 
integration site maps were used from data generated from MDMs and CD4+ T cells (Cohn et al, 
2015; Kok et al, 2016) and R-loop maps were used from data generated from the NT2 cell line 
and K562 cell line (Sanz et al, 2016).  
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This part of the study was completed by the help and work of Constantin Ahlmann-Eltze 
(Heidelberg University).  
The second part of the screen was performed by using the extended list of RIGs from the Lusic 
lab (containing 11.537 genes) (Lucic et al, 2019) which was overlapped with R-loop maps from 
K562 cells (Sanz et al, 2016) using the R statistical software via the application of the sequence 
alignment and analysis plugin Bioconductor, by using a cut-off window for sequence alignment 
of 50 kb. As an internal control and as an outlier of the analysis, LAD maps from human 
fibroblasts (Guelen et al, 2008) and human Jurkat T cell line (Robson et al, 2017) were included 
into the analysis.  
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Abbreviation  Elaboration 
 
 
°C degree Celsius  
Δ Delta  
µg microgram  
µL microliter  
µm micrometer  
µM micromolar  
3 D Tridimensional  
A Alanine  
ACTN1 Alpha actinin  
ADP Adenosindiphosphat  
AIDS Acquired Immune Deficiency Syndrome  
Airn Antisense Igf2r RNA  
Alu Arthrobacter luteus (repetitive genomic sequence)  
ApaLI Acetobacter pateurianus LI (enzyme)  
APC Antigen presenting cell  
APOE Apolipoprotein E  
AT Adenin Thymine  
B cell Bursa Fabricius lymphocyte  
BAC Bacterial artificial chromosome  
BACH2 Basic leucine zipper transcription factor 2  
BAF Barier to autoregulation protein   
bp Base pair  
BTBD19 BTB Domain Containing 19  
C2CD3 C2 Calcium Dependent Domain Containing 3  











CA Capsid protein   
CaCl2 Calcium chloride  
cART Combined antiretroviral therapy  
CCD Catalytic core domain  
CCR5 C-C Motif Chemokine Receptor 5  
CD3 Cluster of Differentiation 3  
CD4 Cluster of Differentiation 4  
CD28 Cluster of Differentiation 28  
CD38 Cluster of Differentiation 38  
CD69 Cluster of Differentiation 69  
cDNA Complementary deoxyribonucleic acid   
C. elegans Caenorhabditis elegans  
ChIP Chromatin immunoprecipitation  
CNTN4 Contactin 4  
CPSF6 Cleavage and polyadenilation specificity factor 6  
CREBBP CREB Binding Protein  
Ct Cycle threshold  
CTCF CCCTC-binding factor  
CTD C-terminal domain  
CXCR4 C-X-C Motif Chemokine Receptor 4  
Cyp A Cyclophilin A  
D Aspartic acid  
DamID Deoxyribonucleic acid adenine methyltransferase identification  
DDR Deoxyribonucleic acid damage response   
Dig Digoxigenin   
DMEM Dulbecco’s modified eagle medium  
DNA Deoxyribonucleic acid   
DNase Deoxyribonuclease  
DNMT1 DNA Methyltransferase 1  
dNTP Deoxyribonucleotide  







DRIP DNA-RNA immunoprecipitation  
dsRNA Double stranded ribonucleic acid  
DTT DL-Dithiothreitol  
E Glutamic acid  
ECL Enhanced chemiluminescence   
eGFP Enhanced green fluorescent protein   
EGR1 Early Growth Response 1  
EGTA Ethylene glycol-bis(ßaminoethyl ether) tetraacetic acid  
EMD Emerin  
env Envelope  
ESC Embryonic stem cell  
ESCRT Endosomal sorting complex required for transport  
F Forward  
FA Formaldehyde  
FACS Fluorescence activated cell sorting  
FACT Facilitates transcription complex  
FBS Fetal bovine serum  
FISH Fluorescent in situ hybridization  
FG Phenylalanine-Glycine  
FSI Full site integration  
Fwd Forward  
G0 Growth 0 phase  
G1 Growth 1 phase  
G2 Growth 2 phase  
GO  Gene ontology  
GC  Guanine Cytosine  
GLP G9a-like protein  
GNB1 Guanine Nucleotide-Binding Protein G(I)/G(S)/G(T) Subunit Beta-1  
GRB2 Growth Factor Receptor Bound Protein 2  
h hours  
H1 Histone 1  







H2A Histone 2 A  
H2A(X) Phosphorylated histone 2  
H2B Histone 2 B  
H2O Water  
H3 Histone 3  
H3K4me3 Histone 3 Lysine 4 trimethylation  
H3K9ac Histone 3 Lysine 9 acetylation  
H3K9me2 Histone 3 Lysine 9 dimethylation  
H3K9me3 Histone 3 Lysine 9 trimethylation  
H3K14ac Histone 3 Lysine 14 acetylation  
H3K27ac Histone 3 Lysine 27 acetylation  
H3K27me3 Histone 3 Lysine 27 trimethylation  
H3K36me3 Histone 3 Lysine 36 trimethylation  
H3S10P Histone 3 serine 10 phosphorylation  
H4 Histone 4  
H4K5ac Histone 4 Lysine 5 acetylation  
H4K8ac Histone 4 Lysine 8 acetylation  
HAT Histone acetyl transferase  
HBD Hybrid binding domain  
HBS HEPES buffered saline  
HDAC Histone deacetylase  
HDAC1 Histone deacetylase 1  
HDM Histone demethylase  
HEK293T Human embryonic kidney 293T cells  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIV-1 Human immunodeficiency virus type 1  
HIV-1 Human immunodeficiency virus type 2  
HMT Histone methyltransferase  
HP1 Heterochromatin protein 1  
HpaI Haemophilus parainfluenza I (enzyme)  
HSI Half site integration  







IBD Integrase binding domain  
IF Immunofluorescence  
IN Integrase protein   
IN.eGFP Vpr.Integrase.enhanced Green Fluorescent Protein-fusion  
K Lysine  
kb kilobase  
KCl Kalium chloride  
kDa kilodalton  
KDM2B Lysine Demethylase 2B protein  
KO Knockout  
L Liter  
LAD Lamina associated domain  
LAM PCR Linear amplification mediated polymerase chain reaction  
LAP2B Lamina associated polypeptide 2  
LBR Lamin B receptor  
LC Linker cassette  
LEDGF Lens epithelium derived growth factor  
LiCl Lithium chloride  
LOCK Large organized chromatin domain  
LRA Latency reversing agent  
LTR Long terminal repeat  
Lys Lysine  
m mili (10-3)  
M Mitosis  
mA miliamper  
Ma Matrix protein  
Mb Megabase  
MDM Monocyte derived macrophage  
Mg Manesium  
MgCl Magnesium chloride  
MHC Major histocompatibility complex  







min Minute  
MluCI Micrococcus luteus CI (enzyme)  
MLV Murine leukemia virus  
MKL2 Myocardin like 2  
mM milimolar  
MNase Micrococcal nuclease  
mRNA Messenger ribonucleic acid  
MseI Micrococcus species (R. Morgan) (enzyme)  
MTT assay 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromidefor 
assay 
 
MYADM Myeloid Associated Differentiation Marker  
N Asparagine  
NaCl Sodium chloride  
NC Nuclear core protein  
NE Nuclear envelope  
nef Negative factor  
NFATC3 Nuclear Factor Of Activated T-Cells 3  
ng nanogram  
NL Nuclear lamina  
NLS Nuclear localization signal  
nm nanometer  
NPC Nuclear pore complex  
NPLOC4 NPL4 Homolog, Ubiquitin Recognition Factor  
NTD N-terminal domain  
NUP Nuclear pore protein  
ON Overnight  
p piko (10-12)  
PACS2 Phosphofurin Acidic Cluster Sorting Protein 2  
PBMC Purified Blood Mononuclear Cell  
PBS Phosphate-buffered saline   











PCR Polymerase chain reaction  
PIC Preintegration complex  
PEI Polyethylenimine  
Pen/Strep Penicillin/Streptomycine  
PFA Paraformaldehyde  
PMSF Phenylmethylsulfonyl fluoride  
pol Polymerase  
polyA Polyadenylated  
ppt Polypurine tract  
PR Protease protein   
PRC2 Polycomb repressive complex 2  
PWWP Proline-Tryptophan-Tryptophan-Proline  
Q Glutamine  
qPCR Quantitative polymerase chain reaction  
R Reverse  
RANBP2 Ran binding protein 2  
Rev Reverse  
RGPD8 RANBP2-like and GRIP domain containing 8  
RIG Recurrent integration gene  
RIPA Radioimmunoprecipitation assay buffer   
RNA Ribonucleic acid  
RNAi Ribonucleic acid interferin  
RNA Pol2 Ribonucleic acid polymerase 2  
RNase Ribonuclease  
RNF157 Ring Finger Protein 157  
RNHL Ribonuclease H-like  
rNTP Ribonucleotide  
RPL13A Ribosomal Protein L13a  
RPMI Roswell Park Memorial Institute medium  















RT Reverse Transcriptase (enzyme), Reverse Transcription (process) or 
Room Temperature 
 
RT-PCR Reverse transcriptase polymerase chain reaction  
s Second  
SA-HRP Streptavidin-horse radish peroxidase   
SAMHD1 SAM domain and HD domain-containing protein  
SDS Sodium dodecyl sulfate  
SETX Senataxin  
SG-PERT SYBR Green PCR-enhanced reverse transcriptase assay  
siRNA Small interfering ribonucleic acid  
SIV Simian immunodeficiency virus  
SMG1 Serine/threonine-protein kinase 1  
SNRPN mall nuclear ribonucleoprotein polypeptide N  
SSC Saline-sodium citrate  
STAT5B Signal transducer and activator of transcription 5B  
STED Stimulated emission depletion (microscopy)  
TAD Topologically associated domain  
T cell Thymus derived lymphocyte  
tat Transactivator of transcription  
TF Transcription factor  
TGF-β1 Transforming Growth Factor Beta 1  
Th T-helper cell  
Top I Topoisomerase 1  
TRC T cell receptor  
Treg T-regulatory cells  
Tris Tris Buffered Saline  
tRNA Transport ribonucleic acid  
TSS Transcription start site  
U Unit  
V Valine (aminoacid) or volt (electrical unit of voltage)  
vDNA Viral Deoxyribonucleic acid  







vpr Viral protein R  
vpu Viral protein U  
VSV-G Vesicular stomatitis virus G protein  
WKKD Tryptophan-Lysine-Lysine-Aspartic acid  
wt Wilde type  
YY1 Ying yang 1 protein   
Zn Zink  
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Cell type Medium Medium composition   









(ThermoFisher) and 5 
ng/mL IL-2  
MDMs 
Jurkat T cell line 












Drug name Supplier 
SAHA Sigma-Aldrich  
JQ1 Sigma-Aldrich  
BIX01294 Sigma-Aldrich  
UNC0642 Sigma-Aldrich  
 
 
















1X SDS running buffer 192 mM Glycine 
0,1% SDS, pH 8.3 
 
2X HBS  
50 mM HEPES 
280 mM NaCl 
1.5 mM Na2HPO4, pH 7.5 
 
SG-PERT cell lysis buffer 
0.25% Triton X-100 
50 mM KCl 
100 mM TrisHCl pH7.4 
40% glycerol 
 
10X SG-PERT dilution buffer 
50 mM (NH4)2SO4 
200 mM KCl  





2X SG-PERT reaction mix  
10 mM (NH4)2SO4 
40 mM KCl  
40 mM Tris–Cl pH 0.3 
10 mM MgCl2 
0.2 mg/ml BSA 
1/10,000 SYBR Green I 
400 μM dNTPs 
1 μM forward primer 
1 μM reverse primer 
1.2 μg/ml BMV RNA 
 
3M LiCl buffer  
10 mM Tris-HCl, pH 7.5 
1 mM EDTA 
3M LiCl 
 
6M LiCl buffer  
10 mM Tris-HCl, pH 7.5 
1 mM EDTA 
6 M LiCl 
IF blocking buffer 4% PFA in 1X PBS 
Cell permeabilization buffer  0,5% Triton 
0,1% Tween in 1X PBS 
IF wash buffer  0,1% Tween in 1X PBS 
FISH permeabilization buffer   0.5% Triton 
0.5% Saponin in 1X PBS 
 
20X SSC buffer  
3M NaCl 
300mM Na3Citrate x 2 H2O 
pH 7 
 
FISH hybridization buffer 
50% Formamide 
2X SSC buffer 










10 mM Tris-Cl pH7.4 
10 mM NaCl2 
3 mM MgCl 
1 mM PMSF and protease 
inhibitors 
Nuclear lysis buffer 1% SDS 
10 mM EDTA 
50 mM Tris-HCl, pH 8 
 
 
5X ChIP buffer 
50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
1 % NP40 
0.25 % Na-DOC 
1 mM EDTA, pH 8 and protease 
inhibitors 
 
ChIP binding buffer 
1X PBS 
 0,1% BSA 
2 mM EDTA, pH7.4 
LiCl buffer 10 mM Tris-HCl, pH8 
250 mM LiCl 
1% IGEPAL 
1% NaDoc 
1 mM EDTA 
TE buffer 10 mM Tris-HCl, pH8 
50 mM NaCl 
1mM EDTA 
 
DRIP binding buffer 
100 mM NaPO4, pH 7 
1,4 M NaCl 
0,5% Triton X100 
DRIP elution buffer  50 mM Tris, pH 8 





In vitro integration assay buffer 
20 mM HEPES pH 7 
15% DMSO 
8% PEG 
10 mM MgCl2 
20 µM ZnCl2 
100 mM NaCl 
10 mM DTT 
Mowiol mounting medium 77 µM Mowiol 4-88 
30% Glycerol 









Amersham ECL Prime Western Blotting Detection Reagent GE Healthcare Life Sciences 
AMPure XP magnetic beads Beckman Coulter 
Cot-1 DNA Roche 
Fixable Viability Dye eFluor 450 eBioscience 
Hering sperm DNA Sigma-Aldrich  
Immunoglobulin-γ and agarose beads Sigma-Aldrich  
MagnaChIP Protein A/G Magnetic Beads Millipore 
PBS Sigma-Aldrich  
PEI Sigma-Aldrich  






DNA Polymerase Invitrogen 
HpaI NEB 
MluCI NEB 
M-MLV Reverse transcriptase Invitrogen 
MseI NEB 
Proteinase K Invitrogen 
PureLink RNase A Invitrogen 
RNase H1 NEB 





Antibody/ target protein Species Supplier 
β-actin mouse Sigma-Aldrich 
dimethyl-Histone H3 (Lys 9) mouse Millipore 
G9a/EMT2 rabbit Cell Signaling Technology 
Histone H3 rabbit Millipore 
Lamin B1 rabbit Abcam 
LEDGF/p75 rabbit  Bethyl Laboratories 
mAb 414 mouse Abcam 
p24 - Beckman Coulter 
S9.6 mouse Kerafast 
trimethyl-Histone H3 (Lys 9) rabbit Abcan 
trimethyl-Histone H3 (Lys 36) rabbit Abcam 
gamma H2A.X (phospho S139) mouse Abcam 
 
 
Secondary antibodies Species Supplier 
anti-digoxigenin - Roche 
Alexa 488 mouse ThermoFisher 
Alexa 568 mouse ThermoFisher 
Alexa 647 rabbit ThermoFisher 
ATTO 594 mouse Sigma-Aldrich  
ATTO 647N rabbit Sigma-Aldrich  
Western blot anti-mouse mouse Jackson immunoresearch 








Plasmid name Description 
pFC53 DNA template for R-loop formation in vitro 
pGZIP-G9a Lentiviral vector for G9a KO 
pMD2.G Expression vector for viral VSV-G presudotyping 
pMMM-FLST Expression vector for RNase H1 overexpression 
pMMM-FLST, RNase H1 D210N Expression vector for RNase H1 D210N mutant overexpression 
pMMM-FLST, RNase H1 WKKD Expression vector for RNase H1 WKKD mutant overexpression 
pNL4.3 Full-length proviral HIV-1 group M sequence containing plasmid 
for virus particle production 
 
pNL4-3/E-R-  
Full-length proviral HIV-1 group M sequence with a frameshift 
mutation in env gene containing plasmid for virus particle 
production 
HIV-1BRU(K264,266,273R)  
Full-length proviral HIV-1 group M sequence with K264, K266 
and R273 mutations in IN C-terminus for virus particle production 
vpr.IN.eGFP Expression vector for fluorescent virus particle labeling  
 
 
Commercial kits  
 
 
Kit name Supplier 
10X hexanucleotide mixture Roche 
Amaxa Cell Line Nucleofector Kit V Lonza 
Bradford assy BioRad 
CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT) assay  Promega 
DIG-Nick Translation kit Roche 
DNeasy Blood & Tissue kit Qiagen 




Kit name Supplier 
Invitrap spin universal RNA mini kit  Stratec biomedical 
Lipofectamine LTX with Plus Reagent kit ThermoFisher 
Nick Translation Kit Roche 
NucleoBond Xtra Maxi kit  Macherey-Nagel 
Plasmid Midi Kit Qiagen 
PromoFectin kit PromoKine 
QIAquick PCR purification kit Qiagen 
RosetteSep™ Human CD4+ T Cell Enrichment Cocktail STEMCELL 
TECHNOLOGIES 
TSA Plus system Perkin Elmer 
 
 




BD FACSVerse flow cytometer BD Biosciences 
BeadArray microarray Technology / HumanHT-12 Expression BeadChip kit.  Illumina 
Bioruptor (sonication device) diagnose 
ddPCR automated droplet generator QX200  BioRad 
ddPCR droplet reader QX200 BioRad 
DNA gel electrophoresis device Biometra Compact Biometra 
Infinite 200 PRO multimode plate reader.  Tecan 
Leica TCS SP8 Laser Confocal Leica Microsystems Scanning Microscope Leica 
MiSeq platform Illumina 





P-class P 300 NanoPhotometer IMPLEN 
PCR Biorad CFX96 Touch platform BioRad 
SimpliAmp Thermal Cycler ThermoFisher 
STED system containing an easy 3D optics module Abberior Instruments 
Trans –Blot device for semi-dry transfer  BioRad 
Transiluminator (GEL-V-U-04-07) Zenith 
Ultracentrifuge L8-M Beckman Beckman Coulter 
Western blot gel running system Biometra 






Software name Application Supplier 
Adobe Illustrator Data graphs and image arranging Adobe 
Adobe Photoshop Image analysis Adobe 
BD FACSuite software FACS data analysis BD Biosciences 
CFX Manager qPCR data analysis BioRad 
GraphPad Prism 
Data organization and statistic analysis GraphPad Software Inc. 
ImageJ Fiji  Image analysis Open source 
Imspector software STED image data deconvolution Abberior Instruments 
R software In silico data analysis; microarray data 
analysis 
R Core Team 
QuantaSoft Software ddPCR droplet analysis BioRad 






Primer and primer probe sequences 
 
 














B13 Fwd primer CCCCAGGGAGTAGGTTGTGA 
B13 Rev primer TGTTATTTGAGAAAAAGCCCAA 
B13 probe CAGCAGGAAAGGAC 
2 LTR circles Fwd primer AACTAGAGATCCCTCAGACCCTTTT 
2LT circle 
quantification 2 LTR circles Rev primer 
CTTGTCTTCGTTGGGAGTGAATT 
2 LTR circles probe CTAGAGATTTTCCACACTGAC 
Total viral DNA Fwd primer TGTGTGCCCGTCTGTTGTGT 
Total viral DNA 
quantification Total viral DNA Rev primer 
GAGTCCTGCGTCGAGAGAGC 
Total viral DNA probe CGCCCGAACAGGGACTTGAA 
LTR I GAGCTCTCTGGCTAACTAGG 
LAM-PCR 
primer LTR II 
AGCTTGCCTTGAGTGCTTCA 




Primer name Primer sequence (5’-3’ direction) Application 
LC I GACCCGGGAGATCTGAATTC 
LC II AGTGGCACAGCAGTTAGG 




U1a Rev primer CAGAATGGGATAGATTGCATCCA 
U1a probe AAGAGACCATCAATGAGGAA 




Nuc1b DNA Rev primer CACTGCTAGACATTTTCCACACTGA 
Nuc1b probe ATCCCTCAGACCCTTT 
BACH2 First intron F GAAGAGTGCCTAGCACAGTAAG 
ChIP-qPCR 
primer 
BACH2 First intron R GAGCACACAGGTTTAGGAGATG 
BACH2 Gene body F CAACTCCAAGGGCCAGAG 
BACH2 Gene body R AGAGGCTGAACCAACAAGAG 
BACH2 Gene end F TCTGCCTCTGATCCCTATGT 
BACH2 Gene end R GGTAGCAAGTAAGGGTCCAAA 
STAT5B First intron F TCAAACGTGGTGGAAGTGTTAG 
STAT5B First intron R CACCCAGCCTACCATCTTATTT 
STAT5B Gene body F GGTGATGGTCATGGTTTCCT 
STAT5B Gene body R  GAGACACCTGCTTCTGCTG 
STAT5B Gene end F CTTCCTCTGAAGGGATGGTATTG 
STAT5B Gene end R TCACGCTGATGACTTGAAACT 
MKL2 First intron F GACCCTTTGCGTACCTTCTT 
MKL2 First intron R GTGGAGCTCAGAGTCTACATTTC 




Primer name Primer sequence (5’-3’ direction) Application 
MKL2 Gene body R GGGAATAAACAGAAATGGTGGAAAT 
MKL2 Gene end F AGAGGAAAGACCACTCCCTAT 
MKL2 Gene end R GGCTTTCTGTTGTGAGTTGTATG 
CNTN4 First intron F CTTACACACCCTTCACCACTAC 
 
CNTN4 First intron R CGCAAGACTCCCACAATAGAA 
CNTN4 Gene body F CAGGAGTGATGGGTGAATATGAG 
CNTN4 Gene body R  TAAAGCAAAGCATTCCAGCTTC 
CNTN4 Gene end F TACTTGTCTTTCGGGAGCATTT 
CNTN4 Gene end R  GCTCTGGGTCATCTAGATTTGG 
RPTOR First intron F TGCTGGCAGATTGTGGTAAA 
RPTOR First intron R GGGAAGGAAGGAAGGAAGAAAG 
NPLOC4 First intron F CCAAGGCCAACTCCAGTATT 
NPLOC4 First intron R GGTCTGTCTCTTCCTGTGTATTT 
KDM2B First intron F  GTTGCTTGGGTTGCAATGG 
KDM2B First intron R AGAGAGCCCGGGACATTAT 
PACS2 First intron F CCCAAATCTCATAGCCAGTAGG 
PACS2 First intron R GTGAGGGAGCACAGGAAATA 
ACTN1 First intron F AGGTAGAGAGGAACCAGAAA 
ACTN1 First intron R AATGCCAGGGAAAGGTAAGG 
APOE F CCGGTGAGAAGCGCAGTCGG 
DRIP-qPCR 
primer 
APOE R CCCAAGCCCGACCCCGAGTA 
MYADM positive F CGTAGGTGCCCTAGTTGGAG 




Primer name Primer sequence (5’-3’ direction) Application 
RPL13A F AATGTGGCATTTCCTTCTCG 
RPL13A R CCAATTCGGCCAAGACTCTA 
EGR1 F CCAATTCGGCCAAGACTCTA 
EGR1 R  CTTGTGGTGAGGGGTCACTT 
BTBD19 F GGCTGCTCAGGAGAGCTAGA 
BTBD19 R ACCAGACTGTGACCCCAAAG 
SNRPN F GCCAAATGAGTGAGGATGGT 
SNRPN R TCCTCTCTGCCTGACTCCAT 
EGR1 negative F GAACGTTCAGCCTCGTTCTC 
EGR1 negative R GGAAGGTGGAAGGAAACACA 
MYADM negative F TGCATCTACATCCGCAAAAG 
MYADM negative R AGAGTGGACGCTGCAGAAAT 
R-loop fragment F  TTTAGAGCTTGACGGGGAAA 
R-loop fragment R CAACAGTTGCGTAGCCTGAA 
Non-R-loop fragment F TTGCCGGGAAGCTAGAGTAA 
Non-R-loop fragment R GCTGCCATAAGCATGAGTGA 
BACH2 F GAAGAGTGCCTAGCACAGTAAG 
BACH2 R GAGCACACAGGTTTAGGAGATG 
STAT5B F TCAAACGTGGTGGAAGTGTTAG 
STAT5B R  CACCCAGCCTACCATCTTATTT 




Early RT products R GTTCGGGCGCCACTGCTAG 




Primer name Primer sequence (5’-3’ direction) Application 
Late RT products F CATGTTTTCAGCATTATCAGAAGGA 
Quantification of 
late RT products Late RT products R 
TGCTTGATGTCCCCCCACT 
Late RT products probe CCACCCCACAAGATTTAAACACCATGCTAA 
2LTR circles ddPCR F CTAACTAGGGAACCCACTGCT 
Quantification of 
2LTR circles 2LTR circles ddPCR R 
GTAGTTCTGCCAATCAGGGAA  
2 LTR circles ddPCR probe AGCCTCAATAAAGCTTGCCTTGAGTGC 
RPP30 F GATTTGGACCTGCGAGCG Normalizer gene 
for absolute 
quantification of 
early and late 
RT products and 
2LTR circles 
RPP30 R GCGGCTGTCTCCACAAGT 
RPP30 probe CTGACCTGAAGGCTCT 
 
 
Gene expression assays 
 
 





















BAC constructs  
 
 
Gene name BAC reference code 
BACH2 RP11-59717 
NPLOC4 RP11-765O14 
MKL2 RP11-1072B15 
STAT5B CTD-3124P7 
DNMT1 
CTD-2240E14 
RPTOR 
RP11-28G8 
SMG1 
RP11-1035H13 
GRB2 
RP11-16C1 
GNB1 
RP11-798H13 
NFATC3 
RP11-67A1 
KDM2B 
RP11-44F24 
ACTN1 
RP11-226F19 
PACS2 
RP11-521B24 
CNTN4 
RP11-63O1 
RNF157 
RP11-449J21 
 
 
 
 
